[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the synonym for Acrokeratosis paraneoplastica is Acrokeratoelastoidosis (AKE).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Yes, Weaver syndrome is similar to Sotos syndrome in that they are both genetic disorders that can cause cerebral gigantism, a condition characterized by abnormally large size of the brain and body. Both disorders are caused by mutations in specific genes, with Sotos syndrome caused by mutations in the UBE2A gene and Weaver syndrome caused by mutations in the PTCH1 gene.\nBoth disorders can also cause neurodevelopmental delay, infantile spasms, and other associated features such as typical facies and growth retardation. However, there are some differences between the two disorders. For example, Sotos syndrome is typically associated with more severe neurological symptoms and a higher risk of seizures, while Weaver syndrome may have a milder neurological presentation.\nIt's worth noting that the case reported in Document-0 is specifically referring to Sotos syndrome, as the child in the case had a large stature, typical facies, and neurodevelopmental delay along with infantile spasms, which are all classic features of Sotos syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both genetic disorders that can cause cerebral gigantism.\n2. Sotos syndrome is caused by mutations in the UBE2A gene.\n3. Weaver syndrome is caused by mutations in the EZH2 gene. (Note: The original answer incorrectly mentions the PTCH1 gene; the correct gene for Weaver syndrome is EZH2.)\n4. Both Weaver syndrome and Sotos syndrome can cause neurodevelopmental delay and infantile spasms.\n5. Sotos syndrome is typically associated with more severe neurological symptoms and a higher risk of seizures compared to Weaver syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both genetic disorders that can cause cerebral gigantism.",
      "Sotos syndrome is caused by mutations in the UBE2A gene.",
      "Weaver syndrome is caused by mutations in the EZH2 gene. (Note: The original answer incorrectly mentions the PTCH1 gene; the correct gene for Weaver syndrome is EZH2.)",
      "Both Weaver syndrome and Sotos syndrome can cause neurodevelopmental delay and infantile spasms.",
      "Sotos syndrome is typically associated with more severe neurological symptoms and a higher risk of seizures compared to Weaver syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Sotos syndrome is caused by mutations in the NSD1 gene.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of JASPAR database are:\n1. JASPAR Release 1.0 (2000): This was the first release of the JASPAR database, which included a set of 123 parameter sets for 105 different radionuclides.\n2. JASPAR Release 2.0 (2003): This release added 10 new parameter sets for a total of 133 parameter sets for 115 radionuclides.\n3. JASPAR Release 3.0 (2006): This release included 15 new parameter sets for a total of 148 parameter sets for 121 radionuclides.\n4. JASPAR Release 4.0 (2010): This release added 20 new parameter sets for a total of 168 parameter sets for 136 radionuclides.\n5. JASPAR Release 5.0 (2015): This release included 30 new parameter sets for a total of 198 parameter sets for 161 radionuclides.\n6. JASPAR Release 6.0 (2020): This is the latest release of the JASPAR database, which includes 40 new parameter sets for a total of 238 parameter sets for 171 radionuclides.\nIt's worth noting that the JASPAR database is continuously updated and new releases are made available as new data becomes available.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was released in 2000 with a set of 123 parameter sets for 105 different radionuclides.\n2. JASPAR Release 2.0 was released in 2003 and included a total of 133 parameter sets for 115 radionuclides.\n3. JASPAR Release 3.0 was released in 2006 with a total of 148 parameter sets for 121 radionuclides.\n4. JASPAR Release 4.0 was released in 2010 and it had a total of 168 parameter sets for 136 radionuclides.\n5. The latest release stated is JASPAR Release 6.0, which occurred in 2020 and included 238 parameter sets for 171 radionuclides.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was released in 2000 with a set of 123 parameter sets for 105 different radionuclides.",
      "JASPAR Release 2.0 was released in 2003 and included a total of 133 parameter sets for 115 radionuclides.",
      "JASPAR Release 3.0 was released in 2006 with a total of 148 parameter sets for 121 radionuclides.",
      "JASPAR Release 4.0 was released in 2010 and it had a total of 168 parameter sets for 136 radionuclides.",
      "The latest release stated is JASPAR Release 6.0, which occurred in 2020 and included 238 parameter sets for 171 radionuclides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific domain knowledge about the \"JASPAR\" releases and their specific release dates, number of parameter sets, and the number of radionuclides they cover, it's not possible to verify the accuracy of these statements. Information on such specific databases or software releases might require specialized knowledge or access to relevant historical release notes or databases.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the function of the viral KP4 protein is to induce early and late viral gene transcription, as well as repress the expression of its own gene and several other viral genes. The protein is phosphorylated at multiple sites, including the serine-rich region (residues 175-198), which appears to be a key site for phosphorylation. The phosphorylation of this region stimulates the phosphorylation of the rest of the molecule, suggesting a sequential phosphorylation mechanism. Additionally, the protein has been shown to have associated kinase activity or autophosphorylation activity that is different from protein kinase A or protein kinase C. These findings suggest that the KP4 protein plays a complex role in the regulation of viral gene expression and may be involved in multiple cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein induces early and late viral gene transcription.\n2. The KP4 protein represses the expression of its own gene and several other viral genes.\n3. KP4 is phosphorylated at multiple sites, including a serine-rich region at residues 175-198.\n4. Phosphorylation of the serine-rich region stimulates phosphorylation of the rest of the KP4 molecule, indicating a sequential phosphorylation mechanism.\n5. The KP4 protein has associated kinase activity that is different from protein kinase A or protein kinase C.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein induces early and late viral gene transcription.",
      "The KP4 protein represses the expression of its own gene and several other viral genes.",
      "KP4 is phosphorylated at multiple sites, including a serine-rich region at residues 175-198.",
      "Phosphorylation of the serine-rich region stimulates phosphorylation of the rest of the KP4 molecule, indicating a sequential phosphorylation mechanism.",
      "The KP4 protein has associated kinase activity that is different from protein kinase A or protein kinase C."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific context or source information about the KP4 protein, its function in viral gene transcription, its regulatory mechanisms, its phosphorylation sites, or its kinase activity, it is not possible to determine the veracity of these statements. They contain specific scientific information that requires a reference to research or expert analysis on the KP4 protein's characteristics and functions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided, DITPA is a thyroid hormone analog that is utilized in experimental and clinical studies to facilitate oligodendrocyte (OL) differentiation and myelination. The monocarboxylate transporter 8 (MCT8) plays a crucial role in TH transport in OLs, and mutations in the gene encoding MCT8, SLC16A2, can lead to Allan-Herndon-Dudley syndrome (AHDS), a psychomotor retardation and hypomyelination disorder. Treatment with DITPA, an MCT8-independent TH analog, up-regulates OL differentiation transcription factors and myelin gene expression, and promotes hESC-derived OL myelination of retinal ganglion axons in co-culture. Additionally, pharmacological and genetic blockade of MCT8 induces significant OL apoptosis, which can be limited by DITPA treatment through AKT phosphorylation-mediated signaling. These findings suggest that DITPA may have potential as a treatment for developmentally-regulated myelination in AHDS.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA facilitates oligodendrocyte differentiation and myelination.\n3. Mutations in the gene SLC16A2, which encodes the monocarboxylate transporter 8 (MCT8), can lead to Allan-Herndon-Dudley syndrome.\n4. DITPA can up-regulate oligodendrocyte differentiation transcription factors and myelin gene expression.\n5. DITPA treatment can limit oligodendrocyte apoptosis through AKT phosphorylation-mediated signaling when MCT8 is blocked.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA facilitates oligodendrocyte differentiation and myelination.",
      "Mutations in the gene SLC16A2, which encodes the monocarboxylate transporter 8 (MCT8), can lead to Allan-Herndon-Dudley syndrome.",
      "DITPA can up-regulate oligodendrocyte differentiation transcription factors and myelin gene expression.",
      "DITPA treatment can limit oligodendrocyte apoptosis through AKT phosphorylation-mediated signaling when MCT8 is blocked."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are all focused on specific scientific information which appears to be accurate based on the context given. As they are highly specialized knowledge, under the assumption that they were drawn from reliable scientific sources, they are likely true. However, without the original context or scientific literature references, it is important to note that this assessment is made on face value of the statements and assumes accurate reporting from a scientific perspective.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the COUGER tool is a carbide bur. The document states that \"The Great White Ultra (carbide bur) showed a significantly higher rate of advancement (0.15 mm/s) and lower applied load (106.46 g) and rpm (304,375.97) compared to the other rotary cutting instruments tested.\" This suggests that the COUGER tool is the carbide bur used in the study, which demonstrated superior cutting efficiency compared to the other rotary cutting instruments tested.",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is a carbide bur.\n2. The Great White Ultra is a carbide bur that demonstrated a higher rate of advancement at 0.15 mm/s in a study.\n3. The Great White Ultra carbide bur required a lower applied load of 106.46 grams in the study.\n4. The Great White Ultra carbide bur operated at lower revolutions per minute (rpm) of 304,375.97 compared to other rotary cutting instruments tested.\n5. The COUGER tool, as the carbide bur used in the study, was found to have superior cutting efficiency compared to other rotary cutting instruments.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is a carbide bur.",
      "The Great White Ultra is a carbide bur that demonstrated a higher rate of advancement at 0.15 mm/s in a study.",
      "The Great White Ultra carbide bur required a lower applied load of 106.46 grams in the study.",
      "The Great White Ultra carbide bur operated at lower revolutions per minute (rpm) of 304,375.97 compared to other rotary cutting instruments tested.",
      "The COUGER tool, as the carbide bur used in the study, was found to have superior cutting efficiency compared to other rotary cutting instruments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: It is highly unlikely that the Great White Ultra carbide bur or any rotary cutting instrument would operate at 304,375.97 rpm, as this number is exceedingly high for such instruments. Typical dental burs operate within the range of 5,000 to 400,000 rpm, with many not exceeding 200,000 rpm.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat Tick-borne Encephalitis (TBE). The document you provided mentions the development of a highly purified, inactivated TBE virus particle vaccine, which can provide protection against TBE virus isolates from different geographical areas. However, it is important to note that this vaccine is still in the development stage and has not yet been widely tested or approved for use.\nCurrently, there are no FDA-approved drugs specifically for treating TBE. However, there are some antiviral medications that have been used to treat TBE, such as ribavirin and acyclovir. These medications can help reduce the severity of symptoms and the duration of the illness, but they are not a cure for TBE.\nIt is important to seek medical attention immediately if you suspect you have TBE, as early treatment can help reduce the risk of serious complications. Your healthcare provider may recommend antiviral medication, as well as other supportive treatments such as rest, hydration, and pain management.\nIn summary, while there is no FDA-approved drug specifically for treating TBE, there are some antiviral medications that can help manage symptoms and reduce the risk of serious complications. It is important to seek medical attention immediately if you suspect you have TBE.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a highly purified, inactivated Tick-borne Encephalitis (TBE) virus particle vaccine in development that aims to provide protection against TBE virus isolates from different geographical areas.\n2. The mentioned TBE vaccine is still in the development stage and has not been widely tested or approved for use.\n3. There are no FDA-approved drugs specifically for treating Tick-borne Encephalitis (TBE).\n4. Antiviral medications such as ribavirin and acyclovir have been used to treat TBE.\n5. Early treatment of TBE is crucial to reduce the risk of serious complications.",
    "llama-2-7b-chat-hf_fact": [
      "There is a highly purified, inactivated Tick-borne Encephalitis (TBE) virus particle vaccine in development that aims to provide protection against TBE virus isolates from different geographical areas.",
      "The mentioned TBE vaccine is still in the development stage and has not been widely tested or approved for use.",
      "There are no FDA-approved drugs specifically for treating Tick-borne Encephalitis (TBE).",
      "Antiviral medications such as ribavirin and acyclovir have been used to treat TBE.",
      "Early treatment of TBE is crucial to reduce the risk of serious complications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific references to current research data or news about vaccine development, it's not possible to verify the status of a TBE vaccine as described.\n2. UNKNOWN: Similar to statement 1, without specific information regarding the development and approval stages of the TBE vaccine, the truth of this statement cannot be established.\n3. TRUE: As of my last update, there are indeed no FDA-approved drugs specifically designed to treat Tick-borne Encephalitis.\n4. FALSE [correction]: There are no specific antiviral medications that have been proven effective for the treatment of TBE. Ribavirin and acyclovir are antiviral medications but they are not typically used to treat TBE as their effectiveness against the disease has not been established.\n5. TRUE: Early treatment of TBE or any serious infectious disease is generally crucial to manage symptoms and reduce the risk of complications, although specific treatment options for TBE are limited to supportive care.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several genome browser databases available for DNA shape annotations. Here are a few options:\n1. Ensembl: Ensembl is a comprehensive and integrated genomic resource that provides access to a wide range of genomic data, including DNA shape annotations. Ensembl's genome browsers allow users to visualize and analyze genomic regions, including the positions of transcription factor binding sites (TFBSs) and other features.\n2. GenBank: GenBank is a comprehensive public database of DNA sequences, including genomic sequences from a wide range of organisms. GenBank provides access to DNA shape annotations, including the positions of TFBSs and other features.\n3. UCSC Genome Browser: The UCSC Genome Browser is a popular genome browser database that provides access to a wide range of genomic data, including DNA shape annotations. The UCSC Genome Browser allows users to visualize and analyze genomic regions, including the positions of TFBSs and other features.\n4. GenePalette: GenePalette is a desktop application that can access any genome sequence and display the positions of various features, including TFBSs, relative to the introns and exons of annotated genes. GenePalette is written in Java and can run on all Java-supporting operating systems.\nIn summary, there are several genome browser databases available for DNA shape annotations, including Ensembl, GenBank, UCSC Genome Browser, and GenePalette. Each of these databases provides access to a wide range of genomic data and tools for visualizing and analyzing DNA shape annotations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ensembl provides access to DNA shape annotations and allows users to visualize and analyze genomic regions.\n2. GenBank is a public database of DNA sequences that includes DNA shape annotations.\n3. The UCSC Genome Browser offers DNA shape annotations and tools for visualizing and analyzing genomic regions.\n4. GenePalette is a desktop application that displays positions of features like transcription factor binding sites relative to the introns and exons of annotated genes.\n5. GenePalette runs on all Java-supporting operating systems.",
    "llama-2-7b-chat-hf_fact": [
      "Ensembl provides access to DNA shape annotations and allows users to visualize and analyze genomic regions.",
      "GenBank is a public database of DNA sequences that includes DNA shape annotations.",
      "The UCSC Genome Browser offers DNA shape annotations and tools for visualizing and analyzing genomic regions.",
      "GenePalette is a desktop application that displays positions of features like transcription factor binding sites relative to the introns and exons of annotated genes.",
      "GenePalette runs on all Java-supporting operating systems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ensembl provides access to genomic data and allows users to visualize and analyze genomic regions, but it does not focus specifically on DNA shape annotations.\n2. FALSE [correction]: GenBank is a public database of DNA and RNA sequences, but it does not include DNA shape annotations.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following syndromes are associated with mutations in the EZH2 gene:\n1. Follicular lymphoma (FL): The document states that EZH2 mutations are present in 27% of FL cases, with variant allele frequencies (VAF) ranging from 2% to 61%.\n2. Transformed follicular lymphoma (tFL): The document also shows that EZH2 mutations are present in 100% of tFL cases, with VAF ranging from 2% to 61%.\nIt is important to note that these findings are based on a small cohort of patients and further studies are needed to confirm these associations. Additionally, the document does not provide information on other syndromes that may be associated with EZH2 mutations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with Follicular lymphoma (FL).\n2. EZH2 mutations occur in 27% of Follicular lymphoma cases.\n3. The variant allele frequencies (VAF) of EZH2 mutations in Follicular lymphoma cases range from 2% to 61%.\n4. Mutations in the EZH2 gene are associated with Transformed follicular lymphoma (tFL).\n5. EZH2 mutations occur in 100% of Transformed follicular lymphoma cases.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with Follicular lymphoma (FL).",
      "EZH2 mutations occur in 27% of Follicular lymphoma cases.",
      "The variant allele frequencies (VAF) of EZH2 mutations in Follicular lymphoma cases range from 2% to 61%.",
      "Mutations in the EZH2 gene are associated with Transformed follicular lymphoma (tFL).",
      "EZH2 mutations occur in 100% of Transformed follicular lymphoma cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE [assuming this is a current statistic, but the exact percentage can vary based on the studied population]\n3. TRUE [VAF can vary, and this range is plausible for somatic mutations in cancer]\n4. TRUE\n5. FALSE [correction]: EZH2 mutations do not occur in 100% of Transformed follicular lymphoma cases; the percentage is significant but not universal.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. CTPR3: The consensus TPR protein CTPR3 has been shown to undergo a dimer-to-tetramer transition in vitro.\n2. Fis1: Human Fis1 has been shown to interconvert between monomer and dimer states in regulating division of peroxisomes and mitochondria, but the ability of Fis1 to undergo a dimer-to-tetramer transition has not been directly demonstrated.\nIt is worth noting that the presence of a consensus proline residue in the TPR domain, such as the one present in yeast Fis1, may prevent TPR oligomerization and dimerization. However, the absence of this residue in human Fis1 does not necessarily mean that it cannot undergo a dimer-to-tetramer transition. Further research is needed to determine whether human Fis1 can also interconvert between monomer and dimer states.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human protein CTPR3 undergoes a dimer-to-tetramer transition in vitro.\n2. Human Fis1 is known to interconvert between monomer and dimer states.\n3. The ability of human Fis1 to undergo a dimer-to-tetramer transition has not been directly demonstrated.\n4. The presence of a consensus proline residue in the TPR domain may prevent TPR oligomerization and dimerization.\n5. Human Fis1 lacks the consensus proline residue that is present in yeast Fis1.",
    "llama-2-7b-chat-hf_fact": [
      "The human protein CTPR3 undergoes a dimer-to-tetramer transition in vitro.",
      "Human Fis1 is known to interconvert between monomer and dimer states.",
      "The ability of human Fis1 to undergo a dimer-to-tetramer transition has not been directly demonstrated.",
      "The presence of a consensus proline residue in the TPR domain may prevent TPR oligomerization and dimerization.",
      "Human Fis1 lacks the consensus proline residue that is present in yeast Fis1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific biochemical or scientific references directly addressing the properties of these proteins, providing corrections or assessing the truth of the last two statements reliably is not possible. These statements would require specific knowledge or a literature review on the structure-function relationship of TPR domains and human versus yeast Fis1 to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Pl-SPH2.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no evidence to suggest that vitamin D supplementation reduces the risk of falls in older people in care homes. The study found that the incidence of falls was similar in both the vitamin D-treated and control groups, with 44% of vitamin D-treated residents and 43% of control residents reporting at least one fall. The study also found that the pre-treatment serum 25-hydroxy vitamin D concentration was high in both groups, which may have limited the potential effect of vitamin D supplementation on falls. Therefore, based on the information provided in the document, the answer to the user's question is \"No, vitamin D supplementation has not been shown to reduce incidence of falls in older people in clinical trials.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no evidence to suggest that vitamin D supplementation reduces the risk of falls in older people in care homes, according to the document referenced.\n2. The incidence of falls was similar in both vitamin D-treated and control groups in the study mentioned.\n3. In the study, 44% of vitamin D-treated residents reported at least one fall.\n4. Similarly, 43% of control residents reported at least one fall in the referenced study.\n5. The pre-treatment serum 25-hydroxy vitamin D concentration was high in both groups in the study.",
    "llama-2-7b-chat-hf_fact": [
      "There is no evidence to suggest that vitamin D supplementation reduces the risk of falls in older people in care homes, according to the document referenced.",
      "The incidence of falls was similar in both vitamin D-treated and control groups in the study mentioned.",
      "In the study, 44% of vitamin D-treated residents reported at least one fall.",
      "Similarly, 43% of control residents reported at least one fall in the referenced study.",
      "The pre-treatment serum 25-hydroxy vitamin D concentration was high in both groups in the study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific document or study being referenced, it is not possible to confirm or deny the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is an association between Jarid2 and miR-155 in Th17 cells. The study found that miR-155 targets the coding sequences (CDS) of TLR3, and the expression of the TLR3 protein can be inhibited by a miR-155 mimic or by a virally encoded orthologue in chick embryo fibroblast cells. Additionally, endogenous miR-155 induction emerged as a negative regulation on TLR3 expression in TLR2, 4 and 7 ligands stimulated HD11 cells, an avian macrophage cell line.\nFurthermore, the study found that miR-155 could inhibit IFN- production possibly through TLR3 signaling pathway. These findings suggest that Jarid2, a protein that is involved in the regulation of gene expression, may play a role in the association between miR-155 and TLR3 in Th17 cells. Specifically, Jarid2 may be involved in the regulation of the expression of miR-155 and its target genes, including TLR3, in Th17 cells.\nIn summary, the study provides evidence for an association between Jarid2 and miR-155 in Th17 cells, and suggests that Jarid2 may play a role in the regulation of the expression of miR-155 and its target genes, including TLR3, in these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is an association between Jarid2 and miR-155 in Th17 cells.\n2. miR-155 targets the coding sequences of TLR3.\n3. The expression of the TLR3 protein can be inhibited by a miR-155 mimic or by a virally encoded orthologue in chick embryo fibroblast cells.\n4. miR-155 induction serves as a negative regulator on TLR3 expression in HD11 cells, which is an avian macrophage cell line.\n5. Jarid2 is involved in the regulation of gene expression and may play a role in the association between miR-155 and TLR3 in Th17 cells.",
    "llama-2-7b-chat-hf_fact": [
      "There is an association between Jarid2 and miR-155 in Th17 cells.",
      "miR-155 targets the coding sequences of TLR3.",
      "The expression of the TLR3 protein can be inhibited by a miR-155 mimic or by a virally encoded orthologue in chick embryo fibroblast cells.",
      "miR-155 induction serves as a negative regulator on TLR3 expression in HD11 cells, which is an avian macrophage cell line.",
      "Jarid2 is involved in the regulation of gene expression and may play a role in the association between miR-155 and TLR3 in Th17 cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the specific and technical nature of these statements, they relate to advanced biology and molecular genetics, particularly focusing on microRNA (miR-155), Toll-like receptor 3 (TLR3), Th17 cells (a type of immune cell), and Jarid2 (a gene involved in regulating other genes). Without the specific scientific contexts or research findings to reference, it's impossible to confirm the veracity of these statements. They would require access to peer-reviewed scientific literature or experimental data for verification.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human hoxD cluster contains at least 16 different genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human hoxD cluster contains at least 16 different genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human hoxD cluster contains at least 16 different genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the phosphorylation consensus motifs for Casein Kinase 1 (CK1) are:\n1. Ser/Thr-Pro-Thr-Ser (STPT)\n2. Ser-Pro-Thr-Ser (SPTS)\n3. Thr-Ser-Tyr (TST)\n4. Ser-Thr-Ser-Pro (STSP)\n5. Ser-Pro-Thr-Ser-Pro (SPTP)\nThese consensus motifs are commonly found in the phosphorylation sites of CK1 and are important for its regulatory functions. The S97C mutation in the kinase domain of CK1, which has been implicated in breast cancer and ductal carcinoma, results in the loss of ATP-binding affinity and leads to a notable loss in 3-D conformation of the kinase domain. These changes are thought to contribute to the observed cancer-associated phenotype.",
    "llama-2-7b-chat-hf_fact_raw": "1. The phosphorylation consensus motif for Casein Kinase 1 (CK1) includes Ser/Thr-Pro-Thr-Ser (STPT).\n2. Another phosphorylation consensus motif for CK1 is Ser-Pro-Thr-Ser (SPTS).\n3. The Thr-Ser-Tyr (TST) sequence is a phosphorylation consensus motif for CK1.\n4. Ser-Thr-Ser-Pro (STSP) is one of the consensus motifs for phosphorylation by CK1.\n5. Ser-Pro-Thr-Ser-Pro (SPTP) is a phosphorylation consensus motif for Casein Kinase 1 (CK1).",
    "llama-2-7b-chat-hf_fact": [
      "The phosphorylation consensus motif for Casein Kinase 1 (CK1) includes Ser/Thr-Pro-Thr-Ser (STPT).",
      "Another phosphorylation consensus motif for CK1 is Ser-Pro-Thr-Ser (SPTS).",
      "The Thr-Ser-Tyr (TST) sequence is a phosphorylation consensus motif for CK1.",
      "Ser-Thr-Ser-Pro (STSP) is one of the consensus motifs for phosphorylation by CK1.",
      "Ser-Pro-Thr-Ser-Pro (SPTP) is a phosphorylation consensus motif for Casein Kinase 1 (CK1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The phosphorylation consensus motif for Casein Kinase 1 (CK1) is generally characterized by serine or threonine followed by acidic residues but not necessarily as a strict sequence of Ser/Thr-Pro-Thr-Ser (STPT). A common motif is pSer/pThr-X-X-Ser/Thr, where X can be any amino acid.\n2. UNKNOWN: While Ser-Pro in the sequence is consistent with CK1 targeting, without a specific and widely recognized motif as Ser-Pro-Thr-Ser (SPTS), it cannot be definitively confirmed as a consensus motif for CK1. CK1 commonly targets sequences where phosphorylated Ser/Thr is followed by acidic residues, but \"SPTS\" as a defined consensus is not common knowledge.\n3. FALSE [correction]: The Thr-Ser-Tyr (TST) sequence is not generally recognized as a phosphorylation consensus motif for CK1. CK1 typically targets serine or threonine residues that are followed by acidic amino acids, and tyrosine is not usually involved in CK1 consensus motifs.\n4. UNKNOWN: As with statement 2, while Ser and Thr are common in CK1 motifs, the specific sequence Ser-Thr-Ser-Pro (STSP) as a consensus motif isn't widely established. CK1 prefers phosphorylated Ser/Thr followed by acidic residues, but the exact STSP motif isn't well-documented as a consensus.\n5. FALSE [correction]: There is no widely recognized consensus motif of Ser-Pro-Thr-Ser-Pro (SPTSP) for Casein Kinase 1 (CK1). Commonly, CK1 phosphorylates serine or threonine residues followed by acidic amino acids, not necessarily another proline as in the sequence provided.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Arylsulfate sulfotransferase (ASST): The gene encodes a protein that transfers a sulfate group from phenolic sulfate esters to a phenolic acceptor substrate.\n2. Secretory signal sequence-containing protein: The gene encodes a protein that has a secretory signal sequence, indicating that it is secreted from the cell.\nNo significant homology to any sequence was found in the database for the astA nucleotide or its deduced amino acid sequence, suggesting that the protein encoded by the gene is unique and has not been identified before.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes for a protein known as Arylsulfate sulfotransferase (ASST).\n2. Arylsulfate sulfotransferase (ASST) transfers a sulfate group from phenolic sulfate esters to a phenolic acceptor substrate.\n3. The ASPH gene also encodes for a protein that contains a secretory signal sequence.\n4. The protein encoded by the ASPH gene with a secretory signal sequence is secreted from the cell.\n5. The database search did not find significant homology for the astA nucleotide or its deduced amino acid sequence, indicating that it may code for a unique protein.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes for a protein known as Arylsulfate sulfotransferase (ASST).",
      "Arylsulfate sulfotransferase (ASST) transfers a sulfate group from phenolic sulfate esters to a phenolic acceptor substrate.",
      "The ASPH gene also encodes for a protein that contains a secretory signal sequence.",
      "The protein encoded by the ASPH gene with a secretory signal sequence is secreted from the cell.",
      "The database search did not find significant homology for the astA nucleotide or its deduced amino acid sequence, indicating that it may code for a unique protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The ASPH gene encodes for a protein known as aspartate beta-hydroxylase.\n2. FALSE [correction]: It is actually sulfotransferase proteins that transfer a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to an acceptor molecule, which can be different for different types of sulfotransferases, but Arylsulfate sulfotransferase (ASST) is not the correct name nor necessarily the correct function for the protein encoded by the ASPH gene.\n3. TRUE\n4. TRUE: Proteins with a secretory signal sequence are typically directed towards the secretory pathway and are secreted from the cell.\n5. UNKNOWN: Without more context regarding the database or the astA nucleotide, it's not possible to verify the accuracy of the statement about its homology and uniqueness.\n",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, empagliflozin was FDA approved in 2014. According to the document, the drug was approved \"in 2014\" without specifying the exact month or date.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the loss of the protein Lon1 in the plant Arabidopsis has several consequences.\nFirstly, the loss of Lon1 leads to the accumulation of 12S globulins and 2S albumins in the seeds of Arabidopsis. This is because Lon1 is involved in the degradation of these proteins, and its absence results in their accumulation.\nSecondly, the analysis of the protein composition of mature Arabidopsis seeds revealed that approximately 84% of protein species are derived from just a few genes coding for 12S globulins and 2S albumins. This suggests that Lon1 plays a critical role in regulating the expression of these genes and the synthesis of these proteins.\nThirdly, the study found that the C-terminal degradation of 12S globulins is repressed under sulfur-deficient conditions. This suggests that Lon1 may play a role in regulating the response of Arabidopsis to sulfur deficiency, possibly by controlling the degradation of seed storage proteins.\nFinally, the study combined transcriptome analysis with proteomic analysis to elucidate the mechanism of changes in seed protein composition in response to sulfur deficiency. The results suggest that seed storage proteins in Arabidopsis undergo multi-layer regulation, with emphasis on post-translational modifications that enable the plant to respond to sulfur deficiency.\nIn summary, the loss of Lon1 in Arabidopsis leads to changes in the composition of seed storage proteins, including the accumulation of 12S globulins and 2S albumins, and affects the response of the plant to sulfur deficiency.",
    "llama-2-7b-chat-hf_fact_raw": "1. The loss of the protein Lon1 in Arabidopsis leads to the accumulation of 12S globulins and 2S albumins in the seeds.\n2. Lon1 is involved in the degradation of 12S globulins and 2S albumins in Arabidopsis seeds.\n3. Approximately 84% of protein species in mature Arabidopsis seeds are derived from genes coding for 12S globulins and 2S albumins.\n4. Under sulfur-deficient conditions, the degradation of 12S globulins is repressed in Arabidopsis, which could be related to Lon1 activity.\n5. A combination of transcriptome and proteome analyses was used to study the changes in seed protein composition in response to sulfur deficiency in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "The loss of the protein Lon1 in Arabidopsis leads to the accumulation of 12S globulins and 2S albumins in the seeds.",
      "Lon1 is involved in the degradation of 12S globulins and 2S albumins in Arabidopsis seeds.",
      "Approximately 84% of protein species in mature Arabidopsis seeds are derived from genes coding for 12S globulins and 2S albumins.",
      "Under sulfur-deficient conditions, the degradation of 12S globulins is repressed in Arabidopsis, which could be related to Lon1 activity.",
      "A combination of transcriptome and proteome analyses was used to study the changes in seed protein composition in response to sulfur deficiency in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While 12S globulins and 2S albumins are major storage proteins in Arabidopsis seeds, claiming that 84% of protein species are derived from them would likely be inaccurate given the complexity of seed protein composition. Without specific evidence, this statement cannot be deemed true.\n4. UNKNOWN: The relationship between sulfur deficiency and Lon1 mediated degradation of 12S globulins needs specific scientific evidence which is not provided, so the impact of sulfur-deficiency on the degradation of 12S globulins in relation to Lon1 is unknown.\n5. TRUE: Using transcriptome and proteome analyses to study changes in seed protein composition is a common and plausible approach in plant science research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no direct answer to the user's question about the existence of linker histones in the yeast genome. The document primarily focuses on the evolutionary history and distribution of linker histones in various species, including bivalves and vertebrates. While the document does mention the presence of H1 histone genes in the sea urchin Strongylocentrotus purpuratus, there is no mention of linker histones in the yeast genome. Therefore, I must assume that linker histones are not present in the yeast genome based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can lower cholesterol levels. According to the document provided, tomato juice contains bioactive components such as phenolic compounds and flavonoids, which have been shown to have antioxidant and cytotoxic effects. The study found that the amount of phenolic acids decreased in all the samples after processing, but the flavonoid content increased after the heat treatment in two samples. These findings suggest that processed yellow tomatoes have a high content of bioactive compounds endowed with cytotoxicity towards cancer cells, which could potentially have a positive impact on cholesterol levels.\nAdditionally, a number of studies have suggested that consuming tomato juice as part of a healthy diet can help lower cholesterol levels. For example, a 2013 study published in the Journal of Medicinal Food found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL (\"bad\") cholesterol levels in a group of healthy adults. Another study published in the Journal of Nutrition in 2010 found that consuming a tomato-based beverage for 12 weeks improved lipid profiles and reduced inflammation in a group of overweight and obese adults.\nIt's worth noting, however, that the evidence for the cholesterol-lowering effects of tomato juice is not yet definitive, and more research is needed to fully understand its potential benefits. Additionally, it's important to consume tomato juice as part of a balanced diet and to talk to a healthcare professional before making any significant changes to your diet.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomato juice contains bioactive components such as phenolic compounds and flavonoids.\n2. Phenolic acids decreased in all the samples after processing, while flavonoid content increased after the heat treatment in two samples.\n3. A 2013 study published in the Journal of Medicinal Food found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n4. A study published in the Journal of Nutrition in 2010 found that consuming a tomato-based beverage for 12 weeks improved lipid profiles and reduced inflammation in overweight and obese adults.\n5. The evidence for the cholesterol-lowering effects of tomato juice is not yet definitive.",
    "llama-2-7b-chat-hf_fact": [
      "Tomato juice contains bioactive components such as phenolic compounds and flavonoids.",
      "Phenolic acids decreased in all the samples after processing, while flavonoid content increased after the heat treatment in two samples.",
      "A 2013 study published in the Journal of Medicinal Food found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "A study published in the Journal of Nutrition in 2010 found that consuming a tomato-based beverage for 12 weeks improved lipid profiles and reduced inflammation in overweight and obese adults.",
      "The evidence for the cholesterol-lowering effects of tomato juice is not yet definitive."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\nWhile the first statement about tomato juice containing bioactive components such as phenolic compounds and flavonoids is true, the specificity of statements 2, 3, and 4 regarding the outcomes of scientific studies requires access to those specific studies to verify their accuracy. Since I cannot access up-to-date databases or specific journals to verify these particular studies, I must categorize these statements as UNKNOWN. The fifth statement is generally TRUE since scientific consensus often requires a significant body of evidence, and a single or a few studies typically do not provide definitive proof of health benefits.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that Hsp70 and Hsp110 can affect mRNA stability in oral tumorigenesis. The study found that abrogation of HSP70 expression using antisense oligonucleotides resulted in decreased expression of the anti-apoptotic protein bcl-2, which is involved in mRNA stability. The study suggests that HSP70 protein may disrupt HSP70-bcl-2 interactions, leading to inhibition of cell proliferation and induction of apoptosis. However, the study does not directly address the effect of Hsp70 and Hsp110 on mRNA stability.\nTherefore, based on the information provided, it can be inferred that Hsp70 and Hsp110 may play a role in regulating mRNA stability in oral tumorigenesis, but further research is needed to confirm this conclusion.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 can affect mRNA stability in oral tumorigenesis according to the study mentioned.\n2. The study found that abrogation of HSP70 expression using antisense oligonucleotides resulted in decreased expression of the anti-apoptotic protein bcl-2.\n3. The anti-apoptotic protein bcl-2 is involved in mRNA stability.\n4. HSP70 protein may disrupt HSP70-bcl-2 interactions, which could lead to inhibition of cell proliferation and induction of apoptosis.\n5. The study suggests a possible role for Hsp70 and Hsp110 in regulating mRNA stability but states that further research is necessary to confirm this conclusion.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 can affect mRNA stability in oral tumorigenesis according to the study mentioned.",
      "The study found that abrogation of HSP70 expression using antisense oligonucleotides resulted in decreased expression of the anti-apoptotic protein bcl-2.",
      "The anti-apoptotic protein bcl-2 is involved in mRNA stability.",
      "HSP70 protein may disrupt HSP70-bcl-2 interactions, which could lead to inhibition of cell proliferation and induction of apoptosis.",
      "The study suggests a possible role for Hsp70 and Hsp110 in regulating mRNA stability but states that further research is necessary to confirm this conclusion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The anti-apoptotic protein bcl-2 is not directly involved in mRNA stability; it is involved in the regulation of cell death (apoptosis). It's possible that there could be an indirect connection to mRNA stability in the broader context of cellular homeostasis, but bcl-2's primary function is related to apoptosis, not mRNA stability.\n4. FALSE [correction]: There seems to be a confusion in the statement as presented. Typically, HSP70 itself would not \"disrupt HSP70-bcl-2 interactions\" as it is part of the interaction; a molecule or compound that inhibits HSP70 could disrupt such interactions. Moreover, the effect on cell proliferation and apoptosis would be a result of the disruption of the interaction, not an action of HSP70 in isolation. \n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are two deiodinases present in skeletal muscle:\n1. Cdk9: This enzyme is involved in the regulation of myogenesis in vitro by activating MyoD-dependent transcription. In myoblasts induced to differentiate, MyoD recruits cdk9 on the chromatin of muscle-specific regulatory regions, leading to the phosphorylation of cdk9-specific target residues at the carboxyl-terminal domain of RNA polymerase II.\n2. Cdk9-55: This is an alternative form of cdk9 that is specifically induced in injured myofibers and plays a fundamental role in muscle regeneration and differentiation in vivo.\nTherefore, the answer to the user's question is: There are two deiodinases present in skeletal muscle: cdk9 and cdk9-55.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are inflammatory caspase proteins:\n1. Caspase-1\n2. Caspase-1 variant (p.C284A)\nThe document highlights the role of caspase-1 in the initiation of pro-inflammatory innate immune responses, and how mutations in the CASP1 gene can result in reduced enzymatic activity of caspase-1 and impaired IL-1 secretion. The study also shows that enzymatically inactive caspase-1 interacts with the apoptosis-associated speck-like protein containing a CARD (ASC) and forms cytosolic macromolecular complexes called pyroptosomes, which are involved in inflammation. The document concludes that variant p.C284A caspase-1 stabilizes pyroptosome formation, potentially enhancing inflammation through two IL-1-independent mechanisms: pyroptosomes convey an enhanced inflammatory stimulus through the recruitment of additional proteins, and pyroptosome and cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is an inflammatory caspase protein.\n2. There is a variant of caspase-1 known as p.C284A.\n3. Caspase-1 plays a role in the initiation of pro-inflammatory innate immune responses.\n4. Mutations in the CASP1 gene can lead to reduced enzymatic activity of caspase-1.\n5. Inactive caspase-1 can form pyroptosomes, which are involved in inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is an inflammatory caspase protein.",
      "There is a variant of caspase-1 known as p.C284A.",
      "Caspase-1 plays a role in the initiation of pro-inflammatory innate immune responses.",
      "Mutations in the CASP1 gene can lead to reduced enzymatic activity of caspase-1.",
      "Inactive caspase-1 can form pyroptosomes, which are involved in inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: It is the active caspase-1 that can lead to the formation of pyroptosomes, which are involved in inflammation. Inactive caspase-1 lacks the enzymatic activity necessary for this process.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there does appear to be a link between the Aurora B kinase and the polycomb protein ring1B. The document states that Aurora B kinase expression is amplified in malignant thyroid cell lines and tissues, and this amplification is mirrored at the mRNA level for Aurora-A and B, but not for Aurora-C. Additionally, the document mentions that the polycomb protein ring1B is involved in the regulation of cell cycle progression, which is a function that overlaps with the role of the Aurora kinases.\nGiven these findings, it is possible that the Aurora B kinase and the polycomb protein ring1B are involved in a complex regulatory pathway that is dysregulated in malignant thyroid cancers. The amplification of Aurora B kinase expression in these cancers may lead to an increase in the activity of the polycomb protein ring1B, which could in turn contribute to the progression of the cancer.\nHowever, it is important to note that the document does not provide direct evidence of a link between the Aurora B kinase and the polycomb protein ring1B, and further research would be needed to confirm this hypothesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase expression is amplified in malignant thyroid cell lines and tissues.\n2. This amplification is mirrored at the mRNA level for Aurora-A and B, but not for Aurora-C.\n3. The polycomb protein ring1B is involved in the regulation of cell cycle progression.\n4. The roles of Aurora kinases overlap with the regulation of cell cycle progression.\n5. There is a hypothesis that Aurora B kinase and the polycomb protein ring1B may be involved in a regulatory pathway that is dysregulated in malignant thyroid cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase expression is amplified in malignant thyroid cell lines and tissues.",
      "This amplification is mirrored at the mRNA level for Aurora-A and B, but not for Aurora-C.",
      "The polycomb protein ring1B is involved in the regulation of cell cycle progression.",
      "The roles of Aurora kinases overlap with the regulation of cell cycle progression.",
      "There is a hypothesis that Aurora B kinase and the polycomb protein ring1B may be involved in a regulatory pathway that is dysregulated in malignant thyroid cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe specific amplification of Aurora kinase expression at the mRNA level for different types can vary and without the original passage these distinctions are difficult to verify. As for the roles of Aurora kinases and the involvement of polycomb protein ring1B in regulatory pathways, particularly within malignant thyroid cancers, these are consistent with known biological functions and hypotheses in cancer biology. Therefore, while the information seems plausible and aligns with known scientific knowledge, without the source document, the accuracy of the second statement remains uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice site motifs:\n* GU (as in GU dinucleotide)\n* AG (as in AG dinucleotide)\nAcceptor splice site motifs:\n* UG (as in UG dinucleotide)\n* GC (as in GC dinucleotide)\nIt is worth noting that the document specifically mentions the use of the splice donor and acceptor sequences of feline leukemia virus (FeLV) as an example, but it is likely that these motifs are also present in other vertebrate species.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GU dinucleotide is a frequent non-canonical sequence motif at the donor splice site in vertebrates.\n2. The AG dinucleotide is a frequent non-canonical sequence motif at the donor splice site in vertebrates.\n3. The UG dinucleotide is a frequent non-canonical sequence motif at the acceptor splice site in vertebrates.\n4. The GC dinucleotide is a frequent non-canonical sequence motif at the acceptor splice site in vertebrates.\n5. The document referenced uses the splice donor and acceptor sequences of feline leukemia virus (FeLV) as an example demonstrating non-canonical sequence motifs.",
    "llama-2-7b-chat-hf_fact": [
      "The GU dinucleotide is a frequent non-canonical sequence motif at the donor splice site in vertebrates.",
      "The AG dinucleotide is a frequent non-canonical sequence motif at the donor splice site in vertebrates.",
      "The UG dinucleotide is a frequent non-canonical sequence motif at the acceptor splice site in vertebrates.",
      "The GC dinucleotide is a frequent non-canonical sequence motif at the acceptor splice site in vertebrates.",
      "The document referenced uses the splice donor and acceptor sequences of feline leukemia virus (FeLV) as an example demonstrating non-canonical sequence motifs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The GU dinucleotide is indeed a frequent canonical sequence motif at the donor splice site in vertebrates, not non-canonical.\n2. FALSE [correction]: The GT dinucleotide, not AG, is the canonical sequence at the donor splice site in vertebrates.\n3. FALSE [correction]: The AG dinucleotide is the canonical sequence motif at the acceptor splice site in vertebrates, not UG.\n4. UNKNOWN: The GC dinucleotide could be a non-canonical sequence motif at the acceptor splice site, but without specific context or reference, it's unclear whether it's frequent or relevant.\n5. UNKNOWN: Without access to or knowledge of the specific document referenced, it is impossible to affirm or correct this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the event that results in the acetylation of S6K1 is G2 phase. According to the text, acetylation of Cep76 occurs in G2 phase and correlates with loss of protein function. Additionally, the document states that deregulation of centriole copy number is a hallmark of cancer, suggesting that any disruptions to the regulation of centriole amplification, including acetylation of Cep76, may contribute to malignancy. Therefore, the answer to the user's question is that the acetylation of S6K1 occurs in G2 phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 occurs in the G2 phase of the cell cycle.\n2. Acetylation of Cep76 also occurs in the G2 phase.\n3. Acetylation of Cep76 correlates with loss of protein function.\n4. Deregulation of centriole copy number is identified as a hallmark of cancer.\n5. Disruptions to the regulation of centriole amplification, such as acetylation of Cep76, may contribute to malignancy.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 occurs in the G2 phase of the cell cycle.",
      "Acetylation of Cep76 also occurs in the G2 phase.",
      "Acetylation of Cep76 correlates with loss of protein function.",
      "Deregulation of centriole copy number is identified as a hallmark of cancer.",
      "Disruptions to the regulation of centriole amplification, such as acetylation of Cep76, may contribute to malignancy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nNote: Statements 1, 2, and 3 need specific biological knowledge about S6K1 and Cep76, and how their acetylation affects their function during the cell cycle. As the provided context does not include detailed information about these statements, a true or false determination can't be accurately provided without additional data from reliable scientific sources.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is likely due to mutations in the KCNA1 gene, specifically in the voltage-gated potassium channel gene located on chromosome 12p. This conclusion is based on linkage studies in four families with the disorder, which suggested that the gene responsible for episodic ataxia type 6 is located near the KCNA1 gene. Additionally, mutation analysis of the KCNA1 coding region in these families identified four different missense point mutations present in the heterozygous state, further supporting the conclusion that mutations in this gene can cause episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is likely caused by mutations in the KCNA1 gene.\n2. The KCNA1 gene is located on chromosome 12p.\n3. Linkage studies in four families with episodic ataxia type 6 suggested the responsible gene is near the KCNA1 gene.\n4. Mutation analysis of the KCNA1 coding region in these families revealed four different missense point mutations.\n5. The identified mutations in the KCNA1 gene were present in the heterozygous state in those families studied for episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is likely caused by mutations in the KCNA1 gene.",
      "The KCNA1 gene is located on chromosome 12p.",
      "Linkage studies in four families with episodic ataxia type 6 suggested the responsible gene is near the KCNA1 gene.",
      "Mutation analysis of the KCNA1 coding region in these families revealed four different missense point mutations.",
      "The identified mutations in the KCNA1 gene were present in the heterozygous state in those families studied for episodic ataxia type 6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 is likely caused by mutations in the CACNA1A gene, not the KCNA1 gene which is associated with episodic ataxia type 1.\n2. FALSE [correction]: The KCNA1 gene is located on chromosome 12p13, not just on 12p.\n3. FALSE [correction]: In the context of episodic ataxia type 6, linkage studies would not be suggestive that the responsible gene is near the KCNA1 gene because KCNA1 gene is associated with episodic ataxia type 1.\n4. FALSE [correction]: Mutation analysis for episodic ataxia type 6 should not reveal different missense point mutations in the KCNA1 coding region if KCNA1 is not the gene associated with this type. Since episodic ataxia type 6 is linked to CACNA1A, any mutation analysis should be directed at that gene instead.\n5. UNKNOWN\n\nPlease note that the corrections are based on the association of different episodic ataxia types with specific genes to the best of the available knowledge at the time. Further research into these conditions could lead to new discoveries or revisions of current understanding.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, chromomethylases are present in animal genomes. The document mentions the differential expression of genes involved in cholesterol synthesis, including the FDFT1 gene, in response to different diets. Chromomethylases are enzymes that play a crucial role in the methylation of chromatin, which can affect gene expression. The fact that the expression of the FDFT1 gene is affected by different diets suggests that chromomethylases may also be involved in regulating gene expression in response to nutrient availability.\nIt is worth noting that the document does not provide direct evidence of the presence of chromomethylases in animal genomes. However, the study of gene expression in response to different diets suggests that chromomethylases may play a role in regulating metabolic pathways, including those involved in cholesterol synthesis. Further research would be needed to confirm the presence of chromomethylases in animal genomes and to fully understand their function in regulating gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that play a crucial role in the methylation of chromatin.\n2. The FDFT1 gene is involved in cholesterol synthesis.\n3. The expression of the FDFT1 gene can be affected by different diets.\n4. Chromomethylases might be involved in regulating gene expression in response to nutrient availability.\n5. The document referenced does not provide direct evidence of the presence of chromomethylases in animal genomes.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that play a crucial role in the methylation of chromatin.",
      "The FDFT1 gene is involved in cholesterol synthesis.",
      "The expression of the FDFT1 gene can be affected by different diets.",
      "Chromomethylases might be involved in regulating gene expression in response to nutrient availability.",
      "The document referenced does not provide direct evidence of the presence of chromomethylases in animal genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBS: This package provides a comprehensive set of tools for the analysis of TFBS, including the identification of TFBS, prediction of TFBS activity, and analysis of the flanking sequences.\n2. TRANSFAC: This package is a widely used tool for the prediction of TFBS and the analysis of their activity. It uses a database of known TFBS and their binding sites in the genome to predict the activity of new TFBS.\n3. CRITIC: This package provides a comprehensive set of tools for the analysis of TFBS, including the identification of TFBS, prediction of TFBS activity, and analysis of the flanking sequences. It also includes a database of known TFBS and their binding sites in the genome.\n4. TFSEARCH: This package provides a set of tools for the identification and analysis of TFBS in the genome. It includes a database of known TFBS and their binding sites, as well as tools for the prediction of TFBS activity and the analysis of the flanking sequences.\n5. EncodeTF: This package provides a set of tools for the analysis of TFBS in the context of the ENCODE project, which is a large-scale effort to map and characterize the epigenetic marks in the human genome. It includes tools for the identification and analysis of TFBS, as well as the prediction of TFBS activity and the analysis of the flanking sequences.\n6. HISAT2: This package is a tool for the analysis of ChIP-seq data, which can be used to identify TFBS in the genome. It includes tools for the peak calling, motif discovery, and the analysis of the flanking sequences.\n7. STAR: This package is another tool for the analysis of ChIP-seq data, which can be used to identify TFBS in the genome. It includes tools for the peak calling, motif discovery, and the analysis of the flanking sequences.\n8. Prodigal: This package provides a set of tools for the analysis of ChIP-seq data, including the identification of TFBS, prediction of TFBS activity, and",
    "llama-2-7b-chat-hf_fact_raw": "1. The package named \"TFBS\" is available in R/Bioconductor and offers tools for TFBS analysis, including identification and prediction of TFBS activity.\n2. \"TRANSFAC\" is a package in R/Bioconductor used for predicting TFBS and analyzing their activity using a database of known TFBS.\n3. The \"CRITIC\" package in R/Bioconductor provides tools for TFBS analysis and includes a database of known TFBS and their sites in the genome.\n4. \"TFSEARCH\" is an R/Bioconductor package that includes a database for identifying and analyzing TFBS in the genome.\n5. \"EncodeTF\" is a package for analyzing TFBS within the context of the ENCODE project, providing identification and analysis tools in R/Bioconductor.",
    "llama-2-7b-chat-hf_fact": [
      "The package named \"TFBS\" is available in R/Bioconductor and offers tools for TFBS analysis, including identification and prediction of TFBS activity.",
      "\"TRANSFAC\" is a package in R/Bioconductor used for predicting TFBS and analyzing their activity using a database of known TFBS.",
      "The \"CRITIC\" package in R/Bioconductor provides tools for TFBS analysis and includes a database of known TFBS and their sites in the genome.",
      "\"TFSEARCH\" is an R/Bioconductor package that includes a database for identifying and analyzing TFBS in the genome.",
      "\"EncodeTF\" is a package for analyzing TFBS within the context of the ENCODE project, providing identification and analysis tools in R/Bioconductor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - The \"TFBS\" package is indeed available in R/Bioconductor and provides tools for transcription factor binding site (TFBS) analysis.\n2. FALSE [correction]: \"TRANSFAC\" is not a package in R/Bioconductor but rather a database of transcription factor binding sites. However, there are R/Bioconductor packages like \"TFBSTools\" that can interface with TRANSFAC data.\n3. UNKNOWN - There is no R/Bioconductor package by the name of \"CRITIC\" widely recognized for TFBS analysis. It's possible that there might be a package with this name, but it's not a well-known resource in the community as of my knowledge cutoff date.\n4. FALSE [correction]: \"TFSEARCH\" does not refer to an R/Bioconductor package but is actually a web-based tool for predicting TFBS.\n5. UNKNOWN - As of my knowledge cutoff date, there is no R/Bioconductor package with the exact name \"EncodeTF\". However, the ENCODE project data is accessible through other packages in Bioconductor.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some clinical trials for the prevention of sarcopenia:\n1. The Sarcopenia Prevention Project (SPP): This study, conducted in Japan, aimed to evaluate the effectiveness of a multidimensional intervention program in preventing sarcopenia in community-dwelling older adults. The intervention included exercise training, nutritional counseling, and social support, and was found to be effective in reducing the risk of sarcopenia.\n2. The European Project on Sarcopenia Research (EPOSER): This study, conducted in Europe, investigated the effectiveness of a comprehensive intervention program that included exercise, nutrition, and social support in preventing sarcopenia in older adults. The study found that the intervention significantly reduced the risk of sarcopenia in the study population.\n3. The National Institute on Aging (NIA) Sarcopenia Prevention Trial (SPT): This study, conducted in the United States, evaluated the effectiveness of a multidimensional intervention program that included exercise, nutrition, and social support in preventing sarcopenia in older adults. The study found that the intervention significantly reduced the risk of sarcopenia in the study population.\n4. The Japanese Society of Sarcopenia Prevention (JSSP) Study: This study, conducted in Japan, investigated the effectiveness of a comprehensive intervention program that included exercise, nutrition, and social support in preventing sarcopenia in older adults. The study found that the intervention significantly reduced the risk of sarcopenia in the study population.\n5. The Sarcopenia Prevention and Management (SPM) Study: This study, conducted in the United States, evaluated the effectiveness of a multidimensional intervention program that included exercise, nutrition, and social support in preventing sarcopenia in older adults. The study found that the intervention significantly reduced the risk of sarcopenia in the study population.\nThese studies suggest that a comprehensive intervention program that includes exercise, nutrition, and social support may be effective in preventing sarcopenia in older adults. However, more research is needed to confirm these findings and to determine the optimal components and",
    "llama-2-7b-chat-hf_fact_raw": "1. The Sarcopenia Prevention Project (SPP) was conducted in Japan to evaluate the effectiveness of preventing sarcopenia with a program including exercise training, nutritional counseling, and social support.\n2. The European Project on Sarcopenia Research (EPOSER) investigated the effectiveness of a comprehensive program for sarcopenia prevention and found significant risk reduction in older adults.\n3. The National Institute on Aging (NIA) conducted the Sarcopenia Prevention Trial (SPT) in the United States, which evaluated a multidimensional intervention program for sarcopenia prevention.\n4. The Japanese Society of Sarcopenia Prevention (JSSP) Study was conducted in Japan focusing on exercise, nutrition, and social support to prevent sarcopenia in older adults.\n5. The Sarcopenia Prevention and Management (SPM) Study in the United States evaluated the effectiveness of a program with exercise, nutrition, and social support in preventing sarcopenia.",
    "llama-2-7b-chat-hf_fact": [
      "The Sarcopenia Prevention Project (SPP) was conducted in Japan to evaluate the effectiveness of preventing sarcopenia with a program including exercise training, nutritional counseling, and social support.",
      "The European Project on Sarcopenia Research (EPOSER) investigated the effectiveness of a comprehensive program for sarcopenia prevention and found significant risk reduction in older adults.",
      "The National Institute on Aging (NIA) conducted the Sarcopenia Prevention Trial (SPT) in the United States, which evaluated a multidimensional intervention program for sarcopenia prevention.",
      "The Japanese Society of Sarcopenia Prevention (JSSP) Study was conducted in Japan focusing on exercise, nutrition, and social support to prevent sarcopenia in older adults.",
      "The Sarcopenia Prevention and Management (SPM) Study in the United States evaluated the effectiveness of a program with exercise, nutrition, and social support in preventing sarcopenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe veracity of these statements cannot be determined without additional specific and reliable information about these projects and studies. The names of the projects do not correspond to well-known studies that can be easily verified, and no background context is provided to establish their existence or findings. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the database of molecular recognition features in membrane proteins is the universally conserved signal recognition particle (SRP) system. The SRP system is a multistep process controlled by GTP hydrolysis that mediates the targeting of membrane proteins to the translocon. The structure of the GTPase domains of the E. coli SRP protein (Ffh) and its receptor (FtsY) in complex with the tetraloop and the distal region of SRP-RNA is presented in the document, which reveals the atomic details of FtsY recruitment and the key RNA residue that stimulates GTP hydrolysis. The complete conservation of the key residues of the SRP-RNA and the SRP protein across all kingdoms implies that the suggested chemical mechanism of GTPase activation is applicable across all kingdoms. Therefore, the database of molecular recognition features in membrane proteins is the SRP system.",
    "llama-2-7b-chat-hf_fact_raw": "1. The signal recognition particle (SRP) system is a database of molecular recognition features in membrane proteins.\n2. The SRP system mediates the targeting of membrane proteins to the translocon through a multistep process controlled by GTP hydrolysis.\n3. The document presents the structure of the GTPase domains of the E. coli SRP protein (Ffh) and its receptor (FtsY) in complex with SRP-RNA.\n4. The key RNA residue that stimulates GTP hydrolysis is revealed in the document.\n5. The key residues of the SRP-RNA and the SRP protein are conserved across all kingdoms.",
    "llama-2-7b-chat-hf_fact": [
      "The signal recognition particle (SRP) system is a database of molecular recognition features in membrane proteins.",
      "The SRP system mediates the targeting of membrane proteins to the translocon through a multistep process controlled by GTP hydrolysis.",
      "The document presents the structure of the GTPase domains of the E. coli SRP protein (Ffh) and its receptor (FtsY) in complex with SRP-RNA.",
      "The key RNA residue that stimulates GTP hydrolysis is revealed in the document.",
      "The key residues of the SRP-RNA and the SRP protein are conserved across all kingdoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The signal recognition particle (SRP) system is not a database; it is a protein-RNA complex that recognizes and targets specific proteins to the endoplasmic reticulum in eukaryotes or the plasma membrane in prokaryotes.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE: The key components of the SRP-RNA and the SRP protein are indeed conserved across all kingdoms of life, reflecting their essential role in protein targeting to membranes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, rivaroxaban is metabolized in the kidneys. The document states that rivaroxaban has several characteristics that are more favorable than warfarin, including a decreased risk of hemorrhage. However, it also notes that one of the characteristics of rivaroxaban is that it is metabolized in the kidneys. This suggests that the drug is processed in the kidneys, which can affect its efficacy and potential side effects. Therefore, it is important for emergency medicine providers to be aware of this fact when treating patients taking rivaroxaban, particularly those with decreased renal function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys according to Document-0.\n2. Rivaroxaban has several characteristics that are more favorable than warfarin.\n3. One of the benefits of rivaroxaban over warfarin is a decreased risk of hemorrhage.\n4. The metabolism of rivaroxaban in the kidneys can affect its efficacy and potential side effects.\n5. Emergency medicine providers need to be aware of rivaroxaban's metabolism when treating patients with decreased renal function.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys according to Document-0.",
      "Rivaroxaban has several characteristics that are more favorable than warfarin.",
      "One of the benefits of rivaroxaban over warfarin is a decreased risk of hemorrhage.",
      "The metabolism of rivaroxaban in the kidneys can affect its efficacy and potential side effects.",
      "Emergency medicine providers need to be aware of rivaroxaban's metabolism when treating patients with decreased renal function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver, not the kidneys. Some of its elimination does occur through the kidneys, but that refers to excretion of the drug, not its metabolism.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genes that are regulated by TRalpha2 in the heart are:\n1. Hypertrophic/dilated cardiomyopathy-related genes: The document mentions that >95% of the hypertrophic/dilated cardiomyopathy-related genes that were significantly upregulated in the MHC-TRAF2(HC) hearts contained  elements in their promoters. However, the specific genes involved are not mentioned in the document.\n2. Matrix metalloproteinase (MMP) genes: The document mentions that there was a significant increase in total MMP activity in the early phases of left ventricular remodeling in the MHC-TRAF2(HC) mice, which corresponded with a decrease in total myocardial fibrillar collagen content. The specific MMP genes involved are not mentioned in the document.\n3. Tissue inhibitor of metalloproteinase-1 (TIMP-1) gene: The document mentions that there was an increase in myocardial TIMP-1 levels in the MHC-TRAF2(HC) mice as they aged, which may contribute to the decreased MMP activity.\n4. Nuclear factor-B (NF-B) activation: The document mentions that there was a significant increase in NF-B activation in the MHC-TRAF2(HC) mice, particularly at 4 to 12 weeks of age.\n5. Jun N-terminal kinases (JNK) activation: The document mentions that there was a significant increase in JNK activation in the MHC-TRAF2(HC) mice at 4 weeks of age.\nIt is important to note that these genes are regulated by TRalpha2 in the heart, but the exact mechanisms by which they are regulated and the specific genetic changes that occur in the MHC-TRAF2(HC) mice are not fully understood and require further investigation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over 95% of hypertrophic/dilated cardiomyopathy-related genes with significant upregulation in MHC-TRAF2(HC) hearts have  elements in their promoters.\n2. There was a significant increase in total Matrix metalloproteinase (MMP) activity in the early phases of left ventricular remodeling in MHC-TRAF2(HC) mice.\n3. Myocardial Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels increased in MHC-TRAF2(HC) mice as they aged.\n4. There was a significant increase in Nuclear factor-B (NF-B) activation in MHC-TRAF2(HC) mice, especially at 4 to 12 weeks of age.\n5. Jun N-terminal kinases (JNK) activation significantly increased in MHC-TRAF2(HC) mice at 4 weeks of age.",
    "llama-2-7b-chat-hf_fact": [
      "Over 95% of hypertrophic/dilated cardiomyopathy-related genes with significant upregulation in MHC-TRAF2(HC) hearts have  elements in their promoters.",
      "There was a significant increase in total Matrix metalloproteinase (MMP) activity in the early phases of left ventricular remodeling in MHC-TRAF2(HC) mice.",
      "Myocardial Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels increased in MHC-TRAF2(HC) mice as they aged.",
      "There was a significant increase in Nuclear factor-B (NF-B) activation in MHC-TRAF2(HC) mice, especially at 4 to 12 weeks of age.",
      "Jun N-terminal kinases (JNK) activation significantly increased in MHC-TRAF2(HC) mice at 4 weeks of age."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or source material these statements are referencing, I'm unable to verify their accuracy. These statements appear to be related to specialized scientific research findings, and as such would require access to the relevant study or publication to determine their truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some available biomedical question answering systems:\n1. Automated Information Retrieval System: This system uses natural language processing techniques to analyze questions posed by clinical users and identify the most relevant generic query. The system then selects an information source automatically, composes a retrieval strategy, and filters and sorts the results for presentation to the user.\n2. Medical Information Retrieval System: This system uses the National Library of Medicine's Unified Medical Language System (UMLS) to derive medical concepts from user-inputted questions and identify potentially relevant questions. The system then selects an information source automatically and composes a retrieval strategy to retrieve relevant information.\n3. Clinical Question Answering System: This system uses a combination of natural language processing techniques and the UMLS to analyze user-inputted questions and identify relevant medical concepts. The system then selects an information source automatically and composes a retrieval strategy to retrieve relevant information.\n4. Electronic Health Record (EHR) Question Answering System: This system uses natural language processing techniques to analyze questions posed by clinical users and identify relevant medical concepts. The system then retrieves information from the EHR database to answer the user's question.\n5. Decision Support System: This system uses natural language processing techniques to analyze user-inputted questions and identify relevant medical concepts. The system then retrieves information from a knowledge base to provide decision support to the user.\n6. Artificial Intelligence-based Question Answering System: This system uses machine learning algorithms to analyze user-inputted questions and identify relevant medical concepts. The system then retrieves information from a database to answer the user's question.\n7. Hybrid Question Answering System: This system combines natural language processing techniques with machine learning algorithms to analyze user-inputted questions and identify relevant medical concepts. The system then retrieves information from a database to answer the user's question.\nThese are some of the available biomedical question answering systems, and the specific system used may depend on the user's input and the specific medical concept being searched.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Automated Information Retrieval System uses natural language processing to analyze questions from clinical users.\n2. The Medical Information Retrieval System applies the National Library of Medicine's Unified Medical Language System to derive medical concepts from questions.\n3. The Clinical Question Answering System combines natural language processing and the UMLS to identify medical concepts in user questions.\n4. The Electronic Health Record (EHR) Question Answering System retrieves information from an EHR database to respond to clinical questions.\n5. The Decision Support System provides decision support by using natural language processing to analyze questions and retrieve information from a knowledge base.",
    "llama-2-7b-chat-hf_fact": [
      "The Automated Information Retrieval System uses natural language processing to analyze questions from clinical users.",
      "The Medical Information Retrieval System applies the National Library of Medicine's Unified Medical Language System to derive medical concepts from questions.",
      "The Clinical Question Answering System combines natural language processing and the UMLS to identify medical concepts in user questions.",
      "The Electronic Health Record (EHR) Question Answering System retrieves information from an EHR database to respond to clinical questions.",
      "The Decision Support System provides decision support by using natural language processing to analyze questions and retrieve information from a knowledge base."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided about various information retrieval systems involve specific details about technologies and their applications, which without additional context about the systems being discussed, cannot be verified as true or false. These are terms common in the field of healthcare informatics, and the technologies described could feasibly exist, but without specific context or source information, it is not possible to ascertain the accuracy of each statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the trancription factor that activates the betalain pathway is Fosl1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fosl1 is a transcription factor that activates the betalain pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Fosl1 is a transcription factor that activates the betalain pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fosl1 is not known to activate the betalain pathway. Instead, transcription factors involved in betalain biosynthesis may include MYB-type transcription factors, which are different from Fosl1. Fosl1 (also known as Fos-like antigen 1) is a member of the Fos family of transcription factors and is involved in various biological processes, but it is not specifically associated with the activation of the betalain pathway.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the preferred technologies for the enrichment of phosphorylated peptides are:\n1. Diamond-lanthanum oxide nanocomposites: These composites have been shown to have high selectivity and sensitivity for the capture of phosphorylated peptides, with a selectivity of 1:3000 and sensitivity down to 1 fmol.\n2. Diamond-samarium oxide nanocomposites: These composites have also been shown to be effective for the enrichment of phosphorylated peptides, with a selectivity of 1:1500 and sensitivity down to 20 fmol.\nBoth of these nanocomposites have been applied to selectively capture phosphorylated peptides from standard proteins, as well as non-fat milk digest and tryptic digest of HeLa cells extracted proteins. Additionally, they have been shown to capture endogenous serum phosphopeptides without any pre-treatment.\nTherefore, based on the information provided in the document, the preferred technologies for the enrichment of phosphorylated peptides are diamond-lanthanum oxide and diamond-samarium oxide nanocomposites.",
    "llama-2-7b-chat-hf_fact_raw": "1. Diamond-lanthanum oxide nanocomposites have a selectivity of 1:3000 for capturing phosphorylated peptides.\n2. Diamond-lanthanum oxide nanocomposites have a sensitivity for capturing phosphorylated peptides down to 1 fmol.\n3. Diamond-samarium oxide nanocomposites have a selectivity of 1:1500 for capturing phosphorylated peptides.\n4. Diamond-samarium oxide nanocomposites have a sensitivity for capturing phosphorylated peptides down to 20 fmol.\n5. Both diamond-lanthanum oxide and diamond-samarium oxide nanocomposites have been used to capture endogenous serum phosphopeptides without any pre-treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Diamond-lanthanum oxide nanocomposites have a selectivity of 1:3000 for capturing phosphorylated peptides.",
      "Diamond-lanthanum oxide nanocomposites have a sensitivity for capturing phosphorylated peptides down to 1 fmol.",
      "Diamond-samarium oxide nanocomposites have a selectivity of 1:1500 for capturing phosphorylated peptides.",
      "Diamond-samarium oxide nanocomposites have a sensitivity for capturing phosphorylated peptides down to 20 fmol.",
      "Both diamond-lanthanum oxide and diamond-samarium oxide nanocomposites have been used to capture endogenous serum phosphopeptides without any pre-treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and technical; without the appropriate scientific context or references, I am unable to verify the accuracy of these statements about the selectivity and sensitivity of diamond-lanthanum oxide and diamond-samarium oxide nanocomposites for capturing phosphorylated peptides. Additionally, the use of these nanocomposites in capturing endogenous serum phosphopeptides without any pre-treatment is outside the scope of general knowledge and requires specialized expertise or access to specific scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorder that is rated by the Palmini classification is Asphyxiating Thoracic Dysplasia (ATD).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that viruses are involved in the etiology of human subacute thyroiditis. The document states that subacute thyroiditis is considered to be a viral disease, and the data collected on 3,344 patients with the condition showed that 48 of them experienced a recurrence of the disease an average of 14.5 years after the first episode. Additionally, the mean age of the patients at the first, second, and third episode was 38.4, 53.1, and 57.8 years old, respectively, indicating that the disease can occur at different ages and in different populations.\nTherefore, based on the information provided in the document, it can be concluded that viruses are involved in the etiology of human subacute thyroiditis, and the disease can recur in some patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses are implicated in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is considered to be a viral disease.\n3. Out of 3,344 patients with subacute thyroiditis, 48 experienced a recurrence of the disease.\n4. The average time between the first episode and recurrence of subacute thyroiditis was 14.5 years.\n5. The mean ages of patients at the first, second, and third episodes of subacute thyroiditis were 38.4, 53.1, and 57.8 years old, respectively.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses are implicated in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is considered to be a viral disease.",
      "Out of 3,344 patients with subacute thyroiditis, 48 experienced a recurrence of the disease.",
      "The average time between the first episode and recurrence of subacute thyroiditis was 14.5 years.",
      "The mean ages of patients at the first, second, and third episodes of subacute thyroiditis were 38.4, 53.1, and 57.8 years old, respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Viruses are indeed implicated in the etiology of subacute thyroiditis, often suggested as a trigger for the condition.\n2. TRUE: Subacute thyroiditis is generally considered to be associated with a viral infection or a post-viral inflammatory process.\n3. UNKNOWN: Without the specific context or study reference, it's not possible to validate the number of patients who experienced a recurrence of subacute thyroiditis.\n4. UNKNOWN: Similar to statement 3, the average time between episodes would require specific study data for verification.\n5. UNKNOWN: The mean ages at different episodes of subacute thyroiditis would also require specific data from a study or clinical finding for verification.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that STAT3 is not directly involved in the suppression of autophagy by EIF2AK2. The study focuses on the effects of 3-methyladenine (3-MA) and wortmannin, two inhibitors of class III phosphatidylinositol 3-kinase (PI3K), on autophagy. The authors found that 3-MA can promote autophagy under nutrient-rich conditions with prolonged treatment, whereas it still suppresses starvation-induced autophagy. The study suggests that the autophagy promotion activity of 3-MA is due to its differential temporal effects on class I and class III PI3K, with persistent blockade of class I PI3K and transient suppression of class III PI3K.\nThere is no direct mention of STAT3 in the study, and the authors do not discuss the potential involvement of STAT3 in the regulation of autophagy. Therefore, based on the information provided in Document-0, it can be concluded that STAT3 is not directly involved in the suppression of autophagy by EIF2AK2.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is not directly involved in the suppression of autophagy by EIF2AK2 according to Document-0.\n2. The study mentioned in the answer discusses the effects of 3-methyladenine (3-MA) and wortmannin on autophagy.\n3. 3-methyladenine (3-MA) can promote autophagy under nutrient-rich conditions with prolonged treatment.\n4. 3-methyladenine (3-MA) suppresses starvation-induced autophagy.\n5. The autophagy promotion activity of 3-MA is suggested to be due to its differential temporal effects on class I and class III PI3K.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is not directly involved in the suppression of autophagy by EIF2AK2 according to Document-0.",
      "The study mentioned in the answer discusses the effects of 3-methyladenine (3-MA) and wortmannin on autophagy.",
      "3-methyladenine (3-MA) can promote autophagy under nutrient-rich conditions with prolonged treatment.",
      "3-methyladenine (3-MA) suppresses starvation-induced autophagy.",
      "The autophagy promotion activity of 3-MA is suggested to be due to its differential temporal effects on class I and class III PI3K."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (As I don't have access to \"Document-0,\" I cannot verify the role of STAT3 in relation to EIF2AK2 and autophagy suppression.)\n2. UNKNOWN (Without access to the specific study, I cannot confirm whether it discusses the effects of 3-MA and wortmannin on autophagy.)\n3. FALSE [correction]: 3-methyladenine is generally known to suppress autophagy, not promote it, particularly under nutrient-rich conditions.\n4. TRUE (3-methyladenine is commonly used to inhibit autophagy, including starvation-induced autophagy.)\n5. UNKNOWN (Without specific study details, it's unclear whether the promotion activity of 3-MA is due to its effects on class I and class III PI3K, although 3-MA is known to inhibit class III PI3K, which is involved in autophagy.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "The Theatre software tool is a flexible computational platform designed for the analysis and manipulation of high-throughput sequencing data, such as DNA-seq, RNA-seq, ChIP-seq, and MethylC-seq. The tool is capable of performing a variety of mathematical operations between sets of genomic regions, enabling the prototyping of computational pipelines that can address a wide spectrum of tasks, including pre-processing and quality control, as well as meta-analyses.\nOne of the key features of Theatre is its ability to analyze large datasets of any size while minimizing memory requirements. This makes it particularly useful for analyzing the large volumes of sequencing data generated by modern high-throughput sequencing technologies. In practical applications, Theatre has been shown to outperform existing tools in terms of both time and memory usage.\nTheatre is available in version 2.0.0, which was implemented in C++. The tool is distributed as an open-source platform, with the source code, documentation, user manual, example datasets, and scripts available online at <http://code.google.com/p/ibm-cbc-genomic-tools>.\nIn summary, Theatre is a powerful and flexible software tool for genomic analysis, designed to efficiently manage computational resources and analyze large datasets of any size. Its ability to perform mathematical operations between sets of genomic regions makes it a valuable tool for prototyping computational pipelines that can address a wide range of tasks in genomics research.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Theatre software tool is designed for the analysis and manipulation of high-throughput sequencing data.\n2. It can perform various mathematical operations between sets of genomic regions.\n3. Theatre is capable of analyzing large datasets while minimizing memory requirements.\n4. Theatre has been shown to outperform other tools in terms of time and memory usage.\n5. Theatre version 2.0.0 was implemented in C++ and is available as open-source.",
    "llama-2-7b-chat-hf_fact": [
      "The Theatre software tool is designed for the analysis and manipulation of high-throughput sequencing data.",
      "It can perform various mathematical operations between sets of genomic regions.",
      "Theatre is capable of analyzing large datasets while minimizing memory requirements.",
      "Theatre has been shown to outperform other tools in terms of time and memory usage.",
      "Theatre version 2.0.0 was implemented in C++ and is available as open-source."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct name of the software is \"BEDTools,\" not \"Theatre.\"\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the first statement had a major error regarding the name of the software, the response assumes the statements refer to \"BEDTools,\" which is indeed a software tool for the analysis and manipulation of high-throughput sequencing data that is implemented in C++ and available as open-source. However, due to the lack of provided context and specific performance comparisons, statements 4 and 5 cannot be verified as true or false without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is quadratic, running in time proportional to the product of the lengths of the sequences being aligned.",
    "llama-2-7b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm is quadratic.\n2. The Smith-Waterman algorithm runs in time proportional to the product of the lengths of the two sequences being aligned.",
    "llama-2-7b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm is quadratic.",
      "The Smith-Waterman algorithm runs in time proportional to the product of the lengths of the two sequences being aligned."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, FLVCR1 is a member of the SLC22A family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC22A family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC22A family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC22A family; it is part of the major facilitator superfamily (MFS) of transporters.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the interacting partners of GATA-1 that have been identified using the in vivo biotinylation tagging approach are:\n1. TLX1: GATA-1 has been shown to interact with TLX1, a homeodomain transcription factor with leukemogenic function, using the in vivo biotinylation tagging approach.\nThe modified technique utilizes two components: a lentiviral vector coexpressing the gene of interest containing a biotinylation tag on a bicistronic transcript together with a downstream yellow fluorescent protein (YFP) gene; and a second lentiviral vector encoding a fusion protein composed of bacterial BirA linked to the green fluorescent protein (GFP). This FACS-based binary in vivo biotinylation tagging system allows precise control over the levels of BirA-mediated biotinylation as well as the expression of the gene of interest, which is especially important if high-level expression negatively impacts cell growth or viability.\nTherefore, the interacting partners of GATA-1 identified using this approach are TLX1 and potentially other proteins that are co-expressed with the gene of interest and the BirA gene in the same cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with TLX1, a homeodomain transcription factor.\n2. TLX1 has leukemogenic function.\n3. The in vivo biotinylation tagging approach includes a lentiviral vector coexpressing a biotinylated gene of interest and a yellow fluorescent protein (YFP) gene.\n4. A second lentiviral vector used in the method encodes a fusion protein of bacterial BirA and green fluorescent protein (GFP).\n5. The biotinylation tagging system facilitates precise control over BirA-mediated biotinylation and the expression of the gene of interest.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with TLX1, a homeodomain transcription factor.",
      "TLX1 has leukemogenic function.",
      "The in vivo biotinylation tagging approach includes a lentiviral vector coexpressing a biotinylated gene of interest and a yellow fluorescent protein (YFP) gene.",
      "A second lentiviral vector used in the method encodes a fusion protein of bacterial BirA and green fluorescent protein (GFP).",
      "The biotinylation tagging system facilitates precise control over BirA-mediated biotinylation and the expression of the gene of interest."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GATA-1 is known to interact with various transcription factors, and while specific interactions can be context-dependent, stating that GATA-1 interacts with TLX1, a homeodomain transcription factor, is plausible given the roles of these proteins in hematopoiesis and their potential involvement in leukemogenic processes.\n2. TRUE: TLX1 (also known as HOX11) is indeed associated with leukemogenesis, particularly in T-cell acute lymphoblastic leukemia.\n3. TRUE: The in vivo biotinylation tagging approach does involve the use of a lentiviral vector for coexpression of a biotinylated gene of interest along with a reporter such as YFP for the identification and tracking of successfully transduced cells.\n4. UNKNOWN: Without more specific information, it cannot be determined whether the second lentiviral vector indeed encodes a fusion protein of bacterial BirA and GFP. This detail may vary depending on the specific experimental design.\n5. TRUE: The biotinylation tagging system is designed to allow for tight regulation of biotinylation through BirA, which can be directed to the biotinylated protein, allowing for controlled biotinylation of the gene of interest. This regulation enables precise control over both the biotinylation process and the expression levels of the targeted protein.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, TAF10 interacting with the GATA1 transcription factor likely leads to the regulation of gene expression, specifically in the context of transcriptional regulation. The document describes the identification of nine specific yeast TBP-associated factors (TAFs), including Taf170, which is encoded by the essential yeast gene MOT1. The authors demonstrate that Taf170 forms a separate complex with TBP distinct from the RNA polymerase II-specific multisubunit transcription factor IID TBP-TAF complex, suggesting that TAF10 may play a role in regulating gene expression through its interaction with TBP. The significance of this unique TBP-Taf170 complex regarding transcriptional regulation is discussed in the document. Therefore, it can be inferred that TAF10 interacting with GATA1 may have a similar function in regulating gene expression, although more research is needed to confirm this hypothesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interaction with the GATA1 transcription factor is believed to be involved in the regulation of gene expression.\n2. The document mentions the identification of nine specific yeast TBP-associated factors (TAFs).\n3. Taf170, encoded by the essential yeast gene MOT1, forms a separate complex with TBP distinct from the RNA polymerase II-specific multisubunit transcription factor IID TBP-TAF complex.\n4. The unique TBP-Taf170 complex plays a role in transcriptional regulation according to the document.\n5. More research is needed to confirm the hypothesis regarding TAF10's specific function in regulating gene expression through its interaction with GATA1.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interaction with the GATA1 transcription factor is believed to be involved in the regulation of gene expression.",
      "The document mentions the identification of nine specific yeast TBP-associated factors (TAFs).",
      "Taf170, encoded by the essential yeast gene MOT1, forms a separate complex with TBP distinct from the RNA polymerase II-specific multisubunit transcription factor IID TBP-TAF complex.",
      "The unique TBP-Taf170 complex plays a role in transcriptional regulation according to the document.",
      "More research is needed to confirm the hypothesis regarding TAF10's specific function in regulating gene expression through its interaction with GATA1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional information from the specific document mentioning these scientific findings, it is not possible to determine the veracity of these statements. Each statement pertains to specialized knowledge in molecular biology, and without access to the original context, one cannot accurately confirm or correct them.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems available for chronic pain management. The study you provided highlights the development of a computer-based system called Pain Audit Collection System (PACS) designed by pain clinicians to monitor performance and evaluate outcomes in pain clinics. While the study focuses on the success of PACS in uptake and data analysis, it suggests that there are decision support systems available to help clinicians manage complex interventions and fulfill clinical governance requirements.\nPACS is a well-developed system that has been designed to monitor performance and evaluate outcomes in pain clinics. By using PACS, clinicians can track patient data, including demographics, medical history, and treatment outcomes, to identify areas of improvement and optimize care. The system also allows clinicians to compare their performance with national standards and benchmarks, providing valuable insights into the effectiveness of their treatment strategies.\nIn addition to PACS, there are other decision support systems available for chronic pain management. These systems may include:\n1. Clinical Practice Guidelines (CPGs): These guidelines provide evidence-based recommendations for the diagnosis, assessment, and management of chronic pain. CPGs can help clinicians make informed decisions about treatment options and improve patient outcomes.\n2. Pain Management Algorithms: These algorithms provide a step-by-step approach to managing chronic pain, including assessment, diagnosis, and treatment. Algorithms can help clinicians identify the underlying causes of pain and develop personalized treatment plans.\n3. Electronic Health Records (EHRs): EHRs contain a patient's medical history, treatment plans, and outcomes. By analyzing EHRs, clinicians can identify patterns and trends in patient data, which can inform treatment decisions and improve patient outcomes.\n4. Telemedicine and Remote Monitoring: Telemedicine and remote monitoring technologies allow clinicians to remotely assess and manage patients with chronic pain. These technologies can improve access to care, reduce healthcare costs, and enhance patient engagement.\nIn conclusion, decision support systems like PACS, CPGs, pain management algorithms, EHRs, and telemedicine can help clinicians manage chronic pain more effectively. By leveraging these systems, clin",
    "llama-2-7b-chat-hf_fact_raw": "1. Pain Audit Collection System (PACS) is a computer-based decision support system designed for chronic pain management.\n2. PACS is used to monitor performance and evaluate outcomes in pain clinics.\n3. Clinical Practice Guidelines (CPGs) provide evidence-based recommendations for the diagnosis, assessment, and management of chronic pain.\n4. Pain Management Algorithms offer a sequential approach to assess, diagnose, and treat chronic pain.\n5. Electronic Health Records (EHRs) contain medical history, treatment plans, and outcomes that can be analyzed to improve patient care in chronic pain management.",
    "llama-2-7b-chat-hf_fact": [
      "Pain Audit Collection System (PACS) is a computer-based decision support system designed for chronic pain management.",
      "PACS is used to monitor performance and evaluate outcomes in pain clinics.",
      "Clinical Practice Guidelines (CPGs) provide evidence-based recommendations for the diagnosis, assessment, and management of chronic pain.",
      "Pain Management Algorithms offer a sequential approach to assess, diagnose, and treat chronic pain.",
      "Electronic Health Records (EHRs) contain medical history, treatment plans, and outcomes that can be analyzed to improve patient care in chronic pain management."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Picture Archiving and Communication System (PACS) is not designed for chronic pain management; it is a medical imaging technology used primarily for securely storing, digitally transmitting, and displaying images and reports.\n2. FALSE [correction]: While PACS is not designed specifically for monitoring performance and evaluating outcomes in pain clinics (its primary use is for storing and accessing medical imaging), a system designed for chronic pain management, such as an Electronic Health Record or a specific pain management system, could serve this function.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the subcellular localization of the protein angiogenin is predicted to be Gram-positive.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ranolazine affects kinase signaling activation in the heart by interacting with the open state and stabilizing the inactivated state of Na(v)1.4 channels. The drug exerts a use-dependent block of these channels, which leads to a reduction in the voltage-dependent block of I(Na) and a suppression of persistent I(Na). This, in turn, can help reduce the sustained action potential firing seen in paramyotonia congenita.\nThe document suggests that ranolazine interacts with the open state of Na(v)1.4 channels and causes a hyperpolarizing shift in the voltage-dependence of inactivation. This suggests that the drug may be useful in reducing the abnormal I(Na) induced by slow voltage ramps, which are characteristic of myotonia.\nIn computer simulations, 3  ranolazine was shown to inhibit the sustained and excessive firing of skeletal muscle action potentials, which are characteristic of paramyotonia congenita. These simulations suggest that ranolazine may be useful in reducing the sustained action potential firing seen in this condition.\nOverall, the information provided in the document suggests that ranolazine affects kinase signaling activation in the heart by interacting with the open state and stabilizing the inactivated state of Na(v)1.4 channels, leading to a reduction in the voltage-dependent block of I(Na) and a suppression of persistent I(Na). This may be useful in reducing the sustained action potential firing seen in paramyotonia congenita.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine interacts with the open state and stabilizes the inactivated state of Na(v)1.4 channels.\n2. The drug ranolazine exerts a use-dependent block of Na(v)1.4 channels.\n3. Ranolazine can lead to a reduction in the voltage-dependent block of I(Na) and a suppression of persistent I(Na).\n4. Ranolazine produces a hyperpolarizing shift in the voltage-dependence of inactivation of Na(v)1.4 channels.\n5. In computer simulations, 3 M ranolazine was shown to inhibit the sustained and excessive firing of skeletal muscle action potentials characteristic of paramyotonia congenita.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine interacts with the open state and stabilizes the inactivated state of Na(v)1.4 channels.",
      "The drug ranolazine exerts a use-dependent block of Na(v)1.4 channels.",
      "Ranolazine can lead to a reduction in the voltage-dependent block of I(Na) and a suppression of persistent I(Na).",
      "Ranolazine produces a hyperpolarizing shift in the voltage-dependence of inactivation of Na(v)1.4 channels.",
      "In computer simulations, 3 M ranolazine was shown to inhibit the sustained and excessive firing of skeletal muscle action potentials characteristic of paramyotonia congenita."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific context or references, it's difficult to confirm or deny the statement about the interaction of ranolazine with Na(v)1.4 channels.\n2. UNKNOWN: Again, without specific data or study results, the use-dependent block of Na(v)1.4 channels by ranolazine cannot be confirmed or refuted.\n3. UNKNOWN: The effect of ranolazine on voltage-dependent block of I(Na) and the suppression of persistent I(Na) requires specific biomedical knowledge or source material to validate.\n4. UNKNOWN: The statement regarding the hyperpolarizing shift in the voltage-dependence of inactivation of Na(v)1.4 channels needs specific research information to determine its accuracy.\n5. UNKNOWN: Computer simulations can have varied outcomes based on the parameters and models used, therefore without the exact simulation study or results, the statement's validity cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the regulation of Vsr endonuclease appears to be independent of the growth phase of bacteria. The study focuses on the mechanism of the Escherichia coli DNA T:G mismatch endonuclease (Vsr) and its interaction with oligodeoxynucleotides, without any mention of growth phase. The document provides detailed information on the binding and kinetic data of Vsr with phosphorothioates and phosphorothiolate, as well as the stereochemical analysis of the enzyme-substrate complex. However, there is no information provided in the document that suggests the regulation of Vsr is dependent on the growth phase of bacteria. Therefore, based on the information provided in Document-0, the answer to the user's question is \"No, the regulation of Vsr endonuclease is independent of the growth phase of bacteria.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease is a DNA T:G mismatch endonuclease found in Escherichia coli.\n2. The regulation of Vsr endonuclease is independent of the growth phase of bacteria according to Document-0.\n3. Document-0 provides detailed information on the binding and kinetic data of Vsr with phosphorothioates and phosphorothiolate.\n4. Document-0 includes a stereochemical analysis of the enzyme-substrate complex of Vsr endonuclease.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease is a DNA T:G mismatch endonuclease found in Escherichia coli.",
      "The regulation of Vsr endonuclease is independent of the growth phase of bacteria according to Document-0.",
      "Document-0 provides detailed information on the binding and kinetic data of Vsr with phosphorothioates and phosphorothiolate.",
      "Document-0 includes a stereochemical analysis of the enzyme-substrate complex of Vsr endonuclease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN [without access to the specific content of \"Document-0,\" we cannot verify the statement regarding the regulation of Vsr endonuclease]\n3. UNKNOWN [similarly, without the specific content of \"Document-0,\" we cannot confirm the details provided about Vsr endonuclease and its interactions with phosphorothioates and phosphorothiolate]\n4. UNKNOWN [without access to \"Document-0,\" the presence or absence of a stereochemical analysis of the enzyme-substrate complex cannot be determined]",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several computational tools available for the prediction of beta-barrel transmembrane proteins:\n1. PROFtmb: As mentioned in the passage, PROFtmb is a profile-based Hidden Markov Model (HMM) that predicts transmembrane beta-barrel proteins in Gram-negative bacteria. It provides both a Z-value indicating the presence of a membrane barrel and a four-state per-residue labeling of upward- and downward-facing strands, periplasmic hairpins, and extracellular loops. PROFtmb is available freely and without registration at <http://rostlab.org/services/proftmb>.\n2. HMMER: HMMER is a suite of tools for protein sequence analysis that can be used for the prediction of transmembrane beta-barrel proteins. It uses HMMs to model the structure of TMBs and can be trained on a dataset of known TMBs. HMMER can be used to predict the presence of TMBs in a query protein or to identify potential TMBs in a protein database.\n3. TMHMM: TMHMM is a tool for the prediction of transmembrane domains in proteins. It uses a combination of sequence analysis and structural information to predict the presence of TMBs. TMHMM can be used to predict the presence of TMBs in a query protein or to identify potential TMBs in a protein database.\n4. I-TASSER: I-TASSER is a tool for protein structure prediction and function annotation. It can be used to predict the structure of TMBs in a query protein and to identify potential TMBs in a protein database. I-TASSER uses a combination of sequence analysis and structural information to make its predictions.\nOverall, these tools can be useful for predicting the presence of beta-barrel transmembrane proteins in a query protein or for identifying potential TMBs in a protein database. However, it is important to note that the accuracy of these tools can vary depending on the quality of the training data and the complexity of the protein structure being predicted.",
    "llama-2-7b-chat-hf_fact_raw": "1. PROFtmb is a profile-based Hidden Markov Model that predicts transmembrane beta-barrel proteins in Gram-negative bacteria.\n2. PROFtmb provides a per-residue labeling of upward- and downward-facing strands, periplasmic hairpins, and extracellular loops.\n3. HMMER is a computational tool suite for protein sequence analysis that can be applied to predict transmembrane beta-barrel proteins.\n4. TMHMM is a prediction tool for transmembrane domains in proteins, which includes the ability to predict the presence of transmembrane beta-barrel proteins.\n5. I-TASSER is a tool for protein structure prediction and function annotation that can predict the structure of transmembrane beta-barrel proteins.",
    "llama-2-7b-chat-hf_fact": [
      "PROFtmb is a profile-based Hidden Markov Model that predicts transmembrane beta-barrel proteins in Gram-negative bacteria.",
      "PROFtmb provides a per-residue labeling of upward- and downward-facing strands, periplasmic hairpins, and extracellular loops.",
      "HMMER is a computational tool suite for protein sequence analysis that can be applied to predict transmembrane beta-barrel proteins.",
      "TMHMM is a prediction tool for transmembrane domains in proteins, which includes the ability to predict the presence of transmembrane beta-barrel proteins.",
      "I-TASSER is a tool for protein structure prediction and function annotation that can predict the structure of transmembrane beta-barrel proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - HMMER is a software suite for sequence analysis, and while it is not specifically designed for beta-barrel prediction, it has been utilized in methods for predicting transmembrane proteins, including beta-barrels.\n4. FALSE [correction]: TMHMM is a prediction tool for alpha-helical transmembrane domains in proteins, not for transmembrane beta-barrel proteins.\n5. TRUE - I-TASSER can be used for modeling the three-dimensional structure of proteins, including transmembrane beta-barrel proteins, although it's known more for general protein structure prediction rather than that specific family of proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Galassi classification is used for the disorder of mental illness. The document suggests that current classifications of mental disorders contain excessively large numbers of categories of limited validity, and that psychiatric research should discard the assumption that current classification is valid. Instead, studies of unselected groups assessed with bottom-up approaches are needed to advance psychiatry. Therefore, Galassi classification is used for the disorder of mental illness, as it is a bottom-up approach that evaluates the validity of diagnostic categories based on research.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some common features of Shapiro syndrome:\n1. Broad thumbs and toes: Shapiro syndrome is characterized by broad thumbs and toes, which are typically present from birth.\n2. Facial abnormalities: The syndrome is also associated with facial abnormalities, such as a flat nasal bridge, narrow eyes, and a small jaw.\n3. Mental retardation: Shapiro syndrome is often accompanied by mental retardation, which can range from mild to severe.\n4. Chromosomal anomalies: Some patients with Shapiro syndrome have been found to have chromosomal anomalies, including 18 different chromosomal abnormalities.\n5. Inheritance pattern: The inheritance pattern of Shapiro syndrome is not well understood, and it is not clear whether it is an autosomal dominant, autosomal recessive, or X-linked disorder.\n6. Recurrence: The disorder is not rare and is present in about 1:600 patients in mental retardation clinics, but recurrence is very unlikely.\nIt is important to note that Shapiro syndrome is a rare genetic disorder, and the features and severity of the disorder can vary widely between individuals. A thorough medical evaluation and genetic testing can help confirm the diagnosis and identify the underlying genetic cause of the disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by broad thumbs and toes from birth.\n2. Facial abnormalities, such as a flat nasal bridge, narrow eyes, and a small jaw, are associated with Shapiro syndrome.\n3. Shapiro syndrome often includes mental retardation, which can range from mild to severe.\n4. Patients with Shapiro syndrome may have chromosomal anomalies, including up to 18 different chromosomal abnormalities.\n5. The disorder is present in approximately 1 out of 600 patients in mental retardation clinics.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by broad thumbs and toes from birth.",
      "Facial abnormalities, such as a flat nasal bridge, narrow eyes, and a small jaw, are associated with Shapiro syndrome.",
      "Shapiro syndrome often includes mental retardation, which can range from mild to severe.",
      "Patients with Shapiro syndrome may have chromosomal anomalies, including up to 18 different chromosomal abnormalities.",
      "The disorder is present in approximately 1 out of 600 patients in mental retardation clinics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the presence of recurrent episodes of hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not broad thumbs and toes from birth.\n2. FALSE [correction]: The facial abnormalities mentioned are not typically associated with Shapiro syndrome, but might be indicative of other genetic conditions.\n3. FALSE [correction]: While some patients with Shapiro syndrome may have developmental delays or neurological symptoms, mental retardation is not a defining feature of the condition.\n4. FALSE [correction]: Shapiro syndrome is not typically associated with chromosomal anomalies; it is defined by the triad of symptoms mentioned earlier (hypothermia, hyperhidrosis, and agenesis of the corpus callosum), and its genetic basis is less understood.\n5. FALSE [correction]: There is no widely recognized prevalence of Shapiro syndrome in mental retardation clinics, and the condition is considered rare.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disease that is linked to mutations within BRAG1 is thyroid papillary cancer (PTC). The document states that a somatic mutation of BRAF, V599E, is the most common genetic change in PTCs, and that this mutation is unique to PTCs and not found in other types of differentiated follicular neoplasms arising from the same cell type. Additionally, the document notes that there is no overlap between PTCs with RET/PTC, BRAF, or RAS mutations, which suggests that BRAG1 mutations are specifically associated with PTCs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within BRAG1 are linked to thyroid papillary cancer (PTC).\n2. The somatic mutation of BRAF, V599E, is the most common genetic change in PTCs.\n3. The V599E mutation is unique to PTCs and not found in other types of differentiated follicular neoplasms.\n4. There is no overlap between PTCs with RET/PTC, BRAF, or RAS mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within BRAG1 are linked to thyroid papillary cancer (PTC).",
      "The somatic mutation of BRAF, V599E, is the most common genetic change in PTCs.",
      "The V599E mutation is unique to PTCs and not found in other types of differentiated follicular neoplasms.",
      "There is no overlap between PTCs with RET/PTC, BRAF, or RAS mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within BRAF, not BRAG1, are linked to thyroid papillary cancer (PTC).\n2. TRUE\n3. FALSE [correction]: The V600E (previously referred to as V599E due to a historical numbering scheme) mutation in BRAF is not unique to PTCs and can also be found in other tumors, including melanoma and colorectal cancer. Additionally, while V600E mutations are common in PTCs, they can also occasionally be found in other types of differentiated thyroid neoplasms.\n4. FALSE [correction]: There can be overlap between PTCs with RET/PTC, BRAF, and RAS mutations, although they are often mutually exclusive. Some tumors may show concomitant mutations, especially in advanced cases, but this is relatively uncommon.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-3 (I3). The document shows that I3 is a potent inhibitor of PP1, and it cannot be replaced in the complex with another PP1 interactor with the same PP1 binding motif. Additionally, the document states that Sds22 and I3 form a heterotrimeric complex with PP1, and that the stability of the complex depends on functional PP1 interaction sites in Sds22 and I3. These findings suggest that I3 is the main inhibitor of PP1 in the complex formed with Sds22.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-3 (I3) is the main inhibitor of protein phosphatase 1 (PP1).\n2. I3 is a potent inhibitor of PP1 and cannot be replaced with another PP1 interactor that has the same PP1 binding motif.\n3. Sds22 and I3 form a heterotrimeric complex with PP1.\n4. The stability of the complex involving Sds22, I3, and PP1 depends on functional PP1 interaction sites in Sds22 and I3.",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-3 (I3) is the main inhibitor of protein phosphatase 1 (PP1).",
      "I3 is a potent inhibitor of PP1 and cannot be replaced with another PP1 interactor that has the same PP1 binding motif.",
      "Sds22 and I3 form a heterotrimeric complex with PP1.",
      "The stability of the complex involving Sds22, I3, and PP1 depends on functional PP1 interaction sites in Sds22 and I3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The main regulatory subunit of protein phosphatase 1 (PP1) is not known as Inhibitor-3 (I3), and the actual main inhibitors of PP1 could be different proteins or molecules depending on the context.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nGiven the specificity of the context in these statements, without additional information on the role of a molecule named Inhibitor-3 (I3) in regulating PP1, or specific research findings on the interactions between Sds22, I3, and PP1, definitive evaluations of the statements cannot be made. Therefore, only the first statement can be confidently corrected assuming I3 is not the widely accepted main inhibitor of PP1 and the rest are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. Stationary-phase induction of antimutagenic compounds: The document shows that the bacterial supernatants from exponential and stationary phases of selected strains of Lactobacillus and Bifidobacterium exhibit different patterns of antimutagenic activity against the mutagens benzo[a]pyrene (BaP) and sodium azide (SA). The higher antimutagenic activities of lactobacilli supernatants were observed in the stationary phase against SA, indicating that stationary-phase induction may play a role in the production of antimutagenic compounds.\n2. Growth phase-dependent expression of antimutagenic genes: The document shows that the expression of antimutagenic genes is growth phase-dependent, with some strains exhibiting higher antimutagenic activity in the stationary phase than in the exponential phase. This suggests that the expression of antimutagenic genes may be regulated by the growth phase of the bacteria.\n3. Type-specific antimutagenic responses: The document shows that different bacterial strains exhibit different antimutagenic responses to the same mutagen. For example, B. breve ATCC 15700 expressed a high antimutagenic effect against SA in the stationary phase, while Bifidobacterium adoleascentis ATCC 15703 exhibited higher antimutagenecity against BaP in the exponential phase. This suggests that the antimutagenic responses of bacteria may be strain-specific.\nOverall, the mechanisms that underlie adaptive mutagenesis in Bacillus subtilis involve the induction of antimutagenic compounds during the stationary phase of growth, growth phase-dependent expression of antimutagenic genes, and strain-specific antimutagenic responses.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the cause of erucism is likely a de novo mutation in the KRT10 gene. The mutation, specifically a heterozygous missense mutation 482T>G in the first exon of the KRT10 gene, leads to a p.L161W alteration in the protein product of the gene. This mutation is likely the underlying cause of the disease in the child.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by a de novo mutation in the KRT10 gene.\n2. The specific mutation causing erucism is a heterozygous missense mutation 482T>G in the first exon of the KRT10 gene.\n3. This mutation leads to a p.L161W alteration in the protein product of the gene.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by a de novo mutation in the KRT10 gene.",
      "The specific mutation causing erucism is a heterozygous missense mutation 482T>G in the first exon of the KRT10 gene.",
      "This mutation leads to a p.L161W alteration in the protein product of the gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide are:\n1. Treatment of hypertension: Hydrochlorothiazide is a thiazide diuretic that is used to treat hypertension (high blood pressure).\n2. Less potent than bendroflumethiazide: Compared to bendroflumethiazide, hydrochlorothiazide is less potent in lowering blood pressure and may be less effective in preventing morbidity and mortality events.\n3. Less effective in high doses: Increasing the dose of hydrochlorothiazide can lead to an increase in dose-dependent side effects, making it less tolerable for patients.\n4. Preferable over hydrochlorothiazide: Based on the available evidence, a thiazide-like agent, preferably chlorthalidone, should be employed whenever diuretic treatment is indicated in a hypertensive patient.\nIt is important to note that the half-life of chlorthalidone is longer than that of hydrochlorothiazide, which may make it a more forgiving drug for irregular intake of antihypertensive drugs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used for the treatment of hypertension.\n2. Hydrochlorothiazide is less potent than bendroflumethiazide in lowering blood pressure.\n3. Increasing the dose of hydrochlorothiazide can lead to an increase in dose-dependent side effects.\n4. Chlorthalidone is preferred over hydrochlorothiazide whenever diuretic treatment is indicated in a hypertensive patient.\n5. Chlorthalidone has a longer half-life than hydrochlorothiazide.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used for the treatment of hypertension.",
      "Hydrochlorothiazide is less potent than bendroflumethiazide in lowering blood pressure.",
      "Increasing the dose of hydrochlorothiazide can lead to an increase in dose-dependent side effects.",
      "Chlorthalidone is preferred over hydrochlorothiazide whenever diuretic treatment is indicated in a hypertensive patient.",
      "Chlorthalidone has a longer half-life than hydrochlorothiazide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE: Hydrochlorothiazide is indeed generally less potent than bendroflumethiazide, and thus, higher doses of hydrochlorothiazide might be required to achieve the same blood pressure-lowering effect.\n3. TRUE: Any medication can lead to an increase in dose-dependent side effects when the dose is increased, and hydrochlorothiazide is not an exception.\n4. UNKNOWN: The preference for chlorthalidone or hydrochlorothiazide could depend on various factors including clinical guidelines, individual patient response, and potential side effects. In some guidelines, chlorthalidone is preferred due to its longer duration of action and evidence from some clinical trials suggesting better cardiovascular outcomes. However, this can be physician and patient-specific and can vary by medical practice or locale.\n5. TRUE: Chlorthalidone does have a longer half-life compared to hydrochlorothiazide, which contributes to its once-daily dosing and potentially provides more sustained blood pressure control over 24 hours.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. In the provided information, it is mentioned that Type I polypropylene mesh has been used in gynaecologic surgery for the treatment of pelvic organ prolapse and stress urinary incontinence. While mesh-based operations have shown positive results compared to non-mesh-based surgeries, there have been reports of erosions into adjacent viscera, including the vagina. This suggests that silicon-based materials have been used in the treatment of incontinence, specifically in the form of mesh implants.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Type I polypropylene mesh is used in gynecologic surgery for pelvic organ prolapse and stress urinary incontinence.\n3. Mesh-based operations have shown positive results compared to non-mesh-based surgeries.\n4. There have been reports of erosions into adjacent viscera, including the vagina, due to mesh-based operations.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Type I polypropylene mesh is used in gynecologic surgery for pelvic organ prolapse and stress urinary incontinence.",
      "Mesh-based operations have shown positive results compared to non-mesh-based surgeries.",
      "There have been reports of erosions into adjacent viscera, including the vagina, due to mesh-based operations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of incontinence.\n2. TRUE\n3. VAGUE [correction]: While mesh-based operations have shown positive results in some cases, the overall comparison to non-mesh-based surgeries can vary based on many factors, including the type of surgery and individual patient outcomes.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no clear association between the moon cycle and the rupture risk of intracranial aneurysms. The study found that the annual rupture rate of unruptured intracranial aneurysms (UIAs) was 1.8% per year, and the annual growth rate was 3.9% per year. The factors that influenced aneurysm rupture or growth were found to be aneurysm size and multiplicity, but not the moon cycle.\nThe study did not collect data on the lunar phase at the time of aneurysm rupture or growth, and therefore, it is not possible to draw any conclusions about the potential association between the moon cycle and aneurysm rupture risk based on the data provided.\nIt is important to note that the study only looked at the natural history of UIAs over a 12-year period, and the results may not be generalizable to other populations or time periods. Further research is needed to investigate the potential association between the moon cycle and aneurysm rupture risk.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study found no clear association between the moon cycle and the rupture risk of intracranial aneurysms.\n2. The annual rupture rate of unruptured intracranial aneurysms (UIAs) was reported as 1.8% per year.\n3. The annual growth rate of unruptured intracranial aneurysms was reported as 3.9% per year.\n4. Factors like aneurysm size and multiplicity influenced aneurysm rupture or growth.\n5. The study covered the natural history of UIAs over a 12-year period.",
    "llama-2-7b-chat-hf_fact": [
      "The study found no clear association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "The annual rupture rate of unruptured intracranial aneurysms (UIAs) was reported as 1.8% per year.",
      "The annual growth rate of unruptured intracranial aneurysms was reported as 3.9% per year.",
      "Factors like aneurysm size and multiplicity influenced aneurysm rupture or growth.",
      "The study covered the natural history of UIAs over a 12-year period."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nJustifications:\n1. Without specific context or reference to a particular study, the truthfulness of this statement cannot be determined.\n2. The annual rupture rate of unruptured intracranial aneurysms (UIAs) is indeed often reported in the range of around 1% per year, though estimates can vary slightly based on the study and population; 1.8% per year is within the range of reported values.\n3. The annual growth rate of UIAs depends on many factors, and without context or reference to a specific study, it is not possible to verify this specific figure.\n4. It is well recognized in medical literature that factors like aneurysm size and whether a patient has multiple aneurysms can influence the risk of rupture or growth, making this statement true.\n5. Without specific detail on the study, its duration cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein does regulate the splicing process. According to the provided information, HuR is an RNA-binding protein that plays a critical role in regulating the expression of several genes during replicative senescence. The study found that HuR levels, HuR binding to target mRNAs encoding proliferative genes, and the half-lives of such mRNAs are lower in senescent cells. Additionally, overexpression of HuR in senescent cells restored a \"younger\" phenotype, while a reduction in HuR expression accentuated the senescent phenotype. These findings suggest that HuR plays a crucial role in regulating the splicing process during cellular aging.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein is an RNA-binding protein that regulates the expression of genes during replicative senescence.\n2. HuR levels and HuR binding to target mRNAs encoding proliferative genes are lower in senescent cells.\n3. The half-lives of mRNAs that HuR binds to are lower in senescent cells.\n4. Overexpression of HuR in senescent cells can restore a \"younger\" phenotype.\n5. A reduction in HuR expression accentuates the senescent phenotype.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein is an RNA-binding protein that regulates the expression of genes during replicative senescence.",
      "HuR levels and HuR binding to target mRNAs encoding proliferative genes are lower in senescent cells.",
      "The half-lives of mRNAs that HuR binds to are lower in senescent cells.",
      "Overexpression of HuR in senescent cells can restore a \"younger\" phenotype.",
      "A reduction in HuR expression accentuates the senescent phenotype."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: HuR levels and HuR binding to target mRNAs encoding proliferative genes are generally higher in senescent cells, as HuR regulates the stability of these mRNAs and thus can contribute to increased expression of genes involved in senescence.\n3. FALSE [correction]: The half-lives of mRNAs that HuR binds to are typically increased in senescent cells, as one of the roles of HuR is to stabilize mRNAs.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Isolation: Prothymosin alpha can be isolated from calf thymus using reversed phase HPLC after separating it from parathymosin alpha.\n2. Distribution: Prothymosin alpha has a ubiquitous distribution in human tissues, with levels ranging from 93 ng to 1043 ng of parathymosin alpha(1-30) equivalents/g (wet weight) in various tissues.\n3. Antigenicity: The c-terminal peptide of prothymosin alpha is recognized by antibodies raised in rabbits, which can be used to establish a radioimmunoassay for parathymosin alpha.\n4. Epitope location: An epitope is located in the amino acid sequence 1-12 of prothymosin alpha.\n5. Cross-reactivity: The antiserum raised against the c-terminal peptide of prothymosin alpha does not cross-react with the partly homologous thymosin alpha 1 or prothymosin alpha.\n6. Protease resistance: Prothymosin alpha is more resistant to endogenous proteases than prothymosin alpha, suggesting that it may be more stable in vivo.\nOverall, these functions suggest that the c-terminal peptide of prothymosin alpha is a useful target for isolation, detection, and characterization of prothymosin alpha in various tissues and biological fluids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha can be isolated from calf thymus using reversed phase HPLC.\n2. Prothymosin alpha is ubiquitously distributed in human tissues, with varying levels in different tissues.\n3. The c-terminal peptide of prothymosin alpha is antigenic and can be recognized by antibodies raised in rabbits.\n4. An epitope of prothymosin alpha is located within the amino acid sequence 1-12.\n5. The antiserum raised against the c-terminal peptide of prothymosin alpha does not cross-react with thymosin alpha 1 or the full-length prothymosin alpha.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha can be isolated from calf thymus using reversed phase HPLC.",
      "Prothymosin alpha is ubiquitously distributed in human tissues, with varying levels in different tissues.",
      "The c-terminal peptide of prothymosin alpha is antigenic and can be recognized by antibodies raised in rabbits.",
      "An epitope of prothymosin alpha is located within the amino acid sequence 1-12.",
      "The antiserum raised against the c-terminal peptide of prothymosin alpha does not cross-react with thymosin alpha 1 or the full-length prothymosin alpha."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Prothymosin alpha is a protein that can indeed be isolated from calf thymus using various chromatographic techniques including reversed phase high-performance liquid chromatography (HPLC).\n2. TRUE: Prothymosin alpha has been found to be ubiquitously distributed in human tissues, but its levels may vary among different tissue types.\n3. TRUE: The c-terminal peptide of a protein like prothymosin alpha can be antigenic, and it is common for antibodies to be produced in animals such as rabbits against specific peptides for research purposes.\n4. UNKNOWN: Without the specific sequence data or additional context, it is difficult to confirm the location of an epitope within prothymosin alpha.\n5. UNKNOWN: The specificity of the antiserum raised against the c-terminal peptide of prothymosin alpha concerning cross-reactivity with other related peptides or proteins would depend on the individual antiserum and the experimental conditions. Without specific experimental results, this cannot be determined as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the peptide that plays a pivotal role in human cystatin C fibrillization is cystatin C. The document states that cystatin C is synthesized and secreted by osteoclasts, and it is found in the rough endoplasmic reticulum (ER), Golgi apparatus, vesicles, granules, and vacuoles of osteoclasts. The document also shows that cystatin C immunoreactive products are found in the extracellular spaces of osteoclasts, including the resorption lacuna, and on and between type I collagen fibrils. These findings suggest that cystatin C plays a crucial role in regulating the degradation of bone matrix by cathepsin K, both extracellularly and intracellularly. Therefore, the answer to the user's question is cystatin C.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is synthesized and secreted by osteoclasts.\n3. Cystatin C can be found in the rough endoplasmic reticulum, Golgi apparatus, vesicles, granules, and vacuoles of osteoclasts.\n4. Cystatin C immunoreactive products are found in the extracellular spaces of osteoclasts, including the resorption lacuna.\n5. Cystatin C plays a role in regulating the degradation of bone matrix by cathepsin K.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is synthesized and secreted by osteoclasts.",
      "Cystatin C can be found in the rough endoplasmic reticulum, Golgi apparatus, vesicles, granules, and vacuoles of osteoclasts.",
      "Cystatin C immunoreactive products are found in the extracellular spaces of osteoclasts, including the resorption lacuna.",
      "Cystatin C plays a role in regulating the degradation of bone matrix by cathepsin K."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Cystatin C is not exclusively synthesized and secreted by osteoclasts; it is a cysteine protease inhibitor that is produced by all nucleated cells and found in various body fluids, including blood plasma, cerebrospinal fluid, and urine.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is no direct answer to the question of whether the concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). The document focuses on the effects of various triphenylethylene antioestrogens and pharmacological doses of oestradiol-17 beta (Oe2) on the uterotrophic process and the nuclear accumulation and cytoplasmic depletion and replenishment of uterine oestrogen receptor.\nHowever, there is some relevant information mentioned in the document that could be relevant to the question. For example, the document states that Oe2 causes some receptor replenishment through a recycling process, which suggests that the administration of Oe2 may lead to an increase in the amount of oestrogen receptor protein in the cytoplasm. Additionally, the document mentions that the net increase in cytoplasmic oestrogen receptor at 24 h and 48 h after Oe2 injection was approximately 0.35 and 0.77 pmoles/uterus, respectively.\nBased on these findings, it is possible that the concentration of protein HIF-1 may increase after the administration of amifostine (ethyol), as HIF-1 is a transcription factor that plays a role in the response to hypoxia and can be involved in the regulation of protein synthesis and degradation. However, without additional information or direct evidence, it is impossible to make a definitive statement about the effect of amifostine on HIF-1 concentration.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Set7 is known to deposit the histone marks H3K27me3 and H3K9me3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 deposits the histone mark H3K27me3.\n2. Set7 deposits the histone mark H3K9me3.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 deposits the histone mark H3K27me3.",
      "Set7 deposits the histone mark H3K9me3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set7 (also known as SETD7) is known to deposit the histone mark H3K4me1.\n2. FALSE [correction]: Set7 does not deposit the histone mark H3K9me3; instead, enzymes like SUV39H1 and SUV39H2 are associated with methylation of H3K9.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the localization of the protein encoded by the gene DNAJC11 is likely to be in the cytoplasm.\nThe document mentions that the gene for RNA polymerase subunit alpha is co-transcribed with genes for ribosomal proteins (r-proteins) S11, S4, and L17, and that the DNA sequence analysis of a deletion mutant established that the S13 gene is a part of the alpha operon. The promoter (P alpha) of the alpha operon is located 94 nucleotides upstream from the initiation codon (GUG) of the S13 gene.\nSince the S13 gene is a ribosomal protein gene, it is likely that the protein encoded by the DNAJC11 gene is also a ribosomal protein. Ribosomal proteins are synthesized in the cytoplasm and are involved in the translation of messenger RNA (mRNA) into protein. Therefore, based on the information provided in the document, it can be inferred that the localization of the protein encoded by the DNAJC11 gene is in the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is likely localized in the cytoplasm.\n2. The gene for RNA polymerase subunit alpha is co-transcribed with genes for ribosomal proteins S11, S4, and L17.\n3. DNA sequence analysis of a deletion mutant established that the S13 gene is part of the alpha operon.\n4. The promoter of the alpha operon is located 94 nucleotides upstream from the initiation codon of the S13 gene.\n5. The S13 gene is a ribosomal protein gene.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is likely localized in the cytoplasm.",
      "The gene for RNA polymerase subunit alpha is co-transcribed with genes for ribosomal proteins S11, S4, and L17.",
      "DNA sequence analysis of a deletion mutant established that the S13 gene is part of the alpha operon.",
      "The promoter of the alpha operon is located 94 nucleotides upstream from the initiation codon of the S13 gene.",
      "The S13 gene is a ribosomal protein gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The subcellular localization of specific proteins such as the one encoded by DNAJC11 requires empirical evidence that is not provided in this statement. DNAJC11 could be localized in various cellular compartments, including the cytoplasm, but without specific information, the statement remains unverified.\n\n2. FALSE [correction]: The gene for RNA polymerase subunit alpha (rpoA) in E. coli is not co-transcribed with genes for ribosomal proteins S11, S4, and L17. These ribosomal protein genes are part of separate operons. Specifically, rpsK (S11) and rpsD (S4) are part of the str operon, while rplQ (L17) is part of the S10 operon.\n\n3. UNKNOWN: The statement about the S13 gene being part of the alpha operon requires specific genetic information or empirical evidence from a particular organism, which has not been provided. In E. coli, the S13 gene is known as rpsM and it is part of the S10 operon, but the context does not specify the organism, so the operon naming may differ.\n\n4. UNKNOWN: The location of the promoter relative to the initiation codon of a gene is a specific detail that would need to be validated with empirical evidence, such as DNA sequence analysis. Without such data, the statement remains unverified.\n\n5. TRUE: The \"S\" designation generally refers to ribosomal proteins involved in the small ribosomal subunit, and S13 is a known ribosomal protein gene, but the statement does lack the context of which organism it pertains to. In E. coli, for example, the S13 equivalent is rpsM, which is indeed a ribosomal protein gene.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, there is no evidence to suggest that ultraconserved elements are depleted among copy number variants (CNVs) in the population studied. The study found that there was a nonsignificant trend for excess of rare CNVs in schizophrenia, but did not confirm the previously implicated association for very large CNVs (>500 kilobase [kb]) in this population. Additionally, the study provided support for three previous findings in schizophrenia, including one deletion in a case at 1q21.1, one deletion within NRXN1, and four duplications in cases and one in a control subject at 16p13.1, a locus first implicated in autism and later in schizophrenia.\nUltraconserved elements are a class of genomic elements that are characterized by their high degree of conservation across species, and are thought to play important roles in regulating gene expression and other cellular processes. However, the study did not investigate the specific role of ultraconserved elements in the context of CNVs and schizophrenia, and therefore cannot draw conclusions about their depletion among CNVs in this population.\nIn summary, while the study provides some support for the role of CNVs in schizophrenia, it does not provide evidence for the depletion of ultraconserved elements among CNVs in this population. Further research is needed to investigate the relationship between ultraconserved elements and CNVs in the context of schizophrenia.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study found no evidence that ultraconserved elements are depleted among copy number variants (CNVs) in the population studied.\n2. There was a nonsignificant trend for excess of rare CNVs in schizophrenia observed in the study.\n3. The study did not confirm the association for very large CNVs (>500 kilobase [kb]) with schizophrenia in the population studied.\n4. The study confirmed a deletion in a case at 1q21.1 in schizophrenia.\n5. The study reported one deletion within NRXN1 and four duplications in cases (and one in a control subject) at 16p13.1, a locus associated with both autism and schizophrenia.",
    "llama-2-7b-chat-hf_fact": [
      "The study found no evidence that ultraconserved elements are depleted among copy number variants (CNVs) in the population studied.",
      "There was a nonsignificant trend for excess of rare CNVs in schizophrenia observed in the study.",
      "The study did not confirm the association for very large CNVs (>500 kilobase [kb]) with schizophrenia in the population studied.",
      "The study confirmed a deletion in a case at 1q21.1 in schizophrenia.",
      "The study reported one deletion within NRXN1 and four duplications in cases (and one in a control subject) at 16p13.1, a locus associated with both autism and schizophrenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nTo accurately determine the truth value of these statements, I would need specific information from the pertinent study referenced in the context. Without access to the study's results and conclusions, I cannot provide verification or corrections for these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the substrate of the Haspin kinase during mitosis is Tyr-19. The document states that dephosphorylation of Tyr-19 is required for the segregation of spindle pole bodies (SPBs), which is a critical step in the process of mitosis. The failure of cells to segregate SPBs due to the inability to dephosphorylate Tyr-19 leads to a failure to form bipolar spindles, as observed in cells expressing cdc28-E19 and in cells overexpressing SWE1. Therefore, it can be concluded that Tyr-19 is the substrate of the Haspin kinase during mitosis, and its dephosphorylation is essential for the proper separation of SPBs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is Tyr-19.\n2. Dephosphorylation of Tyr-19 is required for the segregation of spindle pole bodies (SPBs) during mitosis.\n3. Failure to segregate SPBs can lead to the inability to form bipolar spindles.\n4. Cells expressing cdc28-E19 and cells overexpressing SWE1 fail to form bipolar spindles due to the inability to dephosphorylate Tyr-19.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is Tyr-19.",
      "Dephosphorylation of Tyr-19 is required for the segregation of spindle pole bodies (SPBs) during mitosis.",
      "Failure to segregate SPBs can lead to the inability to form bipolar spindles.",
      "Cells expressing cdc28-E19 and cells overexpressing SWE1 fail to form bipolar spindles due to the inability to dephosphorylate Tyr-19."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The substrate of the Haspin kinase during mitosis is Histone H3 at threonine 3 (H3T3), not Tyr-19.\n2. UNKNOWN: While this statement may refer to a specific study or biological context, the known substrate of Haspin kinase is Histone H3 threonine 3, and the general role of Tyr-19 dephosphorylation in SPB segregation is not established in widely recognized literature. Therefore, without specific context, this statement's accuracy cannot be determined.\n3. TRUE: Failure to segregate SPBs properly can indeed lead to the inability to form bipolar spindles, which is crucial for correct chromosome segregation during cell division.\n4. UNKNOWN: The statement contains specifics about mutant forms of cdc28 (cdc28-E19) and overexpression of SWE1, which are genetic manipulations in yeast (Saccharomyces cerevisiae). In general, problems in key regulatory proteins like CDC28 can indeed lead to issues with spindle formation. However, the role of Tyr-19 in this context is not established without further information, so the accuracy of this statement depends on a specific study or source of information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanism of viroid replication is not directly addressed. The passage discusses the replication of hepatitis A virus (HAV) in cell culture, specifically the nonlytic and relatively slow replication of most HAV strains, including the isolate HM-175. However, the observation of a rapidly replicating isolate of HM-175 leading to the development of a plaque assay in FRhK-4 cells suggests that the mechanism of replication may involve the formation of plaques or other structural changes in infected cells.\nViroids, on the other hand, are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from that of viruses. Viroids do not have a cellular host and do not induce a cytopathic effect, unlike some viruses like HAV. Instead, viroids replicate by infecting the plant cells and manipulating the host cell's metabolism to produce more viroids. The exact mechanism of viroid replication is not fully understood, but it is believed to involve the manipulation of the host cell's RNA silencing pathways.\nIn summary, while the passage does not directly address the mechanism of viroid replication, it does provide some insights into the mechanisms of viral replication and the differences between viruses and viroids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids replicate by infecting plant cells.\n3. Viroids manipulate the host cell's metabolism to produce more viroids.\n4. The exact mechanism of viroid replication involves the manipulation of the host cell's RNA silencing pathways.\n5. Viroids do not have a cellular host and do not induce a cytopathic effect like some viruses.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids replicate by infecting plant cells.",
      "Viroids manipulate the host cell's metabolism to produce more viroids.",
      "The exact mechanism of viroid replication involves the manipulation of the host cell's RNA silencing pathways.",
      "Viroids do not have a cellular host and do not induce a cytopathic effect like some viruses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Viroids have a cellular host which they infect (typically plant cells) and can induce a cytopathic effect, leading to diseases in the host plants.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, fibronectin can be considered a potential serum biomarker for Duchenne muscular dystrophy. The study found that the plasma fibronectin level was significantly lower in patients with hypertrophic cardiomyopathy compared to healthy subjects. This suggests that fibronectin may be useful in identifying individuals with hypertrophic cardiomyopathy, which is a common complication of Duchenne muscular dystrophy.\nIt is important to note that this study only investigated the relationship between fibronectin levels and hypertrophic cardiomyopathy, and did not directly examine the relationship between fibronectin and Duchenne muscular dystrophy. However, the findings suggest that fibronectin may be a useful biomarker for identifying individuals with hypertrophic cardiomyopathy, which is a common complication of Duchenne muscular dystrophy.\nIn conclusion, while more research is needed to confirm these findings, the study provides evidence to suggest that fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy.\n2. A study found plasma fibronectin levels to be significantly lower in patients with hypertrophic cardiomyopathy as compared to healthy subjects.\n3. Hypertrophic cardiomyopathy is a common complication of Duchenne muscular dystrophy.\n4. The study discussed did not directly investigate the relationship between fibronectin and Duchenne muscular dystrophy.\n5. There is a suggestion that fibronectin may be useful in identifying individuals with hypertrophic cardiomyopathy.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy.",
      "A study found plasma fibronectin levels to be significantly lower in patients with hypertrophic cardiomyopathy as compared to healthy subjects.",
      "Hypertrophic cardiomyopathy is a common complication of Duchenne muscular dystrophy.",
      "The study discussed did not directly investigate the relationship between fibronectin and Duchenne muscular dystrophy.",
      "There is a suggestion that fibronectin may be useful in identifying individuals with hypertrophic cardiomyopathy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Fibronectin has been researched as a potential serum biomarker for Duchenne muscular dystrophy due to its role in muscle damage and repair processes.\n2. UNKNOWN: Without specific information on the study referred to in the statement, it is not possible to confirm the accuracy of plasma fibronectin levels in patients with hypertrophic cardiomyopathy compared to healthy subjects.\n3. TRUE: Hypertrophic cardiomyopathy can be a complication associated with Duchenne muscular dystrophy, although it is more widely known as a genetic heart condition that can occur independently.\n4. UNKNOWN: Since the statement is missing context about what the study did indeed investigate, it's not possible to determine the veracity of this statement.\n5. UNKNOWN: Similar to statement 2, more information is needed from the study to confirm whether fibronectin is indicated as a useful biomarker for identifying hypertrophic cardiomyopathy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the DeepBlue epigenomic data server contains data from the following major epigenome projects:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. Roadmap Epigenomics\nThese projects have generated large-scale genomic datasets that can be analyzed and interpreted using the Genomic HyperBrowser, as mentioned in the passage.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the Roadmap Epigenomics project.\n3. The ENCODE project is also known as the Encyclopedia of DNA Elements.\n4. The Genomic HyperBrowser can be used to analyze and interpret large-scale genomic datasets from these projects.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the Roadmap Epigenomics project.",
      "The ENCODE project is also known as the Encyclopedia of DNA Elements.",
      "The Genomic HyperBrowser can be used to analyze and interpret large-scale genomic datasets from these projects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the tool that employs self-organizing maps for analyzing synonymous codon usage is likely CODEVIEW.\nSelf-organizing maps (SOMs) are a type of neural network that can be used for dimensionality reduction and visualization of high-dimensional data. In the context of molecular evolution, SOMs have been used to analyze synonymous codon usage patterns in multiple species and identify patterns of codon usage bias.\nCODEVIEW is a tool that specifically uses SOMs to analyze synonymous codon usage and identify patterns of codon usage bias in multiple species. It can be used to compare the codon usage patterns of different species and identify areas of high similarity and difference.\nTherefore, based on the information provided in the document, it is likely that CODEVIEW is the tool that employs self-organizing maps for analyzing synonymous codon usage.",
    "llama-2-7b-chat-hf_fact_raw": "1. CODEVIEW is a tool that uses self-organizing maps (SOMs) to analyze synonymous codon usage.\n2. Self-organizing maps are a type of neural network used for reducing dimensionality and visualizing high-dimensional data.\n3. SOMs can be employed to identify patterns of codon usage bias in multiple species.\n4. CODEVIEW can be used to compare codon usage patterns between different species.\n5. CODEVIEW can identify areas of high similarity and difference in codon usage patterns.",
    "llama-2-7b-chat-hf_fact": [
      "CODEVIEW is a tool that uses self-organizing maps (SOMs) to analyze synonymous codon usage.",
      "Self-organizing maps are a type of neural network used for reducing dimensionality and visualizing high-dimensional data.",
      "SOMs can be employed to identify patterns of codon usage bias in multiple species.",
      "CODEVIEW can be used to compare codon usage patterns between different species.",
      "CODEVIEW can identify areas of high similarity and difference in codon usage patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific context or references, it's not possible to determine the veracity of the statement regarding \"CODEVIEW\" as it is not a well-known term or tool in broader contexts. It may be a specific tool used in a niche area of bioinformatics or computational biology, or the name may be hypothetical for this scenario.\n\n2. TRUE: Self-organizing maps (SOMs) are indeed a type of artificial neural network (ANN) used for clustering, reducing dimensionality, and visualizing complex high-dimensional data in a two-dimensional space.\n\n3. TRUE: SOMs are a technique in computational biology that can be used to analyze and identify patterns, including codon usage bias, across different species.\n\n4. UNKNOWN: Whether CODEVIEW can specifically be used to compare codon usage patterns between different species would depend on its features and functionality, which are not provided here.\n\n5. UNKNOWN: Similar to the previous statement, without specific details on what CODEVIEW is capable of, it's not possible to affirm whether it can identify areas of high similarity and difference in codon usage patterns. The functionality would depend on the tool's design and implementation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MINDY-1 appears to be a reference to 4-Bromo-2,5-dimethoxyphenethylamine (2C-B), a psychoactive analogue of mescaline that is becoming increasingly popular as a rave and club drug. The document mentions that 2C-B is consistently present in the illicit drug market in Spain, and that it elicits perceptual modifications that are analogous to other psychedelics, but with lower impairment and higher pleasurable effects compared to other entactogens like MDMA.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a reference to 4-Bromo-2,5-dimethoxyphenethylamine (2C-B).\n2. 2C-B is a psychoactive analogue of mescaline.\n3. 2C-B has become increasingly popular as a rave and club drug.\n4. In the illicit drug market in Spain, 2C-B is consistently present.\n5. 2C-B causes perceptual modifications similar to other psychedelics but with lower impairment and higher pleasurable effects compared to MDMA.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a reference to 4-Bromo-2,5-dimethoxyphenethylamine (2C-B).",
      "2C-B is a psychoactive analogue of mescaline.",
      "2C-B has become increasingly popular as a rave and club drug.",
      "In the illicit drug market in Spain, 2C-B is consistently present.",
      "2C-B causes perceptual modifications similar to other psychedelics but with lower impairment and higher pleasurable effects compared to MDMA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not a reference to 4-Bromo-2,5-dimethoxyphenethylamine (2C-B); 2C-B does not have a widely recognized nickname as \"MINDY-1.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE (with the caveat that the effects of drugs can be subjective and vary between individuals; however, the description given is consistent with common reports on the effects of 2C-B in comparison to MDMA).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is Genquire. According to the document, Genquire is a software package that allows visualization, querying, hand editing, and de novo markup of complete or partially annotated genomes. It is written in Perl/Tk and uses existing BioPerl data models and methods for representation and manipulation of the sequence and annotation objects. Additionally, Genquire provides an adaptor API to allow it to display a wide range of databases and flat files, and a plugins API to provide an interface to other sequence analysis software.\nGenquire is open-source software and the code is available for download and/or contribution at <http://www.bioinformatics.org/Genquire>. Therefore, users can access and use the software for free, and also contribute to its development and improvement.",
    "llama-2-7b-chat-hf_fact_raw": "1. Genquire is a software package intended for the analysis of conserved genomic loci.\n2. Genquire enables visualization, querying, hand editing, and de novo markup of complete or partially annotated genomes.\n3. The software is written in Perl/Tk and integrates BioPerl data models and methods.\n4. Genquire offers an adaptor API for displaying a variety of databases and flat files.\n5. Genquire is open-source, and its code can be downloaded from http://www.bioinformatics.org/Genquire.",
    "llama-2-7b-chat-hf_fact": [
      "Genquire is a software package intended for the analysis of conserved genomic loci.",
      "Genquire enables visualization, querying, hand editing, and de novo markup of complete or partially annotated genomes.",
      "The software is written in Perl/Tk and integrates BioPerl data models and methods.",
      "Genquire offers an adaptor API for displaying a variety of databases and flat files.",
      "Genquire is open-source, and its code can be downloaded from http://www.bioinformatics.org/Genquire."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are no diseases associated with the PIEZO2 gene. The document specifically mentions the association between the PIEZO2 gene and Charcot-Marie-Tooth disease type 1B, but does not mention any other diseases. Therefore, I cannot provide a list of 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the paper, it appears that ERAP1-ERAP2 dimerization promotes the acceleration of glycoprotein degradation through the ERAD pathway. The paper suggests that overexpression of EDEM1 or its up-regulation by IRE1 can override the requirement for mannose trimming of the N-linked oligosaccharide precursor, leading to the acceleration of ERAD. Additionally, the paper suggests that EDEM1 overexpression can also accelerate the degradation of nonglycosylated substrates. Furthermore, the paper suggests that upon proteasomal inhibition, EDEM1 concentrates with the ERAD substrate in the pericentriolar ER-derived quality control compartment, where ER mannosidase I and ERAD machinery components are localized. These findings suggest that ERAP1-ERAP2 dimerization plays a critical role in the acceleration of glycoprotein degradation through the ERAD pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the acceleration of glycoprotein degradation through the ERAD pathway.\n2. Overexpression of EDEM1 or its up-regulation by IRE1 can override the requirement for mannose trimming of the N-linked oligosaccharide precursor.\n3. EDEM1 overexpression can accelerate the degradation of nonglycosylated substrates.\n4. Upon proteasomal inhibition, EDEM1 concentrates with the ERAD substrate in the pericentriolar ER-derived quality control compartment.\n5. The pericentriolar ER-derived quality control compartment is localized with ER mannosidase I and ERAD machinery components.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the acceleration of glycoprotein degradation through the ERAD pathway.",
      "Overexpression of EDEM1 or its up-regulation by IRE1 can override the requirement for mannose trimming of the N-linked oligosaccharide precursor.",
      "EDEM1 overexpression can accelerate the degradation of nonglycosylated substrates.",
      "Upon proteasomal inhibition, EDEM1 concentrates with the ERAD substrate in the pericentriolar ER-derived quality control compartment.",
      "The pericentriolar ER-derived quality control compartment is localized with ER mannosidase I and ERAD machinery components."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement specifies a role in the ER-associated degradation (ERAD) pathway involving ERAP1-ERAP2 dimerization, but without additional context or specific study references, the accuracy of this statement cannot be determined.\n2. UNKNOWN: This statement requires specific biochemical knowledge about the regulation of endoplasmic reticulum-associated degradation (ERAD) and the role of EDEM1 and IRE1. Without additional context, it's difficult to assess the accuracy of the statement.\n3. UNKNOWN: While EDEM1 does have a role in accelerating the degradation of misfolded glycoproteins in the ERAD pathway, whether it accelerates the degradation of nonglycosylated substrates without additional context or reference is unclear.\n4. UNKNOWN: This statement relates to cellular biology and the behavior of EDEM1 upon proteasomal inhibition, necessitating specific literature or context to verify its accuracy.\n5. UNKNOWN: The statement about the localization of the pericentriolar quality control compartment relative to ER mannosidase I and ERAD machinery components requires specific knowledge in cell biology and empirical evidence, which is not provided in the given context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, R-spondin 1 (hRspo1) and Noggin are involved in the regulation of Wnt signaling in non-damaged gallbladders. Specifically, hRspo1 is a high affinity ligand for the Wnt co-receptor LRP6 and induces its phosphorylation and activation. Additionally, hRspo1 synergizes with Frizzled5 in Xenopus axis induction assays and induces the phosphorylation of Dishevelled, a cytoplasmic component downstream of Frizzled function.\nIn non-damaged gallbladders, the Wnt signaling pathway is likely to be involved in the regulation of various cellular processes, including cell proliferation, differentiation, and tissue maintenance. R-spondin 1 and Noggin may play important roles in modulating the activity of this pathway in these processes.\nIt is worth noting that the study focuses on the mechanism of R-spondin action and its relationship with Wnt signaling, and does not provide direct information on the function of R-spondin 1 and Noggin in non-damaged gallbladders. However, based on the findings of the study, it can be inferred that these proteins play important roles in regulating Wnt signaling in non-damaged gallbladders, and that their dysregulation may contribute to the development of gallbladder diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 (hRspo1) is involved in the regulation of Wnt signaling in non-damaged gallbladders.\n2. R-spondin 1 (hRspo1) is a high-affinity ligand for the Wnt co-receptor LRP6 and induces phosphorylation and activation of LRP6.\n3. R-spondin 1 (hRspo1) synergizes with Frizzled5 in Xenopus axis induction assays and induces phosphorylation of Dishevelled.\n4. Noggin also plays a role in the regulation of Wnt signaling in non-damaged gallbladders.\n5. Dysregulation of R-spondin 1 and Noggin may contribute to the development of gallbladder diseases.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 (hRspo1) is involved in the regulation of Wnt signaling in non-damaged gallbladders.",
      "R-spondin 1 (hRspo1) is a high-affinity ligand for the Wnt co-receptor LRP6 and induces phosphorylation and activation of LRP6.",
      "R-spondin 1 (hRspo1) synergizes with Frizzled5 in Xenopus axis induction assays and induces phosphorylation of Dishevelled.",
      "Noggin also plays a role in the regulation of Wnt signaling in non-damaged gallbladders.",
      "Dysregulation of R-spondin 1 and Noggin may contribute to the development of gallbladder diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Noggin is known for its role in bone morphogenetic protein (BMP) signaling inhibition, not directly in the regulation of Wnt signaling.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that NADPH oxidase 5 does require subunits for its function. The document mentions that the membrane arm of Complex I (NADH:ubiquinone oxidoreductase) contains three large, and closely related subunits, which are called L, M, and N in E. coli. These subunits are homologous to components of multi-subunit Na(+)/H(+) antiporters, and so are implicated in proton translocation. The document also states that site-specific mutations were constructed at two corresponding positions in each of the three subunits, and that these mutations had similar effects on various activities measured, including deamino-NADH oxidase activity, proton translocation, ferricyanide reductase activity, and sensitivity to capsaicin. Additionally, the document notes that the addition of exogenous decylubiquinone stimulated both deamino-NADH oxidase activity and proton translocation by wild type membrane vesicles, but was inhibitory towards the same activities by membrane vesicles bearing the lysine substitution at the L236/M241/N224 positions.\nTherefore, based on the information provided in the document, it can be concluded that NADPH oxidase 5 requires at least three subunits (L, M, and N) for its function, and that these subunits likely play a common role in Complex I.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, there appears to be a connection between furin and hepcidin in the regulation of iron metabolism in patients with chronic kidney disease (CKD).\nHepcidin is a small peptide hormone synthesized in the liver that plays a central role in regulating iron metabolism. In CKD patients, hepcidin generation is dependent on iron status, anemia, inflammation, and hypoxia, as well as erythropoietin levels. Prohepcidin, a precursor to hepcidin, has also been shown to be elevated in CKD patients.\nThe study mentioned in the article investigated the relationship between Prohepcidin levels and inflammation and iron indices in non-diabetic uremic patients. The results showed that Prohepcidin levels were positively correlated with inflammatory markers such as high-sensitive C-reactive protein (hsCRP) and interleukin (IL)-6, and negatively correlated with albumin, total iron binding capacity (TIBC), and glomerular filtration rate (GFR).\nThese findings suggest that Prohepcidin may play a role in the regulation of iron metabolism in CKD patients, and that elevated Prohepcidin levels may be associated with deepening anemia and inflammation. The study also suggests that measuring Prohepcidin levels may be a useful tool in the diagnosis and management of anemia in CKD patients.\nIn terms of the connection between furin and hepcidin, furin is an enzyme that has been shown to be involved in the processing and activation of hepcidin. Furin has been shown to cleave hepcidin into its active form, which then goes on to regulate iron metabolism. Therefore, furin may play a role in the regulation of hepcidin activity and the subsequent regulation of iron metabolism in CKD patients.\nIn summary, the article suggests that Prohepcidin levels are elevated in CKD patients and are positively correlated with inflammatory markers, while furin may play a role in the regulation of hepcidin activity and iron metabol",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a hormone synthesized in the liver that regulates iron metabolism.\n2. In patients with chronic kidney disease, prohepcidin levels are elevated.\n3. Prohepcidin levels were positively correlated with inflammatory markers such as high-sensitive C-reactive protein (hsCRP) and interleukin (IL)-6 in a study.\n4. Prohepcidin levels were negatively correlated with albumin, total iron binding capacity (TIBC), and glomerular filtration rate (GFR).\n5. Furin is an enzyme that processes and activates hepcidin into its active form.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a hormone synthesized in the liver that regulates iron metabolism.",
      "In patients with chronic kidney disease, prohepcidin levels are elevated.",
      "Prohepcidin levels were positively correlated with inflammatory markers such as high-sensitive C-reactive protein (hsCRP) and interleukin (IL)-6 in a study.",
      "Prohepcidin levels were negatively correlated with albumin, total iron binding capacity (TIBC), and glomerular filtration rate (GFR).",
      "Furin is an enzyme that processes and activates hepcidin into its active form."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - In patients with chronic kidney disease (CKD), prohepcidin levels can be elevated due to the body's reduced ability to clear it effectively, as the kidneys are primarily involved in excretion of waste products including proteins.\n3. TRUE - It is biologically plausible that prohepcidin levels could be positively correlated with inflammatory markers such as hsCRP and IL-6, as iron metabolism can be affected by inflammation, and increased hepcidin is a known response to inflammation.\n4. TRUE - Prohepcidin levels being negatively correlated with albumin, TIBC, and GFR makes sense, as elevated prohepcidin (and therefore hepcidin) inhibits iron export, potentially reducing TIBC, and low GFR is characteristic of kidney disease which is associated with elevated prohepcidin levels.\n5. FALSE [correction]: Furin is a proprotein convertase that cleaves various substrates, but it is not primarily responsible for the activation of hepcidin. The enzyme responsible for the maturation of hepcidin is not named furin; it is the BMP (Bone Morphogenetic Protein)-SMAD signaling pathway that leads to the production of active hepcidin.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the largest metabolic gene cluster in yeast is the CAR1 gene.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of LIMT lncRNA in the development of type 2 diabetes mellitus (T2DM) is not directly mentioned. However, the document does provide insight into the regulatory role of lncRNAs in diabetes.\nThe document describes the construction of a T2DM-related competitive endogenous RNA (ceRNA) network (DMCN) that contains 351 nodes, including 98 mRNAs, 86 microRNAs, and 167 lncRNAs. Functional analysis of the network revealed that the mRNAs in DMCN were annotated into some diabetes-related pathways. Additionally, the document mentions the establishment of an mTOR-centered subnetwork and the identification of NEAT1 as a potentially communicated lncRNA that is involved in the mTOR signaling pathway.\nTherefore, based on the information provided in the document, it can be inferred that lncRNAs play a regulatory role in the development of T2DM by interacting with mRNAs and microRNAs to modulate the expression of genes involved in diabetes-related pathways. Specifically, the document suggests that NEAT1 may be involved in the mTOR signaling pathway, which is known to be dysregulated in T2DM.\nIn summary, while the document does not directly mention the role of LIMT lncRNA in T2DM, it provides evidence that lncRNAs play a significant role in the regulation of diabetes-related pathways and may be involved in the development of T2DM.",
    "llama-2-7b-chat-hf_fact_raw": "1. The document discusses the construction of a T2DM-related competitive endogenous RNA (ceRNA) network that contains 351 nodes.\n2. Within this network, there are 98 mRNAs, 86 microRNAs, and 167 lncRNAs.\n3. Functional analysis indicated the mRNAs in the network were annotated into diabetes-related pathways.\n4. An mTOR-centered subnetwork was established according to the document.\n5. NEAT1 was identified as a potentially significant lncRNA involved in the mTOR signaling pathway within the context of T2DM.",
    "llama-2-7b-chat-hf_fact": [
      "The document discusses the construction of a T2DM-related competitive endogenous RNA (ceRNA) network that contains 351 nodes.",
      "Within this network, there are 98 mRNAs, 86 microRNAs, and 167 lncRNAs.",
      "Functional analysis indicated the mRNAs in the network were annotated into diabetes-related pathways.",
      "An mTOR-centered subnetwork was established according to the document.",
      "NEAT1 was identified as a potentially significant lncRNA involved in the mTOR signaling pathway within the context of T2DM."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the highly specific nature of these statements, they are likely directly derived from or summarizing specific details in a scientific document. It would be unusual to have such precise numbers and facts presented incorrectly in a serious summary of research findings. However, without access to the original document to verify these details, an accurate judgement cannot be made on the authenticity of the information. We are assuming these statements to be true based on the given information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R/Bioconductor package used for performing SNP enrichment analysis is RPPApipe.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the key players in radial glial specification to ependymal cells are:\n1. Radial glia: The study shows that a subpopulation of radial glia in the ventricular zone of the neonatal brain undergoes transformation to give rise to mature ependymal cells.\n2. Cre-lox recombination strategy: The study uses a genetic tagging approach to directly test whether radial glia give rise to ependymal cells.\n3. Deuterosomes: The study identifies deuterosomes as a characteristic feature of radial glia in various stages of transformation into ependymal cells.\nThe study suggests that ependymal cells are born in the embryonic and early postnatal brain and do not divide after differentiation, which suggests that they do not function as neural stem cells in the adult.",
    "llama-2-7b-chat-hf_fact_raw": "1. A subpopulation of radial glia in the ventricular zone of the neonatal brain can transform into mature ependymal cells.\n2. The study used a Cre-lox recombination strategy to test whether radial glia give rise to ependymal cells.\n3. Deuterosomes have been identified as a feature of radial glia undergoing transformation into ependymal cells.\n4. The study implies that ependymal cells originate during the embryonic and early postnatal stages of brain development.\n5. Ependymal cells do not divide after they differentiate and are not considered neural stem cells in the adult brain.",
    "llama-2-7b-chat-hf_fact": [
      "A subpopulation of radial glia in the ventricular zone of the neonatal brain can transform into mature ependymal cells.",
      "The study used a Cre-lox recombination strategy to test whether radial glia give rise to ependymal cells.",
      "Deuterosomes have been identified as a feature of radial glia undergoing transformation into ependymal cells.",
      "The study implies that ependymal cells originate during the embryonic and early postnatal stages of brain development.",
      "Ependymal cells do not divide after they differentiate and are not considered neural stem cells in the adult brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Deuterosomes have been identified as a feature of ependymal cells, not specifically of radial glia undergoing transformation into ependymal cells.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, triple negative gliomas are characterized as:\n1. Multicentric: The tumors occur in different locations of the brain, without anatomical continuity between lesions.\n2. Different histopathology: The tumors in the supra- and infratentorial regions have different histopathological features, with one being diffuse astrocytoma and the other being glioblastoma.\n3. Negative for p53 and EGFR: The tumor cells are negative for p53 and EGFR immunostaining, which are genetic markers that are commonly associated with triple negative gliomas.\n4. Positive for IDH1: The tumor cells are negative for IDH1 immunostaining, which is a genetic marker that is commonly associated with glioblastoma.\nTherefore, based on the information provided in the document, the triple negative gliomas in this case are characterized by their multicentric location, different histopathology, and the presence of p53 and EGFR negativity, as well as the absence of IDH1 positivity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas can occur in different locations of the brain without anatomical continuity between lesions.\n2. Triple negative gliomas can have different histopathological features in supra- and infratentorial regions.\n3. The tumor cells in triple negative gliomas can be negative for p53 immunostaining.\n4. The tumor cells in triple negative gliomas can be negative for EGFR immunostaining.\n5. The tumor cells in triple negative gliomas can be positive for IDH1 immunostaining.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas can occur in different locations of the brain without anatomical continuity between lesions.",
      "Triple negative gliomas can have different histopathological features in supra- and infratentorial regions.",
      "The tumor cells in triple negative gliomas can be negative for p53 immunostaining.",
      "The tumor cells in triple negative gliomas can be negative for EGFR immunostaining.",
      "The tumor cells in triple negative gliomas can be positive for IDH1 immunostaining."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The term \"triple negative gliomas\" implies that the tumor cells are negative for three common markers in gliomas, which usually include IDH1. Thus, they would typically be negative, not positive, for IDH1 immunostaining.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, TOPAZ1 appears to be a term related to the study of the molecular mechanisms of the interaction between the drug Topotecan (TPT) and DNA. Specifically, the document discusses the ability of TPT molecules to form dimers with a high affinity for DNA, and how the presence of DNA can increase the effective dimerization constant of TPT by more than 400-fold. The document also suggests that TPT dimers are able to bind DNA by bridging different DNA molecules or distant DNA structural domains, which may lead to modifications of the intrinsic geometry of the cruciform DNA structures and the appearance of new crossover points that serve as the sites of the top1 loading position. Based on these findings, it is possible that TOPAZ1 refers to a specific complex or structure formed by the interaction of TPT and DNA, or a model proposed to explain the molecular mechanisms of this interaction. Without further information, it is difficult to provide a definitive answer to the user's question.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is related to the study of molecular mechanisms of the interaction between the drug Topotecan (TPT) and DNA.\n2. Topotecan molecules can form dimers with a high affinity for DNA.\n3. The presence of DNA can increase the effective dimerization constant of TPT by more than 400-fold.\n4. TPT dimers are capable of binding DNA by bridging different DNA molecules or distant DNA structural domains.\n5. This interaction may lead to modifications of the intrinsic geometry of cruciform DNA structures and the appearance of new crossover points that serve as the sites of the Top1 loading position.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is related to the study of molecular mechanisms of the interaction between the drug Topotecan (TPT) and DNA.",
      "Topotecan molecules can form dimers with a high affinity for DNA.",
      "The presence of DNA can increase the effective dimerization constant of TPT by more than 400-fold.",
      "TPT dimers are capable of binding DNA by bridging different DNA molecules or distant DNA structural domains.",
      "This interaction may lead to modifications of the intrinsic geometry of cruciform DNA structures and the appearance of new crossover points that serve as the sites of the Top1 loading position."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or source material on TOPAZ1 and the specific studies on Topotecan (TPT) interactions with DNA, the veracity of these statements cannot be determined. The statements are very specific and would require specialist knowledge or reference to specific research literature to verify.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the gene that controls the expression of GATA-1 isoforms is GATA-1 itself. The study found that GATA-1 regulates its own expression by recruiting RNA polymerase II (pol II) to specific subregions of the locus control region and the beta-globin promoters. The hematopoietic factor NF-E2 also cooperates with GATA-1 to recruit pol II to the promoters. Therefore, the expression of GATA-1 isoforms is primarily controlled by its own gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene regulates the expression of its own isoforms.\n2. GATA-1 recruits RNA polymerase II to specific subregions of the locus control region.\n3. GATA-1 also recruits RNA polymerase II to the beta-globin promoters.\n4. The hematopoietic factor NF-E2 cooperates with GATA-1 in the recruitment of RNA polymerase II to the promoters.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene regulates the expression of its own isoforms.",
      "GATA-1 recruits RNA polymerase II to specific subregions of the locus control region.",
      "GATA-1 also recruits RNA polymerase II to the beta-globin promoters.",
      "The hematopoietic factor NF-E2 cooperates with GATA-1 in the recruitment of RNA polymerase II to the promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nPlease note, these statements are all specific to molecular biology, specifically gene regulation and the function of transcription factors, and they require domain-specific knowledge to verify. Without the specific passage or definitive references, it's difficult to classify these statements as true or false categorically. But within the typical understanding of molecular biology, GATA-1 is indeed involved in the regulation of erythroid cell development and function, and it does interact with various control regions for gene expression. NF-E2 is a transcription factor known to be involved in the regulation of hematopoietic-specific genes, and it is plausible for it to cooperate with GATA-1 in the recruitment of the transcriptional machinery.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a high-throughput and low-cost single-cell RNA sequencing (scRNA-seq) platform developed in the study described in the provided information. The platform uses simple, inexpensive devices to analyze more than 400,000 single cells covering all major mouse organs and construct a basic scheme for a mouse cell atlas (MCA). The MCA provides a single-cell hierarchy for many tissues that have not been well characterized previously, and a web-based pipeline is used to accurately define cell types based on single-cell digital expression. In summary, MIRA-seq is a powerful tool for analyzing single cells and creating a comprehensive cell atlas for complex mammalian systems.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a single-cell RNA sequencing platform.\n2. MIRA-seq is designed to be high-throughput and low-cost.\n3. The platform was used to analyze over 400,000 single cells from all major mouse organs.\n4. MIRA-seq helped construct a basic scheme for a mouse cell atlas (MCA).\n5. The mouse cell atlas provides a hierarchy for many tissues that were previously not well characterized.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a single-cell RNA sequencing platform.",
      "MIRA-seq is designed to be high-throughput and low-cost.",
      "The platform was used to analyze over 400,000 single cells from all major mouse organs.",
      "MIRA-seq helped construct a basic scheme for a mouse cell atlas (MCA).",
      "The mouse cell atlas provides a hierarchy for many tissues that were previously not well characterized."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for methylation-based inference of regulatory activity sequencing and is not a single-cell RNA sequencing platform but rather a technique to measure genome-wide chromatin accessibility.\n2. UNKNOWN (MIRA-seq aims for high-throughput, but without specific context, it's hard to definitively judge its cost relative to other methods.)\n3. UNKNOWN (This statement cannot be verified without specific reference to a study or source data indicating that MIRA-seq was used on this scale.)\n4. UNKNOWN (While large-scale sequencing platforms can contribute to the construction of cell atlases, without specific information confirming MIRA-seq's contribution to the Mouse Cell Atlas, this statement is undeterminable.)\n5. UNKNOWN (The Mouse Cell Atlas aims to provide comprehensive mapping of mouse cell types and can provide hierarchies for various tissues, but without specific data, the contribution of MIRA-seq to this aspect remains unclear.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the indication of ARCALYST is a pseudo triple-enzyme cascade amplified electrochemical aptasensor for the detection of thrombin (TB). The sensor is based on a bionanocomposite of hemin/G-quadruplex and alcohol dehydrogenase-graphene sheets (ADH-GSs), which simultaneously act as NADH oxidase and HRP-mimicking DNAzyme. The sensor uses a \"sandwich\" reaction to capture hemin/G-quadruplex labeled gold nanoparticles-ADH-GSs bionanocomposite (AuNPs-ADH-GSs) on the electrode surface, followed by the addition of ethanol to catalyze the oxidation of NADH by hemin/G-quadruplex and the production of H2O2. The sensor shows a linear range of 1 pM-50 nM with a detection limit of 0.3 pM, good specificity and sensitivity, and satisfactory stability and reproducibility, indicating promising application for the detection of various proteins in clinical analysis.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 14\n2. Chromosome 21\nThe document describes a familial Robertsonian translocation t(14q;21q), + iso dic (?14?21)(pter----q11.1), which involves the exchange of genetic material between chromosomes 14 and 21. The marker chromosome t(14q;21q) is present in the cell and is thought to play a role in the non-disjunction of chromosome 21.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.\n2. Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.\n3. The familial Robertsonian translocation described involves an exchange of genetic material between chromosomes 14 and 21.\n4. The marker chromosome t(14q;21q) is present in cells that have undergone this specific Robertsonian translocation.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.",
      "The familial Robertsonian translocation described involves an exchange of genetic material between chromosomes 14 and 21.",
      "The marker chromosome t(14q;21q) is present in cells that have undergone this specific Robertsonian translocation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nChromosomes 14 and 21 are indeed acrocentric, and they are among those commonly involved in Robertsonian translocations. The familial Robertsonian translocation involving these chromosomes can lead to the formation of a derivative chromosome 14;21, which would be written as der(14;21)(q10;q10) or simply as t(14;21). The \"t(14q;21q)\" notation refers to a translocation involving the long arms (q) of these chromosomes, which is consistent with the Robertsonian translocation mechanism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package that could be used for the identification of pediatric brain tumors is likely to be \"theranostic\". This is because the document discusses the use of a novel theranostic complex of SPIO-Doxorubicin (DOX)-conjugated microbubbles (SD-MBs) for drug delivery to the brain, which enables direct visualization via magnetic resonance imaging and magnetic targeting to actively enhance targeted deposition of the drug. The use of SD-MBs for the identification of pediatric brain tumors would involve using the magnetic targeting aspect of the complex to enhance the deposition of the drug within the tumor tissue, allowing for more accurate diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is unlikely that NEMO is a zinc finger protein. The information provided suggests that A20/AN1 zinc-finger proteins are well characterized in animals and have been reported from plants, but there is no mention of NEMO as a zinc finger protein. Additionally, the information provided highlights the importance of domain analysis in understanding the biological function of A20/AN1 zinc-finger proteins, and there is no mention of NEMO in this context. Therefore, based on the information provided, it is unlikely that NEMO is a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that TFIIS does affect nucleosome positioning. The study found that the lack of TFIIS leads to general increases in nucleosomal fuzziness and more restricted changes in nucleosome occupancy, which concentrates in some gene categories. Specifically, the study found that TATA-containing genes were preferentially associated with decreased occupancy in gene bodies, while TATA-like genes showed increased fuzziness. These changes in nucleosome positioning were found to correlate with functional defects in nascent transcription, as revealed by genomic run-on experiments.\nTherefore, based on the information provided in the document, the answer to the user's question is yes, TFIIS does affect nucleosome positioning.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS influences nucleosome positioning.\n2. The absence of TFIIS results in an overall increase in nucleosomal fuzziness.\n3. A lack of TFIIS causes more confined changes in nucleosome occupancy.\n4. Nucleosome occupancy decreases in gene bodies of TATA-containing genes when TFIIS is lacking.\n5. TATA-like genes exhibit increased fuzziness in the absence of TFIIS.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS influences nucleosome positioning.",
      "The absence of TFIIS results in an overall increase in nucleosomal fuzziness.",
      "A lack of TFIIS causes more confined changes in nucleosome occupancy.",
      "Nucleosome occupancy decreases in gene bodies of TATA-containing genes when TFIIS is lacking.",
      "TATA-like genes exhibit increased fuzziness in the absence of TFIIS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - TFIIS is known to influence transcription elongation by RNA polymerase II (Pol II) and can indirectly affect chromatin structure and potentially nucleosome positioning.\n2. UNKNOWN - The statement about an overall increase in nucleosomal fuzziness due to the absence of TFIIS is specific and would require empirical data to confirm. Without specific data or a source, the veracity of the claim cannot be determined.\n3. UNKNOWN - Similar to the previous statement, the effect of a lack of TFIIS on changes in nucleosome occupancy is specific and without the right context or data, its accuracy cannot be ascertained.\n4. UNKNOWN - This claim about nucleosome occupancy decreasing in gene bodies of TATA-containing genes when TFIIS is lacking is again specific and would need empirical data to confirm its veracity.\n5. UNKNOWN - The statement regarding increased fuzziness in TATA-like genes in the absence of TFIIS would require specific empirical evidence to confirm or deny.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is difficult to give a definitive answer to the user's question about whether origins of replication close to yeast centromeres fire early or late. The information provided does not specifically address this question, and the focus of the passage is on the history of centromere research and the diversity of centromeres across different organisms.\nHowever, the passage does provide some relevant information that could be used to infer an answer to the user's question. For example, the passage mentions that budding yeast and several other fungi have small centromeres with short, well-defined sequences, known as point centromeres. These small centromeres are likely to fire early in the cell cycle, as they have a well-defined sequence that can be easily recognized by the replication machinery.\nOn the other hand, regional centromeres, which span several kilobases to megabases and do not seem to have DNA sequence specificity, are likely to fire later in the cell cycle. These larger centromeres may require more time to assemble and become fully functional, resulting in a later firing time.\nIn summary, while the passage does not directly address the user's question, it provides some clues about the size and structure of centromeres in yeast and their potential firing time in the cell cycle. However, more research is needed to provide a definitive answer to this question.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the properties of mammalian GA-sequences:\n1. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system (CNS) of vertebrates.\n2. GABA has also been reported in multiple cell types outside the CNS, including pulmonary neuroepithelial bodies (NEBs) in monkey lungs.\n3. The NEB microenvironment in mouse lungs expresses both GABAA and GABAB (R1 and R2) receptors.\n4. The vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are exclusively expressed in NEB cells.\n5. The GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs without the need for prior live visualization.\n6. The present study revealed the presence of a GABAergic signaling pathway in the NEB microenvironment of mouse lungs.\n7. The GAD67-GFP mouse model will certainly boost future functional imaging and gene expression analysis of the mouse NEB microenvironment.\nIn summary, the properties of mammalian GA-sequences in the context of this study are related to the expression of GABA and its receptors in the pulmonary NEB microenvironment, and the potential of the GAD67-GFP mouse model for functional imaging and gene expression analysis of this microenvironment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system of vertebrates.\n2. GABA is present in pulmonary neuroepithelial bodies (NEBs) in monkey lungs.\n3. In mouse lungs, the NEB microenvironment expresses both GABAA and GABAB (R1 and R2) receptors.\n4. The vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are found exclusively in NEB cells.\n5. GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs.",
    "llama-2-7b-chat-hf_fact": [
      "Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system of vertebrates.",
      "GABA is present in pulmonary neuroepithelial bodies (NEBs) in monkey lungs.",
      "In mouse lungs, the NEB microenvironment expresses both GABAA and GABAB (R1 and R2) receptors.",
      "The vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are found exclusively in NEB cells.",
      "GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are not found exclusively in NEB cells; they are also present in other types of cells. \n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 509 genes on the mouse chromosome 16 (Mmu 16) that align with orthologs on the corresponding portions of the human genome. This means that there are 509 Groucho-related genes (GRG) contained in the mouse genome.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit's C-terminal domain (CTD). The study found that the CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro, and that the heptads in the vicinity of 30 to 37 in the CTD contribute modestly more than other sections to the cleavage activity. Additionally, the study found that the nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity, while the remaining 80% directly correlates with CTD length, with significant activity requiring approximately 26 or more repeats. Therefore, the answer to the user's question is that the RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain of the largest subunit.",
    "llama-2-7b-chat-hf_fact_raw": "1. The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.\n2. The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.\n3. The heptads in the vicinity of 30 to 37 in the CTD contribute more to the cleavage activity than other sections.\n4. Nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity.\n5. Approximately 26 or more repeats of the CTD are required for significant cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.",
      "The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.",
      "The heptads in the vicinity of 30 to 37 in the CTD contribute more to the cleavage activity than other sections.",
      "Nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity.",
      "Approximately 26 or more repeats of the CTD are required for significant cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The C-terminal domain (CTD) of the largest subunit of RNA polymerase II does not carry RNA cleavage activity. RNA cleavage activity is typically associated with other proteins and complexes involved in RNA processing.\n2. FALSE [correction]: The CTD is involved in the regulation of several aspects of transcription and RNA processing, but the actual catalysis of pre-mRNA polyadenylation cleavage is performed by the cleavage and polyadenylation specificity factor (CPSF) and other associated factors, not by the CTD itself.\n3. UNKNOWN: Without specific information on the function of different heptad repeats within the CTD, it's difficult to verify the contributions of heptads in the vicinity of 30 to 37.\n4. UNKNOWN: The contribution of nonconsensus CTD heptads to wild-type cleavage activity requires specific experimental data for verification.\n5. UNKNOWN: The exact number of CTD repeats required for significant cleavage activity would need to be supported by empirical data, which is not provided in the statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genetic basis of Ohdo syndrome (also known as Japanese Waardenburg syndrome or WS) is primarily caused by mutations in the PAX3, MITF, SOX10, and EDNRB genes. The study found that 5 families with Ohdo syndrome had PAX3 mutations, 4 families had MITF mutations, 3 families had SOX10 mutations, and 1 family had EDNRB mutations. These genetic mutations were found to be more common in the Japanese population than in other ethnic groups, which suggests that the current W index may not be appropriate for clinical classification of Ohdo syndrome in this population. The study recommends resetting the threshold of the W index or developing a novel index that takes into account the patient's ethnicity to improve the consistency between clinical and genetic classifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the PAX3, MITF, SOX10, and EDNRB genes.\n2. A study found that 5 families with Ohdo syndrome had mutations in the PAX3 gene.\n3. According to the study, 4 families with Ohdo syndrome had mutations in the MITF gene.\n4. The study identified that 3 families with Ohdo syndrome had SOX10 mutations.\n5. One family with Ohdo syndrome was found to have an EDNRB mutation.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the PAX3, MITF, SOX10, and EDNRB genes.",
      "A study found that 5 families with Ohdo syndrome had mutations in the PAX3 gene.",
      "According to the study, 4 families with Ohdo syndrome had mutations in the MITF gene.",
      "The study identified that 3 families with Ohdo syndrome had SOX10 mutations.",
      "One family with Ohdo syndrome was found to have an EDNRB mutation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome, also known as Say-Barber-Biesecker-Young-Simpson variant of Ohdo syndrome, is caused by mutations in the KAT6B gene, not PAX3, MITF, SOX10, and EDNRB genes.\n2. FALSE [correction]: Since Ohdo syndrome is caused by mutations in the KAT6B gene, the statement regarding mutations in the PAX3 gene for 5 families with Ohdo syndrome is incorrect.\n3. FALSE [correction]: Given the correct gene associated with Ohdo syndrome is KAT6B, the statement about the MITF gene is incorrect.\n4. FALSE [correction]: As Ohdo syndrome is related to mutations in the KAT6B gene and not SOX10, the statement is false.\n5. FALSE [correction]: The correct gene associated with Ohdo syndrome is KAT6B, so the statement about an EDNRB mutation is false.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is ChAMP (Chromatin Accessibility and Methylation Package). ChAMP is implemented as a Bioconductor package in R and can be downloaded from bioconductor.org.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called ChAMP.\n2. ChAMP stands for Chromatin Accessibility and Methylation Package.\n3. ChAMP is available for download from bioconductor.org.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called ChAMP.",
      "ChAMP stands for Chromatin Accessibility and Methylation Package.",
      "ChAMP is available for download from bioconductor.org."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package called ChAMP stands for Chip Analysis Methylation Pipeline and is developed for the analysis of DNA methylation data, not specifically for psychiatric disease genes.\n2. FALSE [correction]: ChAMP stands for Chip Analysis Methylation Pipeline, not Chromatin Accessibility and Methylation Package.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a radiological sign that can be observed in intracerebral hemorrhage (ICH) on non-contrast computed tomography (CT) scans. It is characterized by a swirling or spiral pattern of blood in the affected area of the brain. This sign is often seen in the early stages of ICH, before the blood has had time to settle and form a well-defined mass.\nThe swirl sign is thought to be caused by the movement of blood within the affected brain tissue, which can create a spiral or swirling pattern on the CT scan. This movement can be due to a variety of factors, including the movement of the blood within the blood vessels, the movement of the brain tissue itself, or the movement of the entire body due to the patient's position during the scan.\nThe swirl sign can be an important diagnostic indicator of ICH, as it can help doctors to identify areas of active bleeding within the brain. However, it is not a definitive sign of ICH, and other conditions can also produce similar patterns on a CT scan. Therefore, it is important to combine the swirl sign with other diagnostic criteria, such as the patient's symptoms and medical history, to make a definitive diagnosis of ICH.\nIn some cases, the swirl sign may be observed on magnetic resonance imaging (MRI) scans as well, particularly in the subacute phase of ICH. MRI can provide additional information on the location and extent of the hemorrhage, as well as the surrounding brain tissue.\nIn summary, the swirl sign is a radiological sign that can be observed on CT scans in the early stages of intracerebral hemorrhage. It is characterized by a swirling or spiral pattern of blood in the affected area of the brain, and can be an important diagnostic indicator of ICH. However, it is not a definitive sign of ICH, and other conditions can also produce similar patterns on a CT scan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological sign observed on non-contrast computed tomography (CT) scans for intracerebral hemorrhage (ICH).\n2. The swirl sign is characterized by a swirling or spiral pattern of blood in the affected area of the brain.\n3. It is often indicative of the early stages of intracerebral hemorrhage.\n4. The swirl sign can help doctors identify areas of active bleeding within the brain for diagnostic purposes.\n5. The swirl sign may also be observed on magnetic resonance imaging (MRI) scans, particularly in the subacute phase of ICH.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological sign observed on non-contrast computed tomography (CT) scans for intracerebral hemorrhage (ICH).",
      "The swirl sign is characterized by a swirling or spiral pattern of blood in the affected area of the brain.",
      "It is often indicative of the early stages of intracerebral hemorrhage.",
      "The swirl sign can help doctors identify areas of active bleeding within the brain for diagnostic purposes.",
      "The swirl sign may also be observed on magnetic resonance imaging (MRI) scans, particularly in the subacute phase of ICH."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign does not refer to a swirling or spiral pattern of blood but rather it indicates the presence of a mix of blood of different ages due to ongoing bleeding, characterized by areas of different densities on CT.\n3. FALSE [correction]: The swirl sign is usually indicative of an active or ongoing bleed rather than the early stages of intracerebral hemorrhage.\n4. TRUE\n5. FALSE [correction]: The swirl sign is typically associated with CT scans rather than MRI. MRI can detect different stages of blood products but does not show the \"swirl sign\" as classically described for CT.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Arabidopsis ROF1 expression is induced by long summer days (LDs). The transcriptional regulator CONSTANS (CO) promotes flowering, and its transcription is increased under LDs. The document also mentions that the F-box protein FKF1 and the transcription factor GIGANTEA (GI) play a role in regulating CO transcription. Specifically, GI stabilizes FKF1, which in turn reduces the abundance of CYCLING DOF FACTOR 2 (CDF2), allowing for increased transcription of CO. Introducing mutations in the four DOF-encoding genes into GI mutants restored the diurnal rhythm and light inducibility of CO, suggesting that there is an antagonism between GI and DOF transcription factors in regulating photoperiodic flowering.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by long summer days (LDs).\n2. The transcriptional regulator CONSTANS (CO) promotes flowering and has increased transcription under LDs.\n3. The F-box protein FKF1 and the transcription factor GIGANTEA (GI) are involved in the regulation of CONSTANS (CO) transcription.\n4. GIGANTEA (GI) stabilizes FKF1, which in turn reduces the abundance of CYCLING DOF FACTOR 2 (CDF2).\n5. Mutations in the four DOF-encoding genes introduced into GI mutants restored the diurnal rhythm and light inducibility of CO.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by long summer days (LDs).",
      "The transcriptional regulator CONSTANS (CO) promotes flowering and has increased transcription under LDs.",
      "The F-box protein FKF1 and the transcription factor GIGANTEA (GI) are involved in the regulation of CONSTANS (CO) transcription.",
      "GIGANTEA (GI) stabilizes FKF1, which in turn reduces the abundance of CYCLING DOF FACTOR 2 (CDF2).",
      "Mutations in the four DOF-encoding genes introduced into GI mutants restored the diurnal rhythm and light inducibility of CO."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GIGANTEA (GI) stabilizes FKF1, which in turn reduces the abundance of CONSTANS (CO) protein by targeting CYCLING DOF FACTOR (CDFs) proteins for degradation, not specifically \"CYCLING DOF FACTOR 2 (CDF2)\" as stated.\n5. UNKNOWN\n\nNote: The statements on Arabidopsis flowering genetics are based on complex interactions that may not be definitively known without specific experimental context or literature. Therefore, responses are provided to the best general knowledge basis in the field, and detailed molecular functions or interactions may vary based on recent research findings.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the protein that is the most common cause of hereditary renal amyloidosis is apolipoprotein AII (apoAII). The article states that mutations in the gene for apoAII have recently been found to cause hereditary renal amyloidosis, and that in each case, amyloid deposition has been associated with a peptide extension at the carboxyl-terminus of apoAII, resulting from mutations in the normal stop codon. The specific mutation mentioned in the article is a T to C transition at the first position of the stop codon, which replaces the stop codon with l-arginine (Arg) at residue 78. This mutation leads to the production of a variant apoAII that is associated with amyloid fibrils in the proband's case. Therefore, based on the information provided in the article, the answer to the user's question is: apolipoprotein AII (apoAII).",
    "llama-2-7b-chat-hf_fact_raw": "1. Apolipoprotein AII (apoAII) is the most common cause of hereditary renal amyloidosis.\n2. Mutations in the gene for apoAII can cause hereditary renal amyloidosis.\n3. Amyloid deposition in hereditary renal amyloidosis has been associated with a peptide extension at the carboxyl-terminus of apoAII.\n4. A specific mutation contributing to hereditary renal amyloidosis involves a T to C transition at the first position of the stop codon.\n5. The mutation mentioned replaces the stop codon with l-arginine (Arg) at residue 78 of the apoAII protein.",
    "llama-2-7b-chat-hf_fact": [
      "Apolipoprotein AII (apoAII) is the most common cause of hereditary renal amyloidosis.",
      "Mutations in the gene for apoAII can cause hereditary renal amyloidosis.",
      "Amyloid deposition in hereditary renal amyloidosis has been associated with a peptide extension at the carboxyl-terminus of apoAII.",
      "A specific mutation contributing to hereditary renal amyloidosis involves a T to C transition at the first position of the stop codon.",
      "The mutation mentioned replaces the stop codon with l-arginine (Arg) at residue 78 of the apoAII protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Apolipoprotein AI (apoAI) mutations are the most common cause of hereditary renal amyloidosis, not apoAII.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The mutation mentioned replaces the stop codon with an arginine codon, but this results in l-arginine at residue 77 of the apoAII protein, not residue 78.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed in various studies. The hippocampus is a critical region of the brain involved in memory formation and spatial navigation, and its proteome has been extensively studied to understand the underlying mechanisms of memory and cognitive decline.\nOne study published in the journal Nature Communications in 2018 analyzed the proteome of the mouse hippocampus at different stages of aging, including young, middle-aged, and old mice. The study found that the aging process is associated with significant changes in the hippocampal proteome, including the downregulation of proteins involved in synaptic plasticity and the upregulation of proteins involved in oxidative stress and inflammation.\nAnother study published in the journal Aging Cell in 2017 analyzed the proteome of the mouse hippocampus in a model of Alzheimer's disease. The study found that the disease is associated with significant changes in the hippocampal proteome, including the downregulation of proteins involved in synaptic plasticity and the upregulation of proteins involved in amyloid- accumulation and neuroinflammation.\nA review published in the journal Neurobiology of Aging in 2019 summarized the current knowledge on the proteome of the mouse hippocampus in aging and age-related neurodegenerative diseases. The review highlighted the importance of the hippocampal proteome in understanding the underlying mechanisms of cognitive decline and identified potential therapeutic targets for the treatment of age-related neurodegenerative diseases.\nIn summary, the proteome of the mouse hippocampus has been extensively analyzed in various studies, and the results provide valuable insights into the underlying mechanisms of memory and cognitive decline in aging and age-related neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been the subject of various studies.\n2. A study published in Nature Communications in 2018 found significant changes in the hippocampal proteome of mice at different stages of aging.\n3. The 2018 study reported downregulation of proteins involved in synaptic plasticity in aging mice.\n4. A study published in Aging Cell in 2017 analyzed the mouse hippocampus proteome in relation to a model of Alzheimer's disease.\n5. The review published in Neurobiology of Aging in 2019 summarized knowledge about the mouse hippocampus proteome concerning aging and age-related neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been the subject of various studies.",
      "A study published in Nature Communications in 2018 found significant changes in the hippocampal proteome of mice at different stages of aging.",
      "The 2018 study reported downregulation of proteins involved in synaptic plasticity in aging mice.",
      "A study published in Aging Cell in 2017 analyzed the mouse hippocampus proteome in relation to a model of Alzheimer's disease.",
      "The review published in Neurobiology of Aging in 2019 summarized knowledge about the mouse hippocampus proteome concerning aging and age-related neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements are in line with common types of scientific research focusing on the hippocampus, aging, and related neurodegenerative diseases where the mouse is a typical model organism. Specific studies from these years might not be verifiable without additional data, but the general content of the statements fits well within the realm of published scientific research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, mouse chromosomes are not acrocentric. In fact, the document states that the chromosomes of the wild-type mouse are all acrocentric, which means that they have a centromere located near the center of the chromosome. However, the WMP2 cell line, which is derived from wild mice, has metacentric Robertsonian translocation chromosomes, which means that the centromere is located closer to one end of the chromosome rather than the center.",
    "llama-2-7b-chat-hf_fact_raw": "1. Wild-type mouse chromosomes are all acrocentric, indicating that their centromeres are located near one end. \n2. The WMP2 cell line, deriving from wild mice, contains metacentric Robertsonian translocation chromosomes. \n3. In metacentric chromosomes, the centromere is located closer to one end of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Wild-type mouse chromosomes are all acrocentric, indicating that their centromeres are located near one end.",
      "The WMP2 cell line, deriving from wild mice, contains metacentric Robertsonian translocation chromosomes.",
      "In metacentric chromosomes, the centromere is located closer to one end of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: In metacentric chromosomes, the centromere is located near the middle of the chromosome, not closer to one end.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is nab-paclitaxel. The document mentions that nab-paclitaxel and gemcitabine are being used as a neoadjuvant treatment for potentially resectable pancreatic adenocarcinoma, and that the combination of these two drugs resulted in a statistically significant decrease in CA19-9 levels, tumoral size, and SUV of FDG PET-CT scan, as well as an increase in the resection rate and histopathological response. The document also mentions that the median survival and disease-free survival of patients who underwent surgery after treatment with nab-paclitaxel and gemcitabine was 21 months and 19 months, respectively, at a mean follow-up of 38.5 months. Therefore, based on the information provided in the document, the answer to the user's question is that nab-paclitaxel is the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nab-paclitaxel is in clinical trials for the treatment of pancreatic cancer.\n2. Nab-paclitaxel and gemcitabine are used as neoadjuvant treatment for potentially resectable pancreatic adenocarcinoma.\n3. The combination of nab-paclitaxel and gemcitabine resulted in a decrease in CA19-9 levels, tumoral size, and SUV of FDG PET-CT scans.\n4. Treatment with nab-paclitaxel and gemcitabine increased the resection rate and histopathological response in patients.\n5. Median survival and disease-free survival after treatment with nab-paclitaxel and gemcitabine was 21 months and 19 months, respectively, at a mean follow-up of 38.5 months.",
    "llama-2-7b-chat-hf_fact": [
      "Nab-paclitaxel is in clinical trials for the treatment of pancreatic cancer.",
      "Nab-paclitaxel and gemcitabine are used as neoadjuvant treatment for potentially resectable pancreatic adenocarcinoma.",
      "The combination of nab-paclitaxel and gemcitabine resulted in a decrease in CA19-9 levels, tumoral size, and SUV of FDG PET-CT scans.",
      "Treatment with nab-paclitaxel and gemcitabine increased the resection rate and histopathological response in patients.",
      "Median survival and disease-free survival after treatment with nab-paclitaxel and gemcitabine was 21 months and 19 months, respectively, at a mean follow-up of 38.5 months."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Nab-paclitaxel, in combination with gemcitabine, is indeed used for the treatment of pancreatic cancer and has been the subject of various clinical trials.\n2. TRUE: Nab-paclitaxel and gemcitabine are used as a combination in neoadjuvant therapy for pancreatic cancer to shrink the tumor before surgical resection.\n3. TRUE: Clinical studies have shown that the combination of nab-paclitaxel and gemcitabine can result in a decrease in CA19-9 levels, reduction in tumoral size, and lower SUV on FDG PET-CT scans in some patients.\n4. TRUE: Treatment with nab-paclitaxel and gemcitabine has been associated with increased resectability and improved histopathological response in certain clinical trials.\n5. UNKNOWN: Without specific reference to a particular study or dataset, the provided median survival and disease-free survival times cannot be verified, and the mean follow-up duration is not sufficient to determine the veracity of the statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the HPG pore refers to the size of the pores on a glass surface that are coated with bovine lung surfactant. The document mentions that the relaxation times of 83Kr in contact with these pores are similar in size to mammalian alveoli, suggesting that the pore size is on the order of a few micrometers. The term HPG pore is likely a combination of \"hydrophilic\" and \"hyperpolarized\" to indicate that the pores are coated with a hydrophilic material and are also used for hyperpolarized (hp) 83Kr NMR spectroscopy.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is an effort to sequence the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in a wide range of environments, including soil, plants, and animals. The initiative aims to provide a comprehensive understanding of the genetic diversity of nematodes, which are important organisms in many ecosystems, but have been largely understudied due to the difficulty of analyzing their genomes.\nThe information provided in the document you provided suggests that the 959 Nematode Genomes initiative is focused on the genome-wide transcriptional profiling of the nematode Caenorhabditis elegans, a well-characterized metazoan that is widely used as a model organism in scientific research. The initiative aims to use oligonucleotide arrays to quantitate the expression of all genes in C. elegans throughout its development, providing an estimate of the number of expressed genes in the nematode and revealing relations between gene function and gene expression that can guide analysis of uncharacterized worm genes. The initiative also demonstrates a shift in expression from evolutionarily conserved genes to worm-specific genes over the course of development.\nOverall, the 959 Nematode Genomes initiative is an ambitious effort to explore the genetic diversity of nematodes and to better understand their biology and ecology. The initiative has the potential to lead to important discoveries in fields such as agriculture, medicine, and environmental science.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. Nematodes are microscopic worms that are found in a wide range of environments.\n3. The initiative seeks to provide a comprehensive understanding of the genetic diversity of nematodes.\n4. The initiative includes genome-wide transcriptional profiling of the nematode Caenorhabditis elegans.\n5. The 959 Nematode Genomes initiative uses oligonucleotide arrays to quantitate the expression of all genes in C. elegans throughout its development.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "Nematodes are microscopic worms that are found in a wide range of environments.",
      "The initiative seeks to provide a comprehensive understanding of the genetic diversity of nematodes.",
      "The initiative includes genome-wide transcriptional profiling of the nematode Caenorhabditis elegans.",
      "The 959 Nematode Genomes initiative uses oligonucleotide arrays to quantitate the expression of all genes in C. elegans throughout its development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements about the 959 Nematode Genomes initiative and nematodes are true. The 959 Nematode Genomes initiative does indeed aim to sequence the genomes of 959 nematode species to understand their genetic diversity, and nematodes are microscopic worms found in various environments. Including genome-wide transcriptional profiling of the nematode Caenorhabditis elegans is a task one might expect in such an initiative.\n\nHowever, without specific details of the techniques used in the 959 Nematode Genomes initiative for profiling gene expression, the fifth statement's accuracy regarding the use of oligonucleotide arrays for quantitating gene expression throughout C. elegans development remains UNKNOWN. If the statement extract included specific technical details, it would be possible to confirm its truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data. However, the document does mention that logistic regression analysis was used to compare the groups, which is a common statistical technique used in R.\nTherefore, if the user wants to perform similar analyses, they could use R's logistic regression function, specifically the `logistic()` function, to perform the analysis. Additionally, R has a wide range of packages for data manipulation, visualization, and statistical analysis, which could be useful for analyzing NIPT data.\nSome of the relevant packages in R for data manipulation and visualization include:\n* `dplyr`: A package for data manipulation and filtering\n* `ggplot2`: A package for data visualization\n* `tidyr`: A package for data manipulation and tidying\nSome of the relevant packages in R for statistical analysis include:\n* `stats`: A package for statistical analysis\n* `lme4`: A package for linear mixed effects models\n* `nlme`: A package for non-linear mixed effects models\nIt's worth noting that the document does not provide any specific information about the data used in the study, so it's possible that the user may need to use other packages or techniques depending on the specifics of their analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data mentioned in the document.\n2. Logistic regression is a common statistical technique used in R for comparing groups.\n3. The `logistic()` function in R can be used to perform logistic regression analysis.\n4. `dplyr` is an R package used for data manipulation and filtering.\n5. `ggplot2` is an R package used for data visualization.",
    "llama-2-7b-chat-hf_fact": [
      "There is no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data mentioned in the document.",
      "Logistic regression is a common statistical technique used in R for comparing groups.",
      "The `logistic()` function in R can be used to perform logistic regression analysis.",
      "`dplyr` is an R package used for data manipulation and filtering.",
      "`ggplot2` is an R package used for data visualization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (Without the document, it is impossible to verify whether an R package for NIPT data analysis is mentioned or not.)\n2. TRUE (Logistic regression is indeed a common statistical technique used in various statistical software including R for comparing groups.)\n3. FALSE [correction]: The function typically used in R for logistic regression analysis is `glm()` with the family parameter set to \"binomial\", not `logistic()`.\n4. TRUE (`dplyr` is a widely used R package that is part of the tidyverse, designed for data manipulation and filtering.)\n5. TRUE (`ggplot2` is a very popular R package that is designed for creating complex and aesthetically pleasing data visualizations.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare condition that is characterized by the presence of AA amyloid deposits in the kidneys, often associated with systemic vasculitis and autoimmune disorders. The syndrome is named after Dr. Edgar Achenbach, who first described it in the medical literature in the 1960s.\nThe exact cause of Achenbach's syndrome is not fully understood, but it is believed to be related to an abnormal immune response that leads to the deposition of AA amyloid in the kidneys. The condition is often associated with other autoimmune disorders, such as Churg-Strauss syndrome, which is a rare systemic and pulmonary vasculitis that is also characterized by the presence of AA amyloid deposits in the kidneys.\nThe symptoms of Achenbach's syndrome can vary depending on the severity of the condition, but may include:\n* Proteinuria (excess protein in the urine)\n* Hematuria (blood in the urine)\n* Renal insufficiency (reduced kidney function)\n* Hypertension (high blood pressure)\n* Flank pain\n* Fatigue\n* Weight loss\nDiagnosis of Achenbach's syndrome is based on a combination of clinical findings, laboratory tests, and imaging studies. Laboratory tests may include:\n* Urinalysis to detect proteinuria and hematuria\n* Blood tests to measure kidney function and detect inflammatory markers\n* Imaging studies, such as ultrasound or CT scans, to evaluate the kidneys and detect any abnormalities\nTreatment of Achenbach's syndrome typically involves a combination of medications to control inflammation and slow the progression of the disease. These may include:\n* Corticosteroids to reduce inflammation\n* Immunosuppressive drugs to suppress the immune system and prevent further damage to the kidneys\n* Blood pressure medications to control hypertension\n* Proteinuria-lowering medications to reduce the amount of protein in the urine\nIn some cases, dialysis may be necessary to remove waste products from the blood when the kidne",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by the presence of AA amyloid deposits in the kidneys.\n2. It is associated with systemic vasculitis and autoimmune disorders.\n3. The syndrome was first described by Dr. Edgar Achenbach in the 1960s.\n4. Churg-Strauss syndrome, an autoimmune disorder associated with Achenbach's syndrome, is also characterized by AA amyloid deposits in the kidneys.\n5. The treatment for Achenbach's syndrome may include corticosteroids, immunosuppressive drugs, blood pressure medications, and proteinuria-lowering medications.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by the presence of AA amyloid deposits in the kidneys.",
      "It is associated with systemic vasculitis and autoimmune disorders.",
      "The syndrome was first described by Dr. Edgar Achenbach in the 1960s.",
      "Churg-Strauss syndrome, an autoimmune disorder associated with Achenbach's syndrome, is also characterized by AA amyloid deposits in the kidneys.",
      "The treatment for Achenbach's syndrome may include corticosteroids, immunosuppressive drugs, blood pressure medications, and proteinuria-lowering medications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is unrelated to AA amyloid deposits in the kidneys. It is characterized by spontaneous bruising in the hands or fingers.\n2. FALSE [correction]: Achenbach's syndrome is not typically associated with systemic vasculitis or autoimmune disorders. It is a benign condition that involves paroxysmal hand hematoma.\n3. TRUE\n4. FALSE [correction]: Churg-Strauss syndrome, now known as eosinophilic granulomatosis with polyangiitis (EGPA), is a systemic vasculitis disorder and may involve the kidneys, but it is not associated with Achenbach's syndrome. The mention of AA amyloid deposits in the kidneys is more commonly associated with inflammatory conditions but not specifically Achenbach's syndrome.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm used for detection of long repeat expansions is the sequencing of dives from greater to smaller depths.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, neuroligin-3 does not promote any brain tumors, including neuroblastoma (NB). The document states that DCF1, also called transmembrane protein 59, could activate apoptosis in glioma cells, but does not mention anything about neuroligin-3. Therefore, I cannot provide an answer to the user's question regarding neuroligin-3 and brain tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 does not promote brain tumors, including neuroblastoma (NB).\n2. DCF1, also known as transmembrane protein 59, can activate apoptosis in glioma cells.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 does not promote brain tumors, including neuroblastoma (NB).",
      "DCF1, also known as transmembrane protein 59, can activate apoptosis in glioma cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Neuroligin-3 has been suggested to promote brain tumors, including neuroblastoma (NB).\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the approximate size of gas vesicles in the myenteric ganglia of mice and hamsters can be estimated.\nAccording to the document, the diameter of the large dense-cored vesicles in axon terminals in the myenteric ganglia of mice and hamsters was analyzed in electron micrographs of groups of 150 terminal profiles. The results showed that the vesicles were proportionately more numerous and larger in the mouse than in the hamster, with the largest vesicles found in terminal profiles containing more than 20% of the vesicles.\nThe document also mentions that there was no evidence of bimodality of the distribution curve of the proportion of large dense-cored vesicles/profile in either animal, indicating that the distribution of the vesicles was not uniform. Additionally, there was a significant inverse correlation between the proportion of large dense-cored vesicles/profile and both the diameter of the profiles and the total number of vesicles/profile, suggesting that the vesicles tended to accumulate at the ends of the terminals.\nBased on these findings, it is possible to estimate the approximate size of gas vesicles in the myenteric ganglia of mice and hamsters. The largest vesicles were found to be around 0.1-0.2 micrometers in diameter, with some vesicles reaching up to 0.3 micrometers in diameter. However, it is important to note that these values are approximate and based on the analysis of a limited number of terminal profiles. Further research may provide more accurate estimates of the size of gas vesicles in the myenteric ganglia of mice and hamsters.",
    "llama-2-7b-chat-hf_fact_raw": "1. The diameter of the largest dense-cored vesicles could be around 0.1-0.2 micrometers, with some reaching up to 0.3 micrometers.\n2. The large dense-cored vesicles were analyzed in electron micrographs of groups of 150 terminal profiles in the myenteric ganglia of mice and hamsters.\n3. Dense-cored vesicles were found to be more numerous and larger in the mouse than in the hamster.\n4. There was no evidence of bimodality in the distribution curve of the proportion of large dense-cored vesicles/profile in either animal.\n5. There was a significant inverse correlation between the proportion of large dense-cored vesicles/profile and both the diameter of the profiles and the total number of vesicles/profile.\n\nPlease note that even though the answer suggests these facts, they are still presented with a level of uncertainty and caveat that they are based on analysis of a limited number of terminal profiles.",
    "llama-2-7b-chat-hf_fact": [
      "The diameter of the largest dense-cored vesicles could be around 0.1-0.2 micrometers, with some reaching up to 0.3 micrometers.",
      "The large dense-cored vesicles were analyzed in electron micrographs of groups of 150 terminal profiles in the myenteric ganglia of mice and hamsters.",
      "Dense-cored vesicles were found to be more numerous and larger in the mouse than in the hamster.",
      "There was no evidence of bimodality in the distribution curve of the proportion of large dense-cored vesicles/profile in either animal.",
      "There was a significant inverse correlation between the proportion of large dense-cored vesicles/profile and both the diameter of the profiles and the total number of vesicles/profile.",
      "ease note that even though the answer suggests these facts, they are still presented with a level of uncertainty and caveat that they are based on analysis of a limited number of terminal profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The diameter range for large dense-cored vesicles is consistent with scientific observations, where they can be significantly larger than small synaptic vesicles which are typically around 40-50 nanometers.\n2. TRUE: Electron micrographs are a common tool to analyze the ultrastructure of cells, including terminal profiles in ganglia, and specifying the number of profiles (150 in this case) is plausible for a detailed study.\n3. UNKNOWN: Without specific data from the research or passage, its not possible to confirm the comparative number of dense-cored vesicles or their size in mice versus hamsters.\n4. UNKNOWN: The distribution curve of large dense-cored vesicle proportion per profile requires specific data to confirm the presence or absence of bimodality for either animal.\n5. UNKNOWN: A significant inverse correlation between the proportion of large dense-cored vesicles/profile and both the diameter of the profiles and the total number of vesicles/profile is plausible, but specific statistical data or findings would be needed to confirm this statement.\n6. UNKNOWN: This statement seems to be a disclaimer about the results, but without context or the actual content it refers to, it's impossible to assess its accuracy. The statement, as presented, also seems incomplete and lacks clarity.\n\nPlease note that the responses to statement 3, 4, 5, and 6 are marked as UNKNOWN because they refer to specific scientific findings that would require access to the relevant research data or publication to verify.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the BET proteins:\n1. Bet v 1l: A hypoallergenic isoform of the major birch pollen allergen Bet v 1, which belongs to the ubiquitous family of pathogenesis-related plant proteins (PR-10).\n2. Bet v 1: A protein that belongs to the PR-10 family and is produced in defense response to various pathogens. Although its allergenic properties have been extensively studied, its biological function in plants is not known.\n3. Brassinolide: A ubiquitous plant steroid hormone that can bind to Bet v 1l, as revealed by mass spectrometry analysis.\n4. 24-Epicastasterone: Another ubiquitous plant steroid hormone that can bind to Bet v 1l, as revealed by mass spectrometry analysis.\nThese are some of the BET proteins mentioned in the document. It is important to note that there may be other BET proteins that are not mentioned in the provided information.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bet v 1l is a hypoallergenic isoform of the major birch pollen allergen Bet v 1.\n2. Bet v 1 and Bet v 1l belong to the PR-10 family of proteins.\n3. Brassinolide is a plant steroid hormone that can bind to Bet v 1l as shown by mass spectrometry.\n4. 24-Epicastasterone is a plant steroid hormone that can also bind to Bet v 1l as demonstrated by mass spectrometry.",
    "llama-2-7b-chat-hf_fact": [
      "Bet v 1l is a hypoallergenic isoform of the major birch pollen allergen Bet v 1.",
      "Bet v 1 and Bet v 1l belong to the PR-10 family of proteins.",
      "Brassinolide is a plant steroid hormone that can bind to Bet v 1l as shown by mass spectrometry.",
      "24-Epicastasterone is a plant steroid hormone that can also bind to Bet v 1l as demonstrated by mass spectrometry."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Bet v 1l is not a hypoallergenic isoform. It's actually Bet v 1, which is the major birch pollen allergen. Bet v 1l, on the other hand, is a hypoallergenic variant designed for immunotherapy.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm developed for prediction of protein subcellular localization using deep learning is Local Ternary Patterns (LTPs) coupled with data balancing technique. Specifically, the authors used Synthetic Minority Oversampling Technique to balance the feature space for the classification stage. The proposed ensemble based prediction system, which uses 10-fold cross-validation, has shown better performance compared to existing techniques in predicting various subcellular compartments for both 2D HeLa and CHO datasets. The predictor is available online at: http://111.68.99.218/Protein_SubLoc/, which is freely accessible to the public.",
    "llama-2-7b-chat-hf_fact_raw": "1. An algorithm developed for prediction of protein subcellular localization using deep learning is Local Ternary Patterns (LTPs) coupled with data balancing technique.\n2. Synthetic Minority Oversampling Technique was used to balance the feature space for the classification stage of the algorithm.\n3. The proposed system used an ensemble based prediction method.\n4. The system was validated using 10-fold cross-validation.\n5. The predictor developed is publicly available online at: http://111.68.99.218/Protein_SubLoc/.",
    "llama-2-7b-chat-hf_fact": [
      "An algorithm developed for prediction of protein subcellular localization using deep learning is Local Ternary Patterns (LTPs) coupled with data balancing technique.",
      "Synthetic Minority Oversampling Technique was used to balance the feature space for the classification stage of the algorithm.",
      "The proposed system used an ensemble based prediction method.",
      "The system was validated using 10-fold cross-validation.",
      "The predictor developed is publicly available online at: http://111.68.99.218/Protein_SubLoc/."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [Correction]: An algorithm that predicts protein subcellular localization using deep learning wouldn't be described as \"Local Ternary Patterns (LTPs)\" since LTPs are a feature descriptor used in image processing, not a deep learning model.\n2. TRUE: It's plausible that the Synthetic Minority Oversampling Technique (SMOTE) was used to balance the feature space, as this is a common technique used to address imbalances in the training datasets for machine learning algorithms.\n3. UNKNOWN: Without specific details about the algorithm, it's unclear whether an ensemble-based prediction method was used.\n4. UNKNOWN: The use of 10-fold cross-validation would be a standard technique to validate a machine learning model, but without further context, we cannot confirm or refute this statement.\n5. UNKNOWN: The URL provided could represent the location where the predictor is available, but without being able to verify the current existence or functionality of the website, this statement is unknown. URLs can change, and services can be discontinued, so the validity of this statement would need to be checked by accessing the website directly.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be a term related to the study of Pasteurella multocida, a Gram-negative bacterium that causes various diseases in birds and mammals, including humans. Specifically, MULTOVL seems to refer to the NLRP3 inflammasome, a complex involved in inducing the host proinflammatory immune response against P. multocida.\nThe NLRP3 inflammasome is a nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome, which plays a critical role in the host immune response to P. multocida infection. The study found that Nlrp3-/- macrophages exhibited a clear decrease in caspase-1 activation and IL-1 secretion in response to P. multocida infection, indicating the importance of the NLRP3 inflammasome in this cellular response.\nIn summary, MULTOVL appears to be a term related to the study of the NLRP3 inflammasome and its role in the host immune response to P. multocida infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a term related to the study of Pasteurella multocida.\n2. Pasteurella multocida is a Gram-negative bacterium that causes diseases in birds, mammals, and humans.\n3. The NLRP3 inflammasome plays a critical role in the host immune response to P. multocida infection.\n4. Nlrp3-/- macrophages have a decreased activation of caspase-1 and secretion of IL-1 in response to P. multocida infection.\n5. The NLRP3 inflammasome is part of the nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a term related to the study of Pasteurella multocida.",
      "Pasteurella multocida is a Gram-negative bacterium that causes diseases in birds, mammals, and humans.",
      "The NLRP3 inflammasome plays a critical role in the host immune response to P. multocida infection.",
      "Nlrp3-/- macrophages have a decreased activation of caspase-1 and secretion of IL-1 in response to P. multocida infection.",
      "The NLRP3 inflammasome is part of the nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, the term \"MULTOVL\" is not immediately recognizable or verifiable in relation to the study of Pasteurella multocida.\n2. TRUE: Pasteurella multocida is a Gram-negative bacterium known to cause various diseases in birds, mammals, and humans, including respiratory infections, septicemia, and others.\n3. TRUE: The NLRP3 inflammasome is known to be important in the immune response against various pathogens, including bacteria like Pasteurella multocida.\n4. TRUE: In general, Nlrp3-/- (deficient) macrophages would have a reduced activation of caspase-1 and subsequent secretion of interleukin-1 (IL-1) in response to infection, consistent with the role of the NLRP3 inflammasome in these processes.\n5. TRUE: The NLRP3 inflammasome is indeed part of the NLR (nucleotide-binding oligomerization domain-like receptor) family, and it contains a pyrin domain; it is specifically categorized as NLR family, pyrin domain containing 3 (NLRP3).",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, GDF15 can potentially be used as a biomarker for metformin treatment. The document mentions that GDF15 is a cytokine that is implicated in biological and disease processes including metabolism, cancer, and chronic inflammation. Additionally, it states that the receptor for GDF15, GFRAL, has been identified as the receptor for MIC-1/GDF15, signaling through the coreceptor Ret. This suggests that GDF15 may play a role in regulating metabolism, which could be affected by metformin treatment. Therefore, measuring GDF15 levels before and after metformin treatment may provide insight into the effectiveness of the treatment and the potential changes in metabolic processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 is a cytokine implicated in metabolic processes.\n2. GDF15 is also implicated in disease processes such as cancer and chronic inflammation.\n3. The receptor for GDF15 is GFRAL.\n4. GDF15 signals through the coreceptor Ret.\n5. Measuring GDF15 levels may provide insight into the effectiveness of metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 is a cytokine implicated in metabolic processes.",
      "GDF15 is also implicated in disease processes such as cancer and chronic inflammation.",
      "The receptor for GDF15 is GFRAL.",
      "GDF15 signals through the coreceptor Ret.",
      "Measuring GDF15 levels may provide insight into the effectiveness of metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that recursive splicing is more common in short introns. The document mentions that minor intron splicing plays a central role in human embryonic development and survival, and that biallelic mutations in RNU4ATAC, which is transcribed into the minor spliceosomal U4atac snRNA, are responsible for several rare autosomal recessive multimalformation disorders. The document also states that RNA-seq experiments have been conducted on a few RFMN patient cells, but none have been performed in TALS, and that no in-depth transcriptomic analysis of the approximately 700 human genes containing a minor (U12-type) intron had been published as yet.\nThe document then goes on to describe the results of sequencing RNA from cells derived from five skin, three amniotic fluid, and one blood biosamples obtained from seven unrelated TALS cases and from age- and sex-matched controls. The results show that U12-type intron splicing profiles are distinct in TALS patients compared to controls, but that mRNA expression levels are mostly unchanged. The document also finds that the level of U12-type intron retention is surprisingly low in fibroblasts and amniocytes, and much more pronounced in blood cells. Additionally, the document finds several occurrences of introns that can be spliced using either U2, U12, or a combination of both types of splice site consensus sequences, with a shift towards splicing using preferentially U2 sites in TALS patients' cells compared to controls.\nOverall, the document suggests that recursive splicing is more common in short introns, and that the splicing patterns of these introns can be altered in certain diseases, such as TALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Biallelic mutations in RNU4ATAC are responsible for several rare autosomal recessive multimalformation disorders.\n3. RNA-seq experiments have been conducted on RFMN patient cells, but none on TALS patients.\n4. No in-depth transcriptomic analysis of the approximately 700 human genes containing a minor (U12-type) intron had been published by the date of the document.\n5. U12-type intron splicing profiles are distinct in TALS patients compared to controls.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Biallelic mutations in RNU4ATAC are responsible for several rare autosomal recessive multimalformation disorders.",
      "RNA-seq experiments have been conducted on RFMN patient cells, but none on TALS patients.",
      "No in-depth transcriptomic analysis of the approximately 700 human genes containing a minor (U12-type) intron had been published by the date of the document.",
      "U12-type intron splicing profiles are distinct in TALS patients compared to controls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in longer introns, not short ones.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements on recursive splicing and diseases caused by mutations are factual and can be verified based on current scientific understanding. However, the statements regarding specific experiments conducted on patient cells or the transcriptomic analysis of human genes are specialized and would require access to specific research papers or databases to verify. Without specific context from the document or access to current published literature, it is not possible to definitively classify the statements about RNA-seq experiments and in-depth transcriptomic analysis as true or false. Similarly, the statement about U12-type intron splicing profiles in TALS patients compared to controls can only be verified by referring to specific scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the TALE-iD method is used for genome engineering applications, including transcriptional modulation and genome editing. Specifically, the TALE-iD method involves the use of transcription activator-like effectors (TALEs) to target specific DNA sequences and modify gene expression. The TALE toolbox described in the document facilitates the rapid construction of custom TALE transcription factors (TALE-TFs) and nucleases (TALENs) using a hierarchical ligation procedure, and allows for the testing of the activity of these custom TALEs in mammalian cells using quantitative reverse-transcription PCR and Surveyor nuclease, respectively. Overall, the TALE-iD method provides a powerful tool for manipulating gene expression and editing genes in a wide range of organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome engineering applications.\n2. This method includes transcriptional modulation and genome editing.\n3. It involves the use of transcription activator-like effectors (TALEs) to target specific DNA sequences.\n4. The TALE toolbox facilitates the rapid construction of custom TALE transcription factors (TALE-TFs) and nucleases (TALENs).\n5. The activity of custom TALEs can be tested in mammalian cells using quantitative reverse-transcription PCR and Surveyor nuclease.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for genome engineering applications.",
      "This method includes transcriptional modulation and genome editing.",
      "It involves the use of transcription activator-like effectors (TALEs) to target specific DNA sequences.",
      "The TALE toolbox facilitates the rapid construction of custom TALE transcription factors (TALE-TFs) and nucleases (TALENs).",
      "The activity of custom TALEs can be tested in mammalian cells using quantitative reverse-transcription PCR and Surveyor nuclease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE \n\nWhile the last statement involves a specific application of testing TALEs, which could overlap with various molecular biology methods, quantitative reverse-transcription PCR (qRT-PCR) is indeed a common method for testing gene expression in mammalian cells, and Surveyor nuclease assay is used to detect mutations induced by nucleases like TALENs. Therefore, given the phrasing of the statement, it seems correct in the context of the TALE toolbox, even though there are multiple ways to test the activity of custom TALEs beyond the ones mentioned.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is likely to be the one that uses compactly supported quadratic spline bases for high-quality Magnetic Resonance Imaging (MRI) with a short imaging time. The simulation results suggested that this type of basis is a strong candidate for MRI encoding, and that using three levels of resolution is the best choice.\nThere are several Lisp frameworks available for image processing, including:\n1. CLISP: A Lisp image processing system that provides a comprehensive set of tools for image analysis and processing.\n2. LispMRI: A Lisp framework for MRI image processing that provides a range of tools for image reconstruction, denoising, and segmentation.\n3. LispImage: A Lisp library for image processing that provides a variety of functions for image manipulation and analysis.\nBased on the information provided, it seems that the best option for image processing using Lisp would be LispMRI, as it is specifically designed for MRI image processing and provides a range of tools for high-quality image reconstruction and analysis.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it is difficult to determine the exact number of genes in S. cerevisiae that are the result of an ancient whole genome duplication. The document does not provide direct information on the number of duplicated genes, and the low degree of homology between the S. cerevisiae genes studied and the corresponding S. paradoxus and S. bayanus genes makes it challenging to identify the duplicated genes.\nHowever, the document does mention that chromosome length polymorphism was found in cultured strains of S. cerevisiae, which suggests that the species has undergone chromosomal rearrangements and duplications in the past. Additionally, the fact that the karyotype pattern of S. bayanus is readily distinguishable from that of S. cerevisiae and S. paradoxus suggests that these species have undergone genetic changes that are not present in S. bayanus.\nGiven these observations, it is possible that some of the genes in S. cerevisiae are the result of an ancient whole genome duplication, but without more information, it is difficult to determine the exact number.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the complex that is bound by estrogen-related receptor  (Esrrb) is the bivalent ligand E-4-E. The document states that this ligand binds to ER with a relative affinity of 1-7% that of estradiol and demonstrates structure-specific, negative site-site interaction. Additionally, the document shows that the E-4-E ligand is effective as an estrogen antagonist in both MCF-7 human breast cancer cells and ER-deficient Chinese hamster ovary (CHO) cells transfected with an expression vector encoding ER. Therefore, based on the information provided, it can be concluded that Esrrb is bound by the bivalent ligand E-4-E.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor  (Esrrb) is bound by the bivalent ligand E-4-E.\n2. The ligand E-4-E binds to ER with a relative affinity of 1-7% that of estradiol.\n3. E-4-E demonstrates structure-specific, negative site-site interaction.\n4. The E-4-E ligand acts as an estrogen antagonist in MCF-7 human breast cancer cells.\n5. The E-4-E ligand is effective as an estrogen antagonist in ER-deficient Chinese hamster ovary (CHO) cells transfected with an expression vector encoding ER.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor  (Esrrb) is bound by the bivalent ligand E-4-E.",
      "The ligand E-4-E binds to ER with a relative affinity of 1-7% that of estradiol.",
      "E-4-E demonstrates structure-specific, negative site-site interaction.",
      "The E-4-E ligand acts as an estrogen antagonist in MCF-7 human breast cancer cells.",
      "The E-4-E ligand is effective as an estrogen antagonist in ER-deficient Chinese hamster ovary (CHO) cells transfected with an expression vector encoding ER."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about Esrrb being bound by the bivalent ligand E-4-E is specific and requires knowledge of biochemical interactions that are not common knowledge. Without additional context or scientific references, it is impossible to determine the truth of this statement.\n\n2. UNKNOWN: This statement mentions the relative affinity of the ligand E-4-E compared to estradiol for ER (estrogen receptor). Again, without specific scientific data or knowledge about this ligand's binding affinity, it is not possible to verify the truth of this statement.\n\n3. UNKNOWN: The mention of a \"structure-specific, negative site-site interaction\" is a technical description that requires scientific evidence or context to verify. Without that information, the statement cannot be accurately assessed.\n\n4. UNKNOWN: The activity of the E-4-E ligand as an estrogen antagonist in MCF-7 human breast cancer cells is a statement that would require experimental results or scientific literature for verification.\n\n5. UNKNOWN: Similar to statement 4, this statement regarding the effectiveness of the E-4-E ligand as an estrogen antagonist in a specific cell line with certain conditions introduced also cannot be verified without appropriate biological research data or literature.\n\nIn summary, these statements are highly technical and specific to the fields of biochemistry and molecular biology. Verification would require access to appropriate scientific studies or databases that detail the activity and binding properties of the ligand E-4-E.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ZCCHC17 (also known as hRAD17) plays a role in controlling tumor growth. The document states that the loss of checkpoint control is a common feature of tumor cells, and that the human homolog of the Schizosaccharomyces pombe rad17 protein (hRAD17) delays growth of NIH3T3 fibroblasts transformed by the H-ras oncogene in nude mice. This suggests that ZCCHC17 is involved in the regulation of cell growth and division, and that its dysfunction may contribute to the development of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is also known as hRAD17.\n2. ZCCHC17 plays a role in controlling tumor growth.\n3. Loss of checkpoint control is a common feature of tumor cells.\n4. The human homolog of the Schizosaccharomyces pombe rad17 protein is hRAD17.\n5. hRAD17 delays the growth of NIH3T3 fibroblasts transformed by the H-ras oncogene in nude mice.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is also known as hRAD17.",
      "ZCCHC17 plays a role in controlling tumor growth.",
      "Loss of checkpoint control is a common feature of tumor cells.",
      "The human homolog of the Schizosaccharomyces pombe rad17 protein is hRAD17.",
      "hRAD17 delays the growth of NIH3T3 fibroblasts transformed by the H-ras oncogene in nude mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ZCCHC17 is not known as hRAD17, it is actually known as zinc finger CCHC-type containing 17 and is a different protein.\n2. UNKNOWN: Without specific context or scientific evidence provided, the role of ZCCHC17 in controlling tumor growth cannot be determined from the given statement.\n3. TRUE: It is generally acknowledged in scientific literature that loss of checkpoint control is a common feature of tumor cells, leading to uncontrolled cell division.\n4. TRUE: The human homolog of the Schizosaccharomyces pombe rad17 protein is indeed hRAD17, which is involved in the DNA damage checkpoint.\n5. UNKNOWN: The statement about hRAD17's effect on the growth of NIH3T3 fibroblasts transformed by the H-ras oncogene in nude mice would require specific experimental evidence to verify, and thus the truth value cannot be determined from the given statement alone.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the proteins that form the nuclear pore basket in human cells are Nup53. The document states that Nup53 is an evolutionary conserved nuclear pore protein that binds independently of other proteins to membranes and is crucial for NPC assembly in both yeast and vertebrates. It also mentions that the vertebrate protein comprises two membrane binding sites, with the C-terminal domain having membrane deforming capabilities, and is specifically required for de novo NPC assembly and insertion into the intact NE during interphase. Additionally, the document states that dimerization of Nup53 contributes to its membrane interaction and is crucial for its function in NPC assembly. Therefore, based on the information provided in the document, the answer to the user's question is Nup53.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nup53 is a protein that forms the nuclear pore basket in human cells.\n2. Nup53 is evolutionarily conserved in yeast and vertebrates.\n3. Nup53 binds independently to membranes and is crucial for nuclear pore complex (NPC) assembly.\n4. The vertebrate Nup53 protein contains two membrane binding sites.\n5. Dimerization of Nup53 is important for its function in NPC assembly.",
    "llama-2-7b-chat-hf_fact": [
      "Nup53 is a protein that forms the nuclear pore basket in human cells.",
      "Nup53 is evolutionarily conserved in yeast and vertebrates.",
      "Nup53 binds independently to membranes and is crucial for nuclear pore complex (NPC) assembly.",
      "The vertebrate Nup53 protein contains two membrane binding sites.",
      "Dimerization of Nup53 is important for its function in NPC assembly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Nup153 (not Nup53) is a protein that forms the nuclear pore basket in human cells.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, gepotidacin is a topoisomerase inhibitor. Specifically, it is a novel triazaacenaphthylene that has shown potent in vitro activity against clinical Neisseria gonorrhoeae isolates and international reference strains. The document mentions that the inactivation of the MtrCDE efflux pump, but not the MacAB or NorM efflux pumps, decreased the geometric mean (GM) of gepotidacin minimum inhibitory concentrations (MICs) for most strains. Additionally, the document notes that the ParC D86N mutation, which is associated with fluoroquinolone resistance, was associated with increased gepotidacin MICs.\nTherefore, based on the information provided in the document, the answer to the user's question is:\nGepotidacin is a topoisomerase inhibitor that has shown potent in vitro activity against gonococcal isolates and international reference strains. The inactivation of the MtrCDE efflux pump, but not the MacAB or NorM efflux pumps, decreases the GM of gepotidacin MICs for most strains. The ParC D86N mutation, which is associated with fluoroquinolone resistance, is associated with increased gepotidacin MICs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. Gepotidacin is classified as a novel triazaacenaphthylene.\n3. Gepotidacin has shown potent in vitro activity against clinical Neisseria gonorrhoeae isolates and international reference strains.\n4. Inactivation of the MtrCDE efflux pump decreases the geometric mean of gepotidacin minimum inhibitory concentrations (MICs) for most strains.\n5. The ParC D86N mutation is associated with increased gepotidacin MICs.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "Gepotidacin is classified as a novel triazaacenaphthylene.",
      "Gepotidacin has shown potent in vitro activity against clinical Neisseria gonorrhoeae isolates and international reference strains.",
      "Inactivation of the MtrCDE efflux pump decreases the geometric mean of gepotidacin minimum inhibitory concentrations (MICs) for most strains.",
      "The ParC D86N mutation is associated with increased gepotidacin MICs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Gepotidacin is a topoisomerase inhibitor, specifically inhibiting bacterial type II topoisomerases, DNA gyrase and topoisomerase IV.\n2. TRUE: Gepotidacin is indeed classified as a novel triazaacenaphthylene antibacterial agent.\n3. TRUE: Gepotidacin has been reported to show potent in vitro activity against clinical isolates and reference strains of Neisseria gonorrhoeae.\n4. FALSE [correction]: Inactivation of the MtrCDE efflux pump actually increases the geometric mean of gepotidacin minimum inhibitory concentrations (MICs) for most strains. Efflux pumps typically transport the drug out of the bacterial cell, and their inactivation would generally lead to increased susceptibility of the bacteria to the antibiotic, thereby lowering the MICs.\n5. TRUE: The ParC D86N mutation has been associated with increased resistance to fluoroquinolones and likely affects susceptibility to other topoisomerase targeting agents like gepotidacin, thus is associated with increased MICs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW, or the Simulated Patient Candidate Evaluation tool, is a closed-feedback system designed to provide constructive feedback to final-year medical students after they have completed the Final Year Ward Simulation Exercise (FYWSE). The tool was developed to help simulated patients (SPs) provide more balanced feedback to students, rather than focusing solely on negative aspects of their performance.\nThe SPaCE tool is a structured, standardized feedback system that allows SPs to rate the applicability of the tool by reviewing previous FYWSE videos. The tool is designed to help SPs identify differences between students' performances and provide feedback based on specific interactions they have had with the students during the exercise.\nThe study found that the SPaCE tool is effective in providing constructive feedback to students, with high correlations shown between the SPs' assessment and the marks awarded by the assessment panel. The tool is also easy to use and can be completed quickly, making it a valuable resource for SPs.\nOverall, the Canvas SPW tool is a useful tool for providing structured feedback to medical students during their clinical skills teaching sessions, helping to improve their performance and interpersonal skills.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is also known as the Simulated Patient Candidate Evaluation tool.\n2. The tool is designed to provide feedback to final-year medical students after the Final Year Ward Simulation Exercise (FYWSE).\n3. The purpose of the Canvas SPW tool is for simulated patients to provide more balanced feedback, emphasizing both positive and negative aspects of student performance.\n4. The SPaCE tool is structured and standardized, allowing simulated patients to rate its applicability by reviewing FYWSE videos.\n5. Studies show high correlations between the SPs' assessment using the SPaCE tool and the marks awarded by the assessment panel.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is also known as the Simulated Patient Candidate Evaluation tool.",
      "The tool is designed to provide feedback to final-year medical students after the Final Year Ward Simulation Exercise (FYWSE).",
      "The purpose of the Canvas SPW tool is for simulated patients to provide more balanced feedback, emphasizing both positive and negative aspects of student performance.",
      "The SPaCE tool is structured and standardized, allowing simulated patients to rate its applicability by reviewing FYWSE videos.",
      "Studies show high correlations between the SPs' assessment using the SPaCE tool and the marks awarded by the assessment panel."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or source material provided for the statements regarding the Canvas SPW or the SPaCE tool, it is not possible to accurately determine the truthfulness of the statements. Further information would be required to verify the details provided in these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are STING agonists:\n1. Crotalphine: The novel and potent analgesic peptide derived from the venom of the South American rattlesnake Crotalus durissus terrificus, which was shown to induce a potent and long-lasting opioid-mediated antinociception in cancer pain.\n2. Nor-binaltorphimine: A selective antagonist of -opioid receptors, which antagonized the antinociceptive effect of crotalphine.\n3. N,N-diallyl-Tyr-Aib-Phe-Leu (ICI 174,864): A selective antagonist of -opioid receptors, which partially reversed the antinociceptive effect of crotalphine.\n4. CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide): An antagonist of -opioid receptors, which did not modify crotalphine-induced antinociception.\nIt is important to note that these are the only STING agonists mentioned in the provided document, and there may be other STING agonists that have not been identified or studied in the context of cancer pain.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in the document, here is what I can tell you about SLIC-CAGE:\nSLIC-CAGE stands for Shelter and Locomotion Increase in Cage Environment. It is a type of enrichment that involves adding different elements to a standard laboratory cage to improve the welfare of mice. The three types of enrichment compared in the study were:\n1. Shelter: This involved adding a small shelter or igloo to the cage, providing a place for the mice to hide and rest.\n2. Shelter + Running Wheel: This involved adding a running wheel to the cage, providing the mice with a way to exercise and move around.\n3. Shelter + Novel Objects: This involved adding a variety of novel objects to the cage, such as toys or puzzles, to provide mental stimulation and interest.\nThe study found that each of these enrichment conditions had different effects on the behavior and well-being of the mice. For example, the shelter condition increased the longevity and reduced aggression in male mice, while the running wheel condition increased aggression and changed behavior in the elevated plus maze and open field test. The novel object condition had the most impact on behavioral measures compared to the standard condition.\nOverall, the study suggests that adding shelter and running wheel to a standard laboratory cage can improve the welfare of mice, while adding novel objects can provide additional mental stimulation and interest. However, it is important to consider the potential effects of each enrichment condition on behavior and well-being, and to carefully design and control experiments to minimize confounds and maximize the validity of the results.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE stands for Shelter and Locomotion Increase in Cage Environment.\n2. The study compared three types of enrichment: adding a shelter, adding a shelter with a running wheel, and adding a shelter with novel objects.\n3. The shelter condition was found to increase longevity and reduce aggression in male mice.\n4. The addition of a running wheel led to increased aggression and behavior changes in the elevated plus maze and open field test.\n5. Adding novel objects had a noticeable impact on behavioral measures compared to a standard laboratory cage condition.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE stands for Shelter and Locomotion Increase in Cage Environment.",
      "The study compared three types of enrichment: adding a shelter, adding a shelter with a running wheel, and adding a shelter with novel objects.",
      "The shelter condition was found to increase longevity and reduce aggression in male mice.",
      "The addition of a running wheel led to increased aggression and behavior changes in the elevated plus maze and open field test.",
      "Adding novel objects had a noticeable impact on behavioral measures compared to a standard laboratory cage condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SLIC-CAGE stands for Shelter, Locomotion, and Complex Environment for Welfare Assessment in Laboratory Mice.\n2. TRUE\n3. UNKNOWN (No specific results provided about the effects of the shelter condition on longevity and aggression.)\n4. UNKNOWN (Insufficient information on the specific impact of the running wheel on aggression and behavior in those particular tests.)\n5. UNKNOWN (The statement is vague; it does not specify what the noticeable impact was or provide details on the comparison to standard laboratory cage conditions.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, LEM-3 appears to be a term related to the Lambert-Eaton myasthenic syndrome (LEMS). Specifically, the document mentions the effects of 3,4-diaminopyridine (3,4-DAP) on the decay of postexercise augmentation in patients with LEMS.\nLEM-3 can be inferred to be a term related to the following roles:\n1. Symptomatic treatment: The document mentions that 3,4-DAP is beneficial in the symptomatic treatment of LEMS.\n2. Decay of postexercise augmentation: The document observes that the amplitude of the compound muscle action potential (CMAP) recorded from abductor digiti minimi decays exponentially after an initial rise, and that the rate of decay is increased after treatment with 3,4-DAP.\n3. Calcium ion efflux: The document suggests that 3,4-DAP has an effect on the efflux of calcium ions from the presynaptic nerve terminal, which is a key mechanism in the transmission of nerve impulses.\nTherefore, LEM-3 can be inferred to be related to the roles of symptomatic treatment, decay of postexercise augmentation, and calcium ion efflux in the context of Lambert-Eaton myasthenic syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is related to the Lambert-Eaton myasthenic syndrome (LEMS).\n2. The document mentions that 3,4-diaminopyridine (3,4-DAP) is used in the symptomatic treatment of LEMS.\n3. 3,4-DAP affects the decay of the amplitude of the compound muscle action potential (CMAP) recorded from abductor digiti minimi in patients with LEMS.\n4. The treatment with 3,4-DAP increases the rate of decay of postexercise augmentation in patients with LEMS.\n5. 3,4-DAP has an effect on the efflux of calcium ions from the presynaptic nerve terminal in the context of LEMS.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is related to the Lambert-Eaton myasthenic syndrome (LEMS).",
      "The document mentions that 3,4-diaminopyridine (3,4-DAP) is used in the symptomatic treatment of LEMS.",
      "3,4-DAP affects the decay of the amplitude of the compound muscle action potential (CMAP) recorded from abductor digiti minimi in patients with LEMS.",
      "The treatment with 3,4-DAP increases the rate of decay of postexercise augmentation in patients with LEMS.",
      "3,4-DAP has an effect on the efflux of calcium ions from the presynaptic nerve terminal in the context of LEMS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: 3,4-DAP does not affect the decay of the amplitude of the compound muscle action potential (CMAP) recorded from abductor digiti minimi in patients with LEMS; it actually aims to improve the CMAP by increasing the release of acetylcholine.\n4. FALSE [correction]: The treatment with 3,4-DAP does not increase the rate of decay of postexercise augmentation in patients with LEMS; instead, it helps to increase or maintain the CMAP after exercise.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of tmVar are as follows:\n1. Acetazolamide (AZ):\n\t* Unmodified matrices: 56 days (approximately 25% of the release period)\n\t* Matrices containing 5% PEG: 56 days (accelerated drug release)\n\t* Matrices with 1% PEG: 39 days (shortened drug release duration by one-third)\n2. Timolol maleate (TM):\n\t* Unmodified matrices: Not specified in the document\n\t* Matrices containing 5% PEG: Not specified in the document\n\t* Matrices with increased NVP content: Not specified in the document\nIt is important to note that these releases are based on the specific modifications made to the PPF/PNVP matrices and the drug loads used in the study. The releases may vary depending on the specific conditions and modifications used in different studies.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the database of somatic mutations in normal cells is not explicitly mentioned. However, the study focuses on identifying important functional residues within sets of related genes, including protein kinases, which are commonly mutated in cancer. The study uses somatic cancer mutations to identify Significantly Mutated Positions (SMPs) in the alignment of human kinases, which may be important to many protein kinases.\nTherefore, while the study does not provide a specific database of somatic mutations in normal cells, it does provide insights into the types of mutations that may be present in normal cells and how they may impact the function of protein kinases. The study also highlights the potential importance of these mutations in cancer and warrants further investigation as potential cancer drivers.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are graph kernel libraries available implemented in Java. The UniProtJAPI library you mentioned in the information provided is one such library that facilitates programmatic access to the UniProt Knowledgebase (UniProtKB) and supports queries and similarity searches that return UniProtKB entries in the form of Java objects. These objects contain functional annotations or sequence information associated with a UniProt entry.\nOther graph kernel libraries implemented in Java include:\n1. GraphBLAS: A Java library for graph computations that provides a set of linear algebra operations for graphs. It is designed to be fast and efficient, making it suitable for large-scale graph processing.\n2. JGraphT: A Java library for graph theory that provides a comprehensive set of graph data structures and algorithms. It includes a wide range of graph types, such as directed and undirected graphs, weighted and unweighted graphs, and more.\n3. GraphCrunch: A Java library for graph processing that provides a set of graph algorithms and data structures. It is designed to be fast and efficient, making it suitable for large-scale graph processing.\n4. Java Graph Library (JGL): A Java library for graph theory that provides a set of graph data structures and algorithms. It includes a wide range of graph types, such as directed and undirected graphs, weighted and unweighted graphs, and more.\nThese libraries can be used for a variety of applications, such as social network analysis, recommendation systems, fraud detection, and more. They provide a range of graph algorithms and data structures that can be used to analyze and process graph data in Java.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UniProtJAPI library is a Java library that provides programmatic access to the UniProt Knowledgebase (UniProtKB).\n2. GraphBLAS is a Java library for graph computations that includes linear algebra operations for graphs.\n3. JGraphT is a Java graph theory library that offers a comprehensive set of graph data structures and algorithms.\n4. GraphCrunch is a Java library for graph processing that includes graph algorithms and data structures.\n5. The Java Graph Library (JGL) provides various graph data structures and algorithms, including types like directed and undirected graphs, weighted and unweighted graphs.",
    "llama-2-7b-chat-hf_fact": [
      "The UniProtJAPI library is a Java library that provides programmatic access to the UniProt Knowledgebase (UniProtKB).",
      "GraphBLAS is a Java library for graph computations that includes linear algebra operations for graphs.",
      "JGraphT is a Java graph theory library that offers a comprehensive set of graph data structures and algorithms.",
      "GraphCrunch is a Java library for graph processing that includes graph algorithms and data structures.",
      "The Java Graph Library (JGL) provides various graph data structures and algorithms, including types like directed and undirected graphs, weighted and unweighted graphs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GraphBLAS is not specifically a Java library; it is a specification for building graph algorithms in the language of linear algebra, and there are implementations in various programming languages. One such implementation is SuiteSparse:GraphBLAS, which is written in C.\n3. TRUE\n4. FALSE [correction]: GraphCrunch is not a Java library; it is software for analyzing the structural and functional properties of biological networks. Also, it is not limited to Java as it was originally implemented in C++.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the four advances integrated into the SHERLOCKv2 platform are:\n1. Molecular dynamics simulations with explicit inclusion of solvent and counterions: The simulations were performed to investigate the structural and dynamic properties of the frame-shifting pseudoknot from beet western yellows virus (BWYV) at room temperature. The inclusion of solvent and counterions in the simulations allowed for a more realistic representation of the molecule's behavior in its native environment.\n2. Investigation of the effects of N3-protonation of C8: The simulations showed that N3-protonation of C8 is important for the stability of the native structure of the pseudoknot. The presence of a proton on C8 stabilizes the molecule and prevents it from unfolding, as observed in the crystal structure.\n3. Study of the effects of mutations on the structure and dynamics of the pseudoknot: The simulations investigated the effects of selected mutations on the structure and dynamics of the pseudoknot. These mutations included changing the G4 x C17 base-pair to A4 x U17, which weakens the trans sugar-edge interaction between positions 4 and 20, and mutating C8 to U8, which correlates with experimental and phylogenetic studies. The simulations showed that these mutations can significantly affect the structure and dynamics of the pseudoknot, leading to changes in the labile regions and the stability of the molecule.\n4. Identification of critical hydration sites: The simulations revealed several critical, highly ordered hydration sites with close to 100 % occupancies and residency times of individual water molecules of up to 5 ns. These sites are important for the stability and function of the pseudoknot, and their identification can provide insights into the mechanisms of protein folding and function.\nOverall, the advances integrated into the SHERLOCKv2 platform provide a more detailed understanding of the structural and dynamic properties of the frame-shifting pseudoknot from BWYV, and can be used to inform models of protein folding and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 platform integrates molecular dynamics simulations with explicit inclusion of solvent and counterions.\n2. The SHERLOCKv2 simulations investigated the effects of N3-protonation of C8 on the stability of a pseudoknot's native structure.\n3. The SHERLOCKv2 platform studied the impact of mutations on the structure and dynamics of a pseudoknot.\n4. SHERLOCKv2 identified critical hydration sites important for the stability and function of the pseudoknot.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 platform integrates molecular dynamics simulations with explicit inclusion of solvent and counterions.",
      "The SHERLOCKv2 simulations investigated the effects of N3-protonation of C8 on the stability of a pseudoknot's native structure.",
      "The SHERLOCKv2 platform studied the impact of mutations on the structure and dynamics of a pseudoknot.",
      "SHERLOCKv2 identified critical hydration sites important for the stability and function of the pseudoknot."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nWith the given context, all statements about the SHERLOCKv2 platform's capabilities and its investigations seem to be true. However, without specific information on whether the simulations actually made those particular findings (such as the impact of N3-protonation or the identification of critical hydration sites), the responses to statements 2 and 4 are based on the assumed capabilities of the platform. If this specific information is not from an authoritative source discussing SHERLOCKv2's findings, the statements would require further verification.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a method for calculating diagonal and off-diagonal matrix elements of quantum mechanical Hamiltonian operators, as described in the paper you provided. The algorithm is an extension of the recursion method of Haydock, Heine, and Kelly, which was originally developed for calculating diagonal matrix elements of the resolvent of quantum mechanical Hamiltonian operators.\nIn the bartender algorithm, the recursion method is applied to off-diagonal matrix elements of general (possibly non-Hermitian) operators. This allows for the calculation of matrix elements that are not limited to diagonal operators, but can also include non-diagonal operators.\nThe algorithm is demonstrated with a couple of applications to the optical absorption and photoemission spectra of the caffeine molecule. These applications show how the bartender algorithm can be used to calculate the matrix elements of the resolvent of a quantum mechanical Hamiltonian operator, and how this can be used to simulate the optical absorption and photoemission spectra of a molecule.\nOverall, the bartender algorithm is a powerful tool for calculating matrix elements of quantum mechanical Hamiltonian operators, and can be used to simulate the optical absorption and photoemission spectra of molecules using time-dependent density-functional and many-body perturbation theories.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm calculates diagonal and off-diagonal matrix elements of quantum mechanical Hamiltonian operators.\n2. It is an extension of the recursion method of Haydock, Heine, and Kelly.\n3. The recursion method was originally developed for calculating diagonal matrix elements of the resolvent of quantum mechanical Hamiltonian operators.\n4. The bartender algorithm is applicable to general (possibly non-Hermitian) operators.\n5. The bartender algorithm has been applied to simulate the optical absorption and photoemission spectra of the caffeine molecule.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm calculates diagonal and off-diagonal matrix elements of quantum mechanical Hamiltonian operators.",
      "It is an extension of the recursion method of Haydock, Heine, and Kelly.",
      "The recursion method was originally developed for calculating diagonal matrix elements of the resolvent of quantum mechanical Hamiltonian operators.",
      "The bartender algorithm is applicable to general (possibly non-Hermitian) operators.",
      "The bartender algorithm has been applied to simulate the optical absorption and photoemission spectra of the caffeine molecule."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The term \"bartender algorithm\" does not correspond to any widely recognized algorithm in quantum mechanics or computational physics. It could be a misnomer, a specialized algorithm not broadly known, or a fictional concept.\n\n2. FALSE [correction]: The correct name is the Lanczos algorithm, an extension of the recursion method developed by Cornelius Lanczos, not the \"bartender algorithm.\" This method is indeed associated with Haydock, Heine, and Kelly who utilized it for condensed matter physics applications.\n\n3. TRUE: The recursion method, related to the Lanczos algorithm, was indeed developed for calculating diagonal matrix elements of the resolvent of quantum mechanical Hamiltonian operators and can be extended to compute various physical properties.\n\n4. UNKNOWN: Since the \"bartender algorithm\" is not recognizable, its applicability to general (possibly non-Hermitian) operators cannot be confirmed. However, if we assume it is a misnomer for the Lanczos algorithm or a similar technique, such approaches can sometimes be extended to non-Hermitian operators, but specific adaptations would be necessary.\n\n5. UNKNOWN: Without accurate reference to a known algorithm, it is not possible to verify the application to simulate optical absorption and photoemission spectra of specific molecules like caffeine. However, quantum mechanical and computational methods are indeed used to simulate such spectra for various molecules. If the \"bartender algorithm\" is referring to a legitimate but less known or new method in computational chemistry, there is no publicly available information to confirm such applications as of my knowledge cutoff in 2023.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several web-based pedigree editors available that can help correct errors in family data collected for genetic studies. Some of these editors include:\n1. PREST: PREST is a software package that implements allele sharing and likelihood-based statistics to efficiently extract genealogical information from available genome-wide marker data. It provides detailed analytical steps and application examples to help users correct errors in their family data.\n2. Pedigree-X: Pedigree-X is a web-based tool that allows users to create and edit family trees, as well as perform genetic analysis. It offers a range of features, including the ability to import and export data, and to visualize genetic relationships.\n3. GenoGrams: GenoGrams is a web-based tool that provides a simple and intuitive interface for creating and editing family trees. It also offers features such as the ability to import and export data, and to visualize genetic relationships.\n4. Family Tree Builder: Family Tree Builder is a web-based tool that allows users to create and edit family trees, as well as perform genetic analysis. It offers a range of features, including the ability to import and export data, and to visualize genetic relationships.\n5. MyHeritage: MyHeritage is a web-based platform that allows users to create and edit family trees, as well as perform genetic analysis. It offers a range of features, including the ability to import and export data, and to visualize genetic relationships.\nThese are just a few examples of the many web-based pedigree editors available. It's important to note that each editor has its own unique features and capabilities, so it's worth exploring each one to determine which one best meets your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. PREST is a software package that uses allele sharing and likelihood-based statistics for genealogical extraction from genome-wide marker data.\n2. Pedigree-X is a web-based tool for creating and editing family trees and performing genetic analysis.\n3. GenoGrams provides a web-based interface for creating and editing family trees with options to import and export data.\n4. Family Tree Builder is a web-based tool that allows genetic analysis and family tree creation with data import and export capabilities.\n5. MyHeritage is a web-platform for creating and editing family trees and performing genetic analysis, including data import and export features.",
    "llama-2-7b-chat-hf_fact": [
      "PREST is a software package that uses allele sharing and likelihood-based statistics for genealogical extraction from genome-wide marker data.",
      "Pedigree-X is a web-based tool for creating and editing family trees and performing genetic analysis.",
      "GenoGrams provides a web-based interface for creating and editing family trees with options to import and export data.",
      "Family Tree Builder is a web-based tool that allows genetic analysis and family tree creation with data import and export capabilities.",
      "MyHeritage is a web-platform for creating and editing family trees and performing genetic analysis, including data import and export features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Pedigree-X is not a known standard web-based tool or software package for creating and editing family trees and performing genetic analysis. The statement seems to refer to a hypothetical or non-existing tool. However, due to lack of specific reference, it is difficult to provide an exact correction.\n3. UNKNOWN: GenoGrams is not widely recognized in the context provided, and without further context, it is unknown whether this description is accurate.\n4. TRUE: Family Tree Builder is a desktop software provided by MyHeritage that allows users to create family trees and offers genetic analysis features.\n5. TRUE: MyHeritage is a web-platform for creating and editing family trees and performing genetic analysis, including data import and export features.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several curated databases that contain information on spider-venom toxins, including:\n1. Toxinology: This database contains a comprehensive collection of toxins, including spider-venom toxins, with information on their structure, function, and biological activities.\n2. VenomDB: This database is a comprehensive resource for venomous animal venoms, including spider venoms, with information on their composition, structure, and biological activities.\n3. SpiderTox: This database contains a collection of spider-venom toxins, including their structure, function, and biological activities, as well as information on their evolution and phylogenetics.\n4. ToxinTDB: This database is a comprehensive collection of toxins, including spider-venom toxins, with information on their structure, function, and biological activities, as well as tools for searching and analyzing toxin data.\n5. BioToxin: This database contains a collection of toxins, including spider-venom toxins, with information on their structure, function, and biological activities, as well as tools for searching and analyzing toxin data.\nThese databases can be useful resources for researchers studying spider-venom toxins and their potential applications in medicine and biotechnology.",
    "llama-2-7b-chat-hf_fact_raw": "1. Toxinology is a database that contains comprehensive information on toxins, including those from spider venom.\n2. VenomDB provides a comprehensive resource for venomous animal venoms, including information on spider venoms.\n3. SpiderTox offers a collection of spider-venom toxins and includes information on their evolution and phylogenetics.\n4. ToxinTDB is a database that includes spider-venom toxins and provides tools for searching and analyzing toxin data.\n5. BioToxin is a database with a collection of toxins, including spider-venom toxins, and offers tools for analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Toxinology is a database that contains comprehensive information on toxins, including those from spider venom.",
      "VenomDB provides a comprehensive resource for venomous animal venoms, including information on spider venoms.",
      "SpiderTox offers a collection of spider-venom toxins and includes information on their evolution and phylogenetics.",
      "ToxinTDB is a database that includes spider-venom toxins and provides tools for searching and analyzing toxin data.",
      "BioToxin is a database with a collection of toxins, including spider-venom toxins, and offers tools for analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is vague about whether \"Toxinology\" is the actual name of a database or just a field of study related to toxins. Without more information, the truth of this statement cannot be assessed.\n2. TRUE: VenomDB is a known database that provides comprehensive resources on various animal venoms, including spider venoms.\n3. TRUE: SpiderTox is a known database that provides information on spider venom toxins and includes data on their evolution and phylogenetics.\n4. FALSE [correction]: ToxinTDB is not a known database. This could be a typographical error, or the database does not exist. However, there is a database called \"Toxin and Toxin Target Database\" (T3DB) that provides comprehensive information about toxins and their targets.\n5. UNKNOWN: The truth of this statement regarding \"BioToxin\" cannot be assessed without more information, as it is unclear whether this is the name of an actual database or the term refers to a broader concept or different entity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is difficult to definitively say whether Axitinib prolongs the survival of Pancreatic Cancer patients. The document you provided is a case report of a patient who developed acute pancreatitis while receiving Axitinib treatment for renal cell carcinoma. While the patient's symptoms and blood lipase levels normalized after Axitinib was withheld, the report does not provide any data on the patient's overall survival or the impact of Axitinib on their survival.\nIt is important to note that the report highlights the potential for Axitinib to cause acute pancreatitis, which is a known side effect of non-selective tyrosine kinase inhibitors such as sorafenib and sunitinib. However, the report does not provide any information on the long-term safety or efficacy of Axitinib in the treatment of pancreatic cancer.\nTherefore, based on the information provided, it is unclear whether Axitinib prolongs the survival of Pancreatic Cancer patients. Further research and clinical trials are needed to determine the safety and efficacy of Axitinib in the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is used in the treatment of renal cell carcinoma.\n2. The case report mentioned addresses acute pancreatitis as a side effect of Axitinib.\n3. Acute pancreatitis is a known side effect of non-selective tyrosine kinase inhibitors.\n4. Sorafenib and sunitinib are examples of non-selective tyrosine kinase inhibitors.\n5. The case report does not provide data on the overall survival impact of Axitinib on pancreatic cancer patients.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is used in the treatment of renal cell carcinoma.",
      "The case report mentioned addresses acute pancreatitis as a side effect of Axitinib.",
      "Acute pancreatitis is a known side effect of non-selective tyrosine kinase inhibitors.",
      "Sorafenib and sunitinib are examples of non-selective tyrosine kinase inhibitors.",
      "The case report does not provide data on the overall survival impact of Axitinib on pancreatic cancer patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (Without access to the specific case report mentioned, it's unclear if it addresses acute pancreatitis as a side effect of Axitinib.)\n3. TRUE (While acute pancreatitis is a known side effect of some tyrosine kinase inhibitors, it's not clear if it is associated with all non-selective tyrosine kinase inhibitors, but it is recognized with some of them.)\n4. TRUE (Sorafenib and sunitinib are indeed examples of non-selective tyrosine kinase inhibitors.)\n5. UNKNOWN (Without access to the specific case report, it's impossible to determine whether it provides data on the overall survival impact of Axitinib on pancreatic cancer patients.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, MLP regulates F-actin dynamics through protein interaction with actin-binding membrane proteins. The study found that 8 polypeptides in liver cell membranes of mature rats bind F-actin directly, and among these, the abundance of three polypeptides (130, 50, and 36 kDa) increases considerably during postnatal development. This suggests that MLP may play a role in regulating the interaction between F-actin and actin-binding membrane proteins during development.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through protein interaction with actin-binding membrane proteins.\n2. The study referenced found that 8 polypeptides in liver cell membranes of mature rats bind F-actin directly.\n3. Among the polypeptides that bind F-actin, the abundance of three specific polypeptides (130, 50, and 36 kDa) increases during postnatal development.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through protein interaction with actin-binding membrane proteins.",
      "The study referenced found that 8 polypeptides in liver cell membranes of mature rats bind F-actin directly.",
      "Among the polypeptides that bind F-actin, the abundance of three specific polypeptides (130, 50, and 36 kDa) increases during postnatal development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or reference to a specific study or body of research, it is difficult to determine the veracity of this statement about MLP regulating F-actin dynamics. MLP could refer to one of several things, including Myosin Light Chain Phosphatase or Muscle LIM Protein, both of which could potentially interact with actin in certain contexts. More information is required to evaluate this claim.\n2. UNKNOWN: This statement is also too specific to evaluate without access to the referenced study or additional context. The binding of polypeptides to F-actin in liver cell membranes could be a finding from a particular piece of research, not widely known or verifiable without the specific reference.\n3. UNKNOWN: Similar to the previous statements, the veracity of this statement regarding the abundance of polypeptides increasing during postnatal development can't be determined without the specific study or context. This information might be accurate within the context of the referenced study, but it is not possible to say for sure without more details.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are approximately 1.6 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are three apoE mimetics:\n1. 1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane: This compound was shown to have a similar behavior to apoE in terms of its ability to mimic beta-adrenergic receptors, as described by Hoefle [8].\n2. 1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride: This compound exhibited a particularly strong and long-lasting sympathicomimetic effect, which is a characteristic of apoE.\n3. 1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride: This compound reduced the beta-adrenergic blockade and suppressed the sympathicomimetic action, which is similar to the action of apoE.\nIt is important to note that these compounds are not apoE itself, but rather mimetics that mimic the action of apoE on beta-adrenergic receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. 1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane is an apoE mimetic that mimics beta-adrenergic receptors.\n2. 1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that exhibited a strong and long-lasting sympathicomimetic effect.\n3. 1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that reduced beta-adrenergic blockade and suppressed sympathicomimetic action.",
    "llama-2-7b-chat-hf_fact": [
      "1-(3',4'-Dimethoxyphenylethylamino)-2-hydroxy-3-phenoxypropane is an apoE mimetic that mimics beta-adrenergic receptors.",
      "1-[beta-(3-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that exhibited a strong and long-lasting sympathicomimetic effect.",
      "1-[beta-(4-Nitrophenylamino)ethylamino]-2-hydroxy-3-phenoxypropane hydrochloride is an apoE mimetic that reduced beta-adrenergic blockade and suppressed sympathicomimetic action."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement describes a chemical compound but does not provide enough context to assess its biological activity or function as an apoE mimetic or its specificity towards beta-adrenergic receptors.\n2. TRUE, assuming the chemical description correlates with a known compound with these properties. However, without additional context or scientific references, it is difficult to confirm the pharmacological effects stated.\n3. UNKNOWN, as the statement mixes pharmacological terminology ('reduced beta-adrenergic blockade' which suggests it would counteract the effects of beta-blockers) with 'suppressed sympathicomimetic action' (which could imply it reduces the effects that mimic the sympathetic nervous system). Without further context, it's unclear whether the chemical compound indeed possesses these properties or if there is an error in the description.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are sex differences in SAMHD1 activity. Specifically, the study found that the expression level of SAMHD1 mRNA and protein is lower in HIV-1-permissive cells compared to HIV-1-non-permissive cells. Additionally, the study found that the regulatory mechanism of SAMHD1 expression is still unclear, but that microRNA-181 (miR-181) level is negatively correlated with SAMHD1 expression level.\nThe study also found that miR-181 acts directly on the SAMHD1 3' untranslated region (UTR) and regulates SAMHD1 mRNA levels after transcription. Over-expression of miR-181 reduced the level of SAMHD1 expression in THP-1 cells, while inhibition of miR-181 up-regulated SAMHD1 expression in THP-1 and Jurkat cells. These findings suggest that miR-181 regulates the level of post-transcriptional SAMHD1 expression negatively by directly binding to the 3' UTR in SAMHD1.\nTherefore, based on the information provided in the document, there are sex differences in SAMHD1 activity, with lower expression levels in HIV-1-permissive cells, and miR-181 playing a negative regulatory role in SAMHD1 expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The expression level of SAMHD1 mRNA and protein is lower in HIV-1-permissive cells compared to HIV-1-non-permissive cells.\n2. The regulatory mechanism of SAMHD1 expression is associated with microRNA-181 (miR-181) levels.\n3. MicroRNA-181 (miR-181) level is negatively correlated with SAMHD1 expression level.\n4. MicroRNA-181 (miR-181) acts directly on the SAMHD1 3' untranslated region (UTR) and affects mRNA levels post-transcription.\n5. Over-expression of miR-181 reduces SAMHD1 expression in THP-1 cells, while inhibition of miR-181 up-regulates SAMHD1 expression in THP-1 and Jurkat cells.",
    "llama-2-7b-chat-hf_fact": [
      "The expression level of SAMHD1 mRNA and protein is lower in HIV-1-permissive cells compared to HIV-1-non-permissive cells.",
      "The regulatory mechanism of SAMHD1 expression is associated with microRNA-181 (miR-181) levels.",
      "MicroRNA-181 (miR-181) level is negatively correlated with SAMHD1 expression level.",
      "MicroRNA-181 (miR-181) acts directly on the SAMHD1 3' untranslated region (UTR) and affects mRNA levels post-transcription.",
      "Over-expression of miR-181 reduces SAMHD1 expression in THP-1 cells, while inhibition of miR-181 up-regulates SAMHD1 expression in THP-1 and Jurkat cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It has been reported that the expression level of SAMHD1 mRNA and protein is lower in HIV-1-permissive cells compared to HIV-1-non-permissive cells, which suggests that SAMHD1 might have a role in the susceptibility of cells to HIV-1 infection.\n2. TRUE: Several studies have suggested that microRNAs, including microRNA-181 (miR-181), may be involved in the regulatory mechanism of SAMHD1 expression in various cell types.\n3. TRUE: A negative correlation between microRNA-181 (miR-181) level and SAMHD1 expression level would mean that higher levels of miR-181 are associated with lower levels of SAMHD1 expression, which is consistent with miR-181 potentially acting as a regulator of SAMHD1.\n4. TRUE: MicroRNAs, including miR-181, typically function by binding to the 3' untranslated region (UTR) of their target mRNAs, leading to the repression of gene expression post-transcriptionally either by degradation of the mRNA or by repression of translation.\n5. TRUE: The statement is consistent with known roles of microRNAs in gene expression regulation. Over-expression of a microRNA typically leads to down-regulation of its target gene, while inhibition of a microRNA can up-regulate the expression of the target gene. This is in line with experimental results from studies involving manipulation of miR-181 levels and observing the effects on SAMHD1 expression in different cell lines such as THP-1 and Jurkat cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that RUNX2 does inhibit astrocyte differentiation. The study found that mature astrocytes have a reduced capacity and different molecular bases for supporting neurite outgrowth compared to immature astrocytes. The results suggest that functional changes during astrocyte maturation may contribute to regulating axon growth in the mammalian central nervous system (CNS).\nTherefore, the answer to the user's question is yes, RUNX2 inhibits astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 inhibits astrocyte differentiation.\n2. Mature astrocytes have a reduced capacity for supporting neurite outgrowth compared to immature astrocytes.\n3. Functional changes during astrocyte maturation may regulate axon growth in the mammalian central nervous system (CNS).",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 inhibits astrocyte differentiation.",
      "Mature astrocytes have a reduced capacity for supporting neurite outgrowth compared to immature astrocytes.",
      "Functional changes during astrocyte maturation may regulate axon growth in the mammalian central nervous system (CNS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nIn the absence of the specific passage the statements were extracted from, I'm providing responses based on general scientific consensus as of my knowledge cutoff in 2023. RUNX2 is a transcription factor known for its role in bone development and has been implicated in inhibiting the differentiation of neural stem cells into astrocytes. Mature astrocytes are generally considered to have a reduced capacity for supporting neurite outgrowth when compared to their immature counterparts, and the functional changes that astrocytes undergo during maturation can indeed regulate axon growth in the CNS. However, these statements are subject to the context and details provided in the specific passage they are extracted from.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Cobb-Stainsby excision arthroplasty would be performed in the knee joint, specifically at the patellofemoral articulation. This is the area where the patella (kneecap) meets the femur (thighbone). The procedure involves removing the accumulated hypertrophic fibrous tissue at the superior margin of the patellar button, which can cause symptoms such as catching or \"clunking\" of the extensor mechanism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed in the knee joint.\n2. It is specifically done at the patellofemoral articulation.\n3. The patellofemoral articulation is where the patella meets the femur.\n4. The procedure involves removing hypertrophic fibrous tissue at the superior margin of the patellar button.\n5. The surgery can address symptoms like catching or \"clunking\" of the extensor mechanism.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed in the knee joint.",
      "It is specifically done at the patellofemoral articulation.",
      "The patellofemoral articulation is where the patella meets the femur.",
      "The procedure involves removing hypertrophic fibrous tissue at the superior margin of the patellar button.",
      "The surgery can address symptoms like catching or \"clunking\" of the extensor mechanism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is not performed specifically at the patellofemoral articulation; it is a procedure performed to manage hip joint pathology.\n3. TRUE\n4. FALSE [correction]: The Cobb-Stainsby excision arthroplasty does not involve removing hypertrophic fibrous tissue at the superior margin of the patellar button, as it is a procedure related to the hip joint, not the knee.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that GRHL2 over-expression does not directly lead to EMT. The document states that silencing or removal of the histone variant H2A.X induces mesenchymal-like characteristics, including activation of the EMT transcription factors Slug and Zeb1 in human colon cancer cells. However, in the breast cell line MCF10A, H2A.X loss leads to a robust EMT activation, as substantiated by a genome-wide expression analysis.\nAdditionally, the document mentions that H2A.X expression level tightly correlates with Twist1, and to a lesser extent with Slug in the panel of human breast cancer cell lines of the NCI-60 datasets. This suggests that H2A.X may be involved in the EMT processes in cells of different origins, but the specific transcription factors involved in EMT may be tissue-specific.\nTherefore, based on the information provided in the document, it can be concluded that while H2A.X is involved in EMT processes, GRHL2 over-expression does not directly lead to EMT in all cell types.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silencing or removal of the histone variant H2A.X induces mesenchymal-like characteristics in human colon cancer cells.\n2. Activation of EMT transcription factors Slug and Zeb1 occurs in human colon cancer cells with H2A.X loss.\n3. In the breast cell line MCF10A, loss of H2A.X leads to a robust activation of EMT, as shown by genome-wide expression analysis.\n4. H2A.X expression level correlates with Twist1 and, to a lesser extent, with Slug in the panel of human breast cancer cell lines of the NCI-60 datasets.\n5. GRHL2 over-expression does not directly lead to EMT in all cell types.",
    "llama-2-7b-chat-hf_fact": [
      "Silencing or removal of the histone variant H2A.X induces mesenchymal-like characteristics in human colon cancer cells.",
      "Activation of EMT transcription factors Slug and Zeb1 occurs in human colon cancer cells with H2A.X loss.",
      "In the breast cell line MCF10A, loss of H2A.X leads to a robust activation of EMT, as shown by genome-wide expression analysis.",
      "H2A.X expression level correlates with Twist1 and, to a lesser extent, with Slug in the panel of human breast cancer cell lines of the NCI-60 datasets.",
      "GRHL2 over-expression does not directly lead to EMT in all cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage or study these statements are drawn from, it is impossible to determine the truth or falsehood of these technical assertions relating to molecular biology, cellular behavior, and genomics. Each statement would need to be evaluated against current, credible scientific data or the specific context they were drawn from to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in lung cancer:\n1. Bladder urothelial cell carcinoma (UCC): The document specifically mentions that bladder UCC is an increasingly prevalent cancer worldwide, and that gaining a better understanding of its identifiable risk factors is a global priority. The study evaluated the genomic instability in bladder cancer patients and controls, and found that the frequencies of micronuclei (MN) in urothelial exfoliated cells (UEC), buccal exfoliated cells (BEC), and peripheral blood lymphocytes (PBL) were significantly higher in patients than in controls.\n2. Lung cancer: While the document does not specifically mention lung cancer, the study's focus on identifying risk factors for bladder UCC suggests that the methods used in the study could also be applied to other types of cancer, including lung cancer.\nIt is important to note that the study only evaluated the genomic instability in bladder cancer patients and controls, and did not directly investigate the relationship between T-UCRs and lung cancer. However, the findings of the study suggest that MN assays, particularly in UEC, may be used to identify individuals who are at high risk of developing UCC, and could potentially be used as a triage test to identify individuals who may benefit from further testing for lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, GPR151 is an orphan receptor that is related to GPR88, another orphan receptor that has been identified as an attractive therapeutic target for various basal ganglia-associated disorders. While GPR88 has been the focus of limited pharmacological characterization due to the lack of potent and selective agonists and antagonists, GPR151 has been identified as a potential alternative target for modulating cAMP levels through the use of small molecule agonists and antagonists.\nThe information provided suggests that GPR151 is coupled to G proteins and modulates cAMP levels, similar to GPR88. However, the specific mechanism of action of GPR151 is not fully understood, and further research is needed to determine its full potential as a therapeutic target.\nThe structure-activity relationship (SAR) studies mentioned in the passage suggest that the amine group in 2-AMPP can be replaced by hydroxyl, ester, and amide groups, resulting in analogues with good to moderate potency. The phenyl group on the amide cap is also essential for activity, but has limited size, shape, and electronic tolerance. These findings suggest that GPR151 may be a promising target for the development of new drugs, particularly those that can modulate cAMP levels and potentially treat basal ganglia-associated disorders.\nIn summary, while GPR151 is an orphan receptor that is related to GPR88, it has the potential to be a distinct and valuable target for the development of new drugs for treating various diseases. Further research is needed to fully understand the mechanism of action of GPR151 and to identify potent and selective agonists and antagonists for this receptor.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor related to another orphan receptor, GPR88.\n2. GPR88 has been identified as an attractive therapeutic target for basal ganglia-associated disorders.\n3. GPR151 has been identified as a potential target for modulating cAMP levels using small molecule agonists and antagonists.\n4. GPR151 is coupled to G proteins and affects cAMP levels.\n5. Structure-activity relationship (SAR) studies have shown that replacing the amine group in 2-AMPP with hydroxyl, ester, and amide groups results in analogues with good to moderate potency for targeting GPR151.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor related to another orphan receptor, GPR88.",
      "GPR88 has been identified as an attractive therapeutic target for basal ganglia-associated disorders.",
      "GPR151 has been identified as a potential target for modulating cAMP levels using small molecule agonists and antagonists.",
      "GPR151 is coupled to G proteins and affects cAMP levels.",
      "Structure-activity relationship (SAR) studies have shown that replacing the amine group in 2-AMPP with hydroxyl, ester, and amide groups results in analogues with good to moderate potency for targeting GPR151."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n1. X-31 ca, H3N2 (a live attenuated influenza vaccine)\nThe document mentions that this vaccine was evaluated in a study as a fast-acting prophylaxis against both heterologous (A/New Caledonia/99, H1N1) and heterotypic (B/Shangdong/97, influenza B) infection, and that vaccination resulted in the generation of a significant pool of reassortant virus between the vaccine and virulent strains, suggesting that the acquisition of attenuating gene(s) from the live vaccine contributes to the attenuation of virulence.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains X-31 ca, an H3N2 live attenuated influenza vaccine.\n2. The vaccine is assessed for its effectiveness as a fast-acting prophylaxis against heterologous and heterotypic infections.\n3. The heterologous infection mentioned is A/New Caledonia/99, H1N1.\n4. The heterotypic infection mentioned is B/Shangdong/97, influenza B.\n5. The study suggested that the reassortant virus between the vaccine and virulent strains may result in the attenuation of virulence due to the acquisition of attenuating gene(s) from the live vaccine.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains X-31 ca, an H3N2 live attenuated influenza vaccine.",
      "The vaccine is assessed for its effectiveness as a fast-acting prophylaxis against heterologous and heterotypic infections.",
      "The heterologous infection mentioned is A/New Caledonia/99, H1N1.",
      "The heterotypic infection mentioned is B/Shangdong/97, influenza B.",
      "The study suggested that the reassortant virus between the vaccine and virulent strains may result in the attenuation of virulence due to the acquisition of attenuating gene(s) from the live vaccine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluzone intradermal quadrivalent vaccine is an inactivated vaccine, not a live attenuated influenza vaccine. Live attenuated vaccines, like the one that could contain a strain such as X-31 ca, are different from inactivated vaccines like Fluzone.\n2. TRUE, although the specific context of the statement is not provided, vaccines are generally assessed for their effectiveness against various infections, including heterologous (different strains within the same subtype) and heterotypic (different types) infections.\n3. UNKNOWN because there is no specific context given that allows verification of the exact strain of the heterologous infection being referred to, and \"A/New Caledonia/99, H1N1\" might be an example used in a particular study.\n4. UNKNOWN because, similarly to statement 3, without further context or reference to a specific study or assessment, it is difficult to determine the accuracy of the statement about the heterotypic infection.\n5. UNKNOWN because this is a specific scientific claim that requires a detailed context or reference to a study to verify its accuracy. Without additional information, it is not possible to determine the truthfulness of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "According to the provided information, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus (SLE) is the TNFSF4 gene. Specifically, two single-nucleotide polymorphisms (SNPs) in the TNFSF4 gene, rs2205960 and rs10489265, were found to be associated with renal involvement in SLE patients in the Chinese population. These SNPs were found to be correlated with lower TNFSF4 expression, and strong TNFSF4 expression was detected in lymph nodes and \"apparently normal\" paratumor renal biopsy but not in renal biopsies from lupus nephritis. Additionally, TNFSF4 was downregulated in glomeruli and tubulointerstitium from kidney biopsies in SLE patients. These findings suggest that the TNFSF4 gene may play a role in the pathogenesis of SLE and could potentially be used as a marker for lupus nephritis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFSF4 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. The single-nucleotide polymorphisms (SNPs) rs2205960 and rs10489265 in the TNFSF4 gene have been associated with renal involvement in SLE patients within the Chinese population.\n3. These SNPs are correlated with lower TNFSF4 gene expression.\n4. Strong TNFSF4 gene expression was detected in lymph nodes and \"apparently normal\" paratumor renal biopsy but not in renal biopsies from lupus nephritis.\n5. TNFSF4 was downregulated in glomeruli and tubulointerstitium from kidney biopsies in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFSF4 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "The single-nucleotide polymorphisms (SNPs) rs2205960 and rs10489265 in the TNFSF4 gene have been associated with renal involvement in SLE patients within the Chinese population.",
      "These SNPs are correlated with lower TNFSF4 gene expression.",
      "Strong TNFSF4 gene expression was detected in lymph nodes and \"apparently normal\" paratumor renal biopsy but not in renal biopsies from lupus nephritis.",
      "TNFSF4 was downregulated in glomeruli and tubulointerstitium from kidney biopsies in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFSF4 gene (also known as OX40L) has been genetically associated with Systemic Lupus Erythematosus (SLE).\n\n2. UNKNOWN: While the statement is highly specific, and there has been research on associations between SNPs in the TNFSF4 gene and SLE, without access to the specific study or studies that explore these SNPs in the Chinese population, we cannot determine the truth of this statement.\n\n3. UNKNOWN: The correlation between these SNPs and TNFSF4 gene expression would require specific scientific evidence to confirm or refute. Without that information, the truth of this statement remains unknown.\n\n4. UNKNOWN: The expression pattern of TNFSF4 in various tissues and its relation to lupus nephritis would need to be confirmed with specific scientific studies. Without such data, this statement's accuracy cannot be determined.\n\n5. UNKNOWN: The regulation of TNFSF4 expression in glomeruli and tubulointerstitium in kidney biopsies from SLE patients is a specific claim that requires empirical data to confirm. As the information is not provided here, the truth of this statement is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, there is currently no vaccine available for peanut allergy. The article discusses a clinical trial investigating the safety and immunologic effects of a vaccine containing modified peanut proteins, but the results of the trial showed that the vaccine resulted in frequent adverse reactions, including severe allergic reactions in some participants. The article concludes that further research is needed to determine the safety and efficacy of a peanut allergy vaccine. Therefore, as of the publication of the article, there is no approved vaccine for peanut allergy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Currently, no vaccine is available for peanut allergy.\n2. A clinical trial was conducted to investigate the safety and immunologic effects of a vaccine containing modified peanut proteins.\n3. The results of the trial indicated that the vaccine resulted in frequent adverse reactions.\n4. Severe allergic reactions occurred in some participants of the trial.\n5. Further research is needed to determine the safety and efficacy of a peanut allergy vaccine.",
    "llama-2-7b-chat-hf_fact": [
      "Currently, no vaccine is available for peanut allergy.",
      "A clinical trial was conducted to investigate the safety and immunologic effects of a vaccine containing modified peanut proteins.",
      "The results of the trial indicated that the vaccine resulted in frequent adverse reactions.",
      "Severe allergic reactions occurred in some participants of the trial.",
      "Further research is needed to determine the safety and efficacy of a peanut allergy vaccine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (As of my knowledge cutoff in 2023, there is no commercially available vaccine for peanut allergies.)\n2. UNKNOWN (Without additional context, it is not possible to verify whether such a clinical trial took place and what it investigated.)\n3. UNKNOWN (Lacking further information, the frequency of adverse reactions resulting from the trial cannot be determined.)\n4. UNKNOWN (Without additional information, it is impossible to assess the occurrence of severe allergic reactions among trial participants.)\n5. TRUE (It is a common practice that further research is needed to determine the safety and efficacy of new vaccines, including a hypothetical peanut allergy vaccine.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mouse Fxy gene's chromosomal position is unique in that its chromosomal location can be recognized across species boundaries. Specifically, the RNA splice signal and poly(A) addition site of the mouse Fxy gene are utilized only when the fragment is inserted in the \"sense\" orientation, indicating that genomic mouse signals for both splicing and polyadenylation are recognized across species boundaries. Additionally, the document states that only an 18 bp segment was included on the 5' border of the intervening sequence, which allows for a maximum length for this splice signal to be defined.",
    "llama-2-7b-chat-hf_fact_raw": "1. The chromosomal location of the mouse Fxy gene can be recognized across species boundaries.\n2. The RNA splice signal and poly(A) addition site of the mouse Fxy gene are utilized when the fragment is inserted in the \"sense\" orientation.\n3. Genomic mouse signals for splicing and polyadenylation are recognized across species boundaries.\n4. An 18 bp segment is included on the 5' border of the intervening sequence of the mouse Fxy gene.",
    "llama-2-7b-chat-hf_fact": [
      "The chromosomal location of the mouse Fxy gene can be recognized across species boundaries.",
      "The RNA splice signal and poly(A) addition site of the mouse Fxy gene are utilized when the fragment is inserted in the \"sense\" orientation.",
      "Genomic mouse signals for splicing and polyadenylation are recognized across species boundaries.",
      "An 18 bp segment is included on the 5' border of the intervening sequence of the mouse Fxy gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n\nIt's important to note that while statements 1, 2, and 3 are broadly about gene expression and could be true, without specific scientific literature or context for the mouse Fxy gene, these statements are difficult to verify. Statement 4 is especially particular and would require specific knowledge or research on the mouse Fxy gene to confirm its accuracy. Without additional context, the truth of statement 4 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). According to the provided information, MALDI-TOF MS offers a potential alternative for the rapid detection of carbapenemase-producing Enterobacteriaceae (CPE) in the clinical laboratory setting. The method has a sensitivity of 87% and a specificity of 100% when compared to PCR as the reference method.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method is based on matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS).\n2. MALDI-TOF MS is proposed as an alternative method for rapid detection of carbapenemase-producing Enterobacteriaceae (CPE) in clinical laboratory settings.\n3. The sensitivity of the MPE-seq method, when compared to PCR as the reference method, is reported to be 87%.\n4. The specificity of the MPE-seq method, when compared to PCR, is reported to be 100%.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method is based on matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS).",
      "MALDI-TOF MS is proposed as an alternative method for rapid detection of carbapenemase-producing Enterobacteriaceae (CPE) in clinical laboratory settings.",
      "The sensitivity of the MPE-seq method, when compared to PCR as the reference method, is reported to be 87%.",
      "The specificity of the MPE-seq method, when compared to PCR, is reported to be 100%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that the programming language used for implementing GWAR is an object-oriented meta-language. The document mentions that object-oriented languages are suitable for describing structural organization by hierarchical classes and taking advantage of statistical properties to reduce the number of parameters while keeping the complexity of behaviors. Additionally, the document suggests that using an object-oriented language to describe each element and posting it to a public domain should be the next step to build up integrated models of the respiratory control system.\nTherefore, based on the information provided in the document, the answer to the user's question is:\nObject-oriented language.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no conclusive evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS). The document discusses the safety and tolerability of ursodeoxycholic acid, a cytoprotective bile acid, in ALS patients. While the study shows that ursodeoxycholic acid is well absorbed and crosses the blood-brain barrier in a dose-dependent manner, there is no mention of any improvement in the prognosis of ALS patients.\nIn fact, the document states that ALS is a progressive degenerative disease that typically leads to death in 3 to 5 years, highlighting the urgent need for effective treatments. While the study suggests that ursodeoxycholic acid may have neuroprotective effects, more research is needed to determine its efficacy in treating ALS. Therefore, it can be concluded that xaliproden is not a proven treatment for ALS at this time.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no conclusive evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. The discussed document mentions the safety and tolerability of ursodeoxycholic acid in ALS patients.\n3. Ursodeoxycholic acid is well absorbed and crosses the blood-brain barrier in a dose-dependent manner.\n4. Amyotrophic lateral sclerosis (ALS) typically leads to death in 3 to 5 years.\n5. More research is needed to determine the efficacy of ursodeoxycholic acid in treating ALS.",
    "llama-2-7b-chat-hf_fact": [
      "There is no conclusive evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "The discussed document mentions the safety and tolerability of ursodeoxycholic acid in ALS patients.",
      "Ursodeoxycholic acid is well absorbed and crosses the blood-brain barrier in a dose-dependent manner.",
      "Amyotrophic lateral sclerosis (ALS) typically leads to death in 3 to 5 years.",
      "More research is needed to determine the efficacy of ursodeoxycholic acid in treating ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the transgene is inserted in chromosome 3R. Specifically, the insertion site of the transgene at 87C1 is located in the euchromatic arm of chromosome 3R, and the transgene exhibits mosaic expression when targeted by a fusion protein made of the DNA-binding domain of GAL4 and the heterochromatin-associated protein HP1. The document also mentions that the genomic environs of the insertion site at 87C1 comprise the dispersed repetitive elements micropia and alphagamma, and that GAL4-HP1 tethering on one homologue trans-inactivates the reporter on the other. These features suggest that the transgene is inserted in a region of euchromatin on chromosome 3R.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line is inserted in chromosome 3R.\n2. The insertion site of the transgene is at location 87C1 on chromosome 3R.\n3. The transgene is located in the euchromatic arm of chromosome 3R.\n4. The genomic environment of the insertion site at 87C1 includes the dispersed repetitive elements micropia and alphagamma.\n5. The transgene displays mosaic expression when targeted by a fusion protein composed of GAL4's DNA-binding domain and the heterochromatin-associated protein HP1.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line is inserted in chromosome 3R.",
      "The insertion site of the transgene is at location 87C1 on chromosome 3R.",
      "The transgene is located in the euchromatic arm of chromosome 3R.",
      "The genomic environment of the insertion site at 87C1 includes the dispersed repetitive elements micropia and alphagamma.",
      "The transgene displays mosaic expression when targeted by a fusion protein composed of GAL4's DNA-binding domain and the heterochromatin-associated protein HP1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE [assuming \"euchromatic arm\" refers to the gene-rich, less condensed regions of a chromosome; however, it's important to note that 87C1 would have to be a specific annotation confirming this euchromatic location, which I can't verify without additional context]\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific background knowledge about the LiPS-A3S line, the chromosome 3R and its specific sections, or the genetic constructs mentioned, it's impossible to accurately confirm the veracity of statements 1, 2, 4, and 5.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools that can be used for predicting drug synergy. Here are a few options:\n1. CImbinator: As mentioned in the information section, CImbinator is a web-service that can aid in batch-wise and in-depth analysis of data from small-scale and large-scale drug combination screens. It offers to quantify drug combination effects using both the commonly employed median effect equation, as well as advanced experimental mathematical models describing dose response relationships.\n2. DeepDrug: DeepDrug is a deep learning framework for predicting drug synergy and toxicity. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to analyze large-scale drug combination datasets.\n3. DrugCombinator: DrugCombinator is a deep learning tool for predicting drug synergy and toxicity. It uses a combination of CNNs and RNNs to analyze large-scale drug combination datasets and predict the most effective drug combinations.\n4. DrugNet: DrugNet is a deep learning tool for predicting drug synergy and toxicity. It uses a combination of CNNs and RNNs to analyze large-scale drug combination datasets and predict the most effective drug combinations.\n5. RDKit: RDKit is an open-source tool for cheminformatics and drug discovery. It includes a range of tools for predicting drug synergy, including a deep learning model for predicting drug-drug interactions.\nIt's important to note that these are just a few examples of the many deep learning tools available for predicting drug synergy, and the choice of tool will depend on the specific needs and requirements of the user.",
    "llama-2-7b-chat-hf_fact_raw": "1. CImbinator is a web-service tool for analyzing data from drug combination screens and quantifying drug combination effects.\n2. DeepDrug is a deep learning framework that uses convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug synergy and toxicity.\n3. DrugCombinator is a tool for predicting drug synergy and toxicity that employs both CNNs and RNNs for analysis.\n4. DrugNet uses a combination of CNNs and RNNs to predict the most effective drug combinations.\n5. RDKit is an open-source cheminformatics and drug discovery tool that includes a deep learning model for predicting drug-drug interactions.",
    "llama-2-7b-chat-hf_fact": [
      "CImbinator is a web-service tool for analyzing data from drug combination screens and quantifying drug combination effects.",
      "DeepDrug is a deep learning framework that uses convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug synergy and toxicity.",
      "DrugCombinator is a tool for predicting drug synergy and toxicity that employs both CNNs and RNNs for analysis.",
      "DrugNet uses a combination of CNNs and RNNs to predict the most effective drug combinations.",
      "RDKit is an open-source cheminformatics and drug discovery tool that includes a deep learning model for predicting drug-drug interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no widely known tool specifically called \"DrugCombinator\" that is recognized for predicting drug synergy and toxicity using CNNs and RNNs.\n4. UNKNOWN\n5. FALSE [correction]: RDKit is an open-source cheminformatics software, but it does not include a deep learning model as an integral component. It provides tools for cheminformatics, but users would have to integrate it with machine learning libraries to predict drug-drug interactions using deep learning models.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the cloud-based platform that has been developed for comparing GWAS is the improved score test based on the generalized linear model. This test is uniformly more powerful than the commonly used tests, including the Cochran-Armitage trend test, the allelic (2) test, the genotypic (2) test, the haplotypic (2) test, and the multi-marker genotypic (2) test. The improved score test includes these commonly used tests as special cases, making it a more powerful alternative for analyzing large-scale GWAS data.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 (BCNU/cyclophosphamide) may be effective in treating sarcomas. The study mentioned in the passage used the C1300 murine neuroblastoma system to determine the relevance of this chemotherapy model to human disease, and found that the combination of BCNU/cyclophosphamide increased the median lifespan of mice bearing the C1300 tumor by 300%. While the study did not specifically mention sarcomas, the results suggest that this chemotherapy combination may be effective in treating other types of cancer as well, including sarcomas. However, it is important to note that this is based on a study in mice, and further research is needed to determine the efficacy of CMB305 in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 may be effective in treating sarcomas.\n2. The study used the C1300 murine neuroblastoma system to determine the relevance to human disease.\n3. The combination of BCNU/cyclophosphamide increased the median lifespan of mice bearing the C1300 tumor by 300%.\n4. There is an implication that the chemotherapy combination might be effective against other types of cancer, including sarcomas. \n5. Further research is needed to determine the efficacy of CMB305 in humans.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 may be effective in treating sarcomas.",
      "The study used the C1300 murine neuroblastoma system to determine the relevance to human disease.",
      "The combination of BCNU/cyclophosphamide increased the median lifespan of mice bearing the C1300 tumor by 300%.",
      "There is an implication that the chemotherapy combination might be effective against other types of cancer, including sarcomas.",
      "Further research is needed to determine the efficacy of CMB305 in humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWithout additional context to verify the specific research findings mentioned in statements 1-4, the truthfulness of those statements cannot be determined. However, statement 5 is generally true as further research is typically necessary to determine the efficacy of any treatment, such as CMB305, in humans after initial studies or findings.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the manifestations of the Saint's Triad are:\n1. Transient syncope (fainting): The first clinical manifestation of the Saint's Triad is transient syncope, which is a sudden loss of consciousness that lasts for a short period of time.\n2. Bilateral calcification of the stylohyoid ligament: The neck radiographic examination showed bilateral calcification of the stylohyoid ligament, which is a fibrous band that connects the styloid process of the temporal bone to the hyoid bone.\n3. Doubly articulated extension: The calcification of the stylohyoid ligament is doubly articulated, meaning that it extends to both the superior and inferior surfaces of the ligament.\n4. Compression of the internal carotid artery: The calcification of the stylohyoid ligament compresses the internal carotid artery, which is a major blood vessel that supplies blood to the brain.\nTherefore, the Saint's Triad is a combination of transient syncope, bilateral calcification of the stylohyoid ligament, doubly articulated extension, and compression of the internal carotid artery.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first clinical manifestation of the Saint's Triad is transient syncope, which is a temporary loss of consciousness.\n2. Bilateral calcification of the stylohyoid ligament is a manifestation of the Saint's Triad.\n3. The calcification of the stylohyoid ligament in Saint's Triad is doubly articulated, extending to both the superior and inferior surfaces of the ligament.\n4. In Saint's Triad, calcification of the stylohyoid ligament causes compression of the internal carotid artery.",
    "llama-2-7b-chat-hf_fact": [
      "The first clinical manifestation of the Saint's Triad is transient syncope, which is a temporary loss of consciousness.",
      "Bilateral calcification of the stylohyoid ligament is a manifestation of the Saint's Triad.",
      "The calcification of the stylohyoid ligament in Saint's Triad is doubly articulated, extending to both the superior and inferior surfaces of the ligament.",
      "In Saint's Triad, calcification of the stylohyoid ligament causes compression of the internal carotid artery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Saints Triad typically does not include transient syncope as a clinical manifestation. The term is generally used to refer to the combination of hiatal hernia, gallstones, and diverticulosis. Transient syncope is not a classic feature of these conditions.\n2. FALSE [correction]: Bilateral calcification of the stylohyoid ligament is not a manifestation of the Saint's Triad. It can occur in a condition known as Eagle syndrome.\n3. UNKNOWN: The description of the stylohyoid ligament's calcification as \"doubly articulated\" is not clear in the context of known medical terminology. Without further context or definition of what's meant by \"doubly articulated,\" it's difficult to assess the truth of this statement.\n4. FALSE [correction]: In the context of Saint's Triad, there is no direct correlation with calcification of the stylohyoid ligament causing compression of the internal carotid artery. Saint's Triad refers to the coexistence of hiatal hernia, gallstones, and diverticulosis, none of which involve the internal carotid artery. In the case of Eagle syndrome, elongation or calcification of the stylohyoid ligament can cause various symptoms, which may include vascular compression, but this is separate from Saint's Triad.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer patients. In fact, the study suggests that overexpression of H694R or E1384K mutant ALK leads to hyperphosphorylation of ALK, which can result in enhanced cell proliferation, colony formation, cell migration, and tumor growth in xenograft models. Additionally, the study found that the activated phospho-Y1604 ALK was increasingly detected in 13 human lung cancer cell lines and 263 lung cancer specimens, regardless of tumor stages and types. These findings suggest that overexpression of LY6K may not be a favorable prognostic marker for non-small cell lung cancer patients.\nIt is important to note that this study focused specifically on the ALK gene and its mutations in lung cancer, and did not examine the prognostic significance of LY6K in this context. Therefore, further research is needed to confirm whether LY6K overexpression is associated with a better or worse prognosis in non-small cell lung cancer patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer patients according to the study mentioned.\n2. Overexpression of H694R or E1384K mutant ALK leads to hyperphosphorylation of ALK.\n3. Hyperphosphorylation of ALK can result in enhanced cell proliferation, colony formation, cell migration, and tumor growth in xenograft models.\n4. Activated phospho-Y1604 ALK was increasingly detected in 13 human lung cancer cell lines and 263 lung cancer specimens in the study mentioned.\n5. The study which is the basis for this information specifically focused on the ALK gene and its mutations in lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer patients according to the study mentioned.",
      "Overexpression of H694R or E1384K mutant ALK leads to hyperphosphorylation of ALK.",
      "Hyperphosphorylation of ALK can result in enhanced cell proliferation, colony formation, cell migration, and tumor growth in xenograft models.",
      "Activated phospho-Y1604 ALK was increasingly detected in 13 human lung cancer cell lines and 263 lung cancer specimens in the study mentioned.",
      "The study which is the basis for this information specifically focused on the ALK gene and its mutations in lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (without specific reference to the study, it's unclear if these findings are from the mentioned study or another source)\n5. UNKNOWN (the provided statements don't explicitly confirm whether the study focused solely on the ALK gene and its mutations or involved other genes and factors as well)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are CDK targets that are dephosphorylated during cytokinesis:\n1. RPA32: Cdk5 can carry out the RPA32 priming phosphorylations on serines 23, 29, and 33, which are necessary for intra-S checkpoint activation.\n2. SMC1: Cdk5 depletion was associated with reduced phosphorylation of SMC1-Serine 966, which is involved in the intra-S checkpoint activation.\n3. RPA: Cdk5 depletion led to lower levels of RPA serine 4 and 8 phosphorylation, which are important for DNA repair and checkpoint activation.\n4. DNA damage: Cdk5 depletion was associated with higher levels of DNA damage, as measured by the alkaline Comet assay, gamma-H2AX signal intensity, RPA and Rad51 foci, and sister chromatid exchanges.\nIn summary, Cdk5 plays a critical role in the intra-S checkpoint activation by phosphorylating and activating key repair proteins, such as RPA32, SMC1, and DNA damage response proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdk5 is responsible for phosphorylating RPA32 on serines 23, 29, and 33 during cytokinesis.\n2. Dephosphorylation of SMC1-Serine 966 is associated with Cdk5 depletion during cytokinesis.\n3. Cdk5 depletion leads to reduced phosphorylation levels of RPA serine 4 and 8.\n4. Higher levels of DNA damage are associated with Cdk5 depletion as measured by several methods including the alkaline Comet assay, gamma-H2AX signal intensity, RPA and Rad51 foci, and sister chromatid exchanges.\n5. Cdk5 plays a role in the activation of the intra-S checkpoint by phosphorylating key repair proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Cdk5 is responsible for phosphorylating RPA32 on serines 23, 29, and 33 during cytokinesis.",
      "Dephosphorylation of SMC1-Serine 966 is associated with Cdk5 depletion during cytokinesis.",
      "Cdk5 depletion leads to reduced phosphorylation levels of RPA serine 4 and 8.",
      "Higher levels of DNA damage are associated with Cdk5 depletion as measured by several methods including the alkaline Comet assay, gamma-H2AX signal intensity, RPA and Rad51 foci, and sister chromatid exchanges.",
      "Cdk5 plays a role in the activation of the intra-S checkpoint by phosphorylating key repair proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cdk5 is known for its role in neuronal development, not cytokinesis, and it primarily phosphorylates substrates like tau, not RPA32. The specific serines listed are not established targets of Cdk5.\n2. UNKNOWN: There is limited information to validate or refute the statement about dephosphorylation of SMC1-Serine 966 in relation to Cdk5 during cytokinesis without specific scientific context or references.\n3. UNKNOWN: Similarly, without specific context or scientific literature to back the statement, the relationship between Cdk5 depletion and RPA serine 4 and 8 phosphorylation levels cannot be confirmed or denied.\n4. FALSE [correction]: Cdk5 is primarily associated with neuronal functions and not directly linked to DNA damage response pathways typically involving signaling by gamma-H2AX, RPA, Rad51, and sister chromatid exchanges as indicated. However, Cdk5 may indirectly affect DNA damage response pathways through complex cell signaling mechanisms, but the direct association as stated is not accurate.\n5. FALSE [correction]: Cdk5 is not directly involved in the activation of the intra-S checkpoint, which is more commonly associated with ATR, Chk1, and other specific checkpoint kinases. Cdk5's role is primarily related to neuronal development and function, and although it may have some influence on cell cycle processes, it is not known for directly phosphorylating key repair proteins in this checkpoint pathway.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem appears to be a new species of insect, specifically a type of wasp, that has been discovered in areas of moderately high altitude in Northeastern Brazil. The species is described in a document titled \"Xylocopa (Monoxylocopa) macambirae sp. nov.\" The document provides a detailed diagnosis of the species and also presents a complementary diagnosis for the subgenus.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the Hof1-Cyk3 interaction in yeast is to facilitate the ubiquitination of the Upf1 protein by the E2 Ubc3 enzyme. The CH domain of Upf1, which is rich in cysteine and histidine residues, plays a RING-related role in the ubiquitination process, allowing Upf1 to act as an E3 ubiquitin ligase. The interaction between Hof1 and Cyk3 is necessary for the ubiquitination of Upf1, as substitution of the coordinated cysteine and histidine residues in the CH domain impairs both self-ubiquitination of Upf1 and the rapid decay of aberrant mRNAs. These results suggest that the Hof1-Cyk3 interaction plays an important role in signaling to the nonsense-mediated mRNA decay (NMD) pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast facilitates the ubiquitination of the Upf1 protein.\n2. The E2 Ubc3 enzyme is involved in the ubiquitination process of Upf1 protein in yeast.\n3. The CH domain of Upf1 is rich in cysteine and histidine residues.\n4. Upf1 can act as an E3 ubiquitin ligase due to its CH domain.\n5. Substitution of coordinated cysteine and histidine residues in the CH domain impairs self-ubiquitination of Upf1 and the rapid decay of aberrant mRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast facilitates the ubiquitination of the Upf1 protein.",
      "The E2 Ubc3 enzyme is involved in the ubiquitination process of Upf1 protein in yeast.",
      "The CH domain of Upf1 is rich in cysteine and histidine residues.",
      "Upf1 can act as an E3 ubiquitin ligase due to its CH domain.",
      "Substitution of coordinated cysteine and histidine residues in the CH domain impairs self-ubiquitination of Upf1 and the rapid decay of aberrant mRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Hof1-Cyk3 interaction in yeast is involved in cytokinesis, not in the ubiquitination of the Upf1 protein.\n2. UNKNOWN\n3. FALSE [correction]: The CH domain usually refers to a Calponin Homology domain, which is typically not rich in cysteine and histidine residues; rather, it is a conserved domain found in cytoskeletal and signal transduction proteins.\n4. FALSE [correction]: Upf1 is known as a component of the nonsense-mediated mRNA decay (NMD) pathway and does not act as an E3 ubiquitin ligase due to its CH domain.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the following T-UCRs have been implicated in gastric cancer:\n1. T-cells: The document mentions that immune response of regional lymph nodes, their function, and tumor localization in the stomach appear to influence metastatic involvement most. This suggests that T-cells play a crucial role in the progression of gastric cancer.\n2. Ubiquitin C-terminal Ras (UCR): The document does not specifically mention UCR, but it does discuss the role of immune response in gastric cancer metastasis. UCR is a protein that is involved in cell signaling pathways and has been implicated in various types of cancer, including gastric cancer.\nTherefore, based on the information provided in Document-0, T-cells and UCR have been implicated in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Immune response of regional lymph nodes, their function, and tumor localization in the stomach appear to influence metastatic involvement in gastric cancer.\n2. T-cells play a crucial role in the progression of gastric cancer.\n3. Ubiquitin C-terminal Ras (UCR) is a protein involved in cell signaling pathways.\n4. UCR has been implicated in various types of cancer, including gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Immune response of regional lymph nodes, their function, and tumor localization in the stomach appear to influence metastatic involvement in gastric cancer.",
      "T-cells play a crucial role in the progression of gastric cancer.",
      "Ubiquitin C-terminal Ras (UCR) is a protein involved in cell signaling pathways.",
      "UCR has been implicated in various types of cancer, including gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Ubiquitin C-terminal Hydrolase L1 (UCH-L1) is a protein involved in cell signaling pathways, not Ubiquitin C-terminal Ras (UCR).\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various organs and tissues in the body. The LSI was developed based on the findings of a study that classified SLE patients into mild or more severe groups based on renal biopsy changes and the degree of proteinuria (excess protein in the urine).\nThe study found that HLA phenotype A2 plus B7 was associated with mild cases of SLE, while HLA phenotype A1 plus B8 was associated with more severe disease. The LSI takes into account these immunogenetic factors and assigns a score based on the combination of HLA-A and -B locus antigens present in the patient's genetic makeup.\nThe LSI score can range from 0 to 10, with higher scores indicating more severe disease. A score of 0-3 indicates mild disease, 4-6 indicates moderate disease, and 7-10 indicates severe disease.\nIn summary, the Lupus Severity Index is a tool used to assess the severity of SLE based on immunogenetic factors, such as HLA phenotype, and can help healthcare providers identify patients who may require more aggressive treatment or monitoring.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI classification is based on renal biopsy changes and the degree of proteinuria.\n3. HLA phenotype A2 plus B7 is associated with mild cases of SLE according to the study linked with LSI development.\n4. HLA phenotype A1 plus B8 is associated with more severe cases of SLE according to the study linked with LSI development.\n5. The LSI scores range from 0 to 10, with higher scores indicating more severe disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI classification is based on renal biopsy changes and the degree of proteinuria.",
      "HLA phenotype A2 plus B7 is associated with mild cases of SLE according to the study linked with LSI development.",
      "HLA phenotype A1 plus B8 is associated with more severe cases of SLE according to the study linked with LSI development.",
      "The LSI scores range from 0 to 10, with higher scores indicating more severe disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence and use of a Lupus Severity Index (LSI) to assess the severity of systemic lupus erythematosus (SLE) are not standard or widely recognized in medical literature. Typically, the SLE Disease Activity Index (SLEDAI) or the British Isles Lupus Assessment Group (BILAG) index is used. Without specific details about the LSI, the truth of this statement cannot be determined.\n\n2. UNKNOWN: Since the LSI is not a well-established or recognized tool, the basis of its classification cannot be confirmed. Typically, renal involvement in SLE is assessed by different means, such as the renal domain of the SLEDAI or direct biopsy findings and proteinuria levels, but this is not specific to an \"LSI.\"\n\n3. UNKNOWN: HLA phenotype associations with SLE severity can vary based on studies and specific genetic backgrounds; without the specific study linked to the development of the LSI mentioned, this statement's validity cannot be confirmed.\n\n4. UNKNOWN: Similar to the previous statement on HLA phenotypes, without direct access to the study linked to the supposed development of the LSI, the association between HLA phenotype A1 plus B8 and severe cases of SLE in the context of LSI cannot be verified.\n\n5. UNKNOWN: Given that the legitimacy and specifics of the LSI as a scale for SLE severity are unknown and it is not a standard assessment measure, the score range and its implications cannot be confirmed or denied.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, de novo mutations in the ZSWIM6 gene have been associated with the following disorders:\n1. Amyotrophic lateral sclerosis (ALS): The document mentions that de novo mutations in the FUS gene (which is also known as ZSWIM6) have been found in approximately 1% to 2% of sporadic ALS cases, highlighting the importance of screening ALS patients for FUS mutations.\nTherefore, based on the information provided, de novo mutations in ZSWIM6 have been linked to ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene are associated with amyotrophic lateral sclerosis (ALS).\n2. The FUS gene is also known as ZSWIM6.\n3. De novo mutations in the FUS/ZSWIM6 gene are found in approximately 1% to 2% of sporadic ALS cases.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene are associated with amyotrophic lateral sclerosis (ALS).",
      "The FUS gene is also known as ZSWIM6.",
      "De novo mutations in the FUS/ZSWIM6 gene are found in approximately 1% to 2% of sporadic ALS cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in the ZSWIM6 gene are associated with a rare neurodevelopmental disorder, not amyotrophic lateral sclerosis (ALS).\n2. FALSE [correction]: The FUS gene is a separate gene and is not also known as ZSWIM6. De novo mutations in the FUS gene, however, are associated with amyotrophic lateral sclerosis (ALS).\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is Parkinson's disease. The article discusses the use of the Koos Classification in the three-class case, specifically for the classification of subjects into three ordered categories based on a continuous diagnostic marker. The article also provides methods for estimating the true class fractions that correspond to the optimal cut-off points estimated by the generalized Youden index, and obtains joint confidence regions for the optimal true class fractions in three- and multi-dimensional spaces. The application of these methods is illustrated with an example using the Trail Making Test Part A, which has been used to characterize cognitive impairment in patients with Parkinson's disease. Therefore, based on the information provided, Parkinson's disease is the disease that can be classified using the Koos Classification.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify Parkinson's disease.\n2. The Koos Classification involves classifying subjects into three ordered categories based on a continuous diagnostic marker.\n3. Methods for estimating the true class fractions are provided, which correspond to optimal cut-off points estimated by the generalized Youden index.\n4. The article discusses obtaining joint confidence regions for the optimal true class fractions in three- and multi-dimensional spaces.\n5. The Trail Making Test Part A is used to characterize cognitive impairment in patients with Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify Parkinson's disease.",
      "The Koos Classification involves classifying subjects into three ordered categories based on a continuous diagnostic marker.",
      "Methods for estimating the true class fractions are provided, which correspond to optimal cut-off points estimated by the generalized Youden index.",
      "The article discusses obtaining joint confidence regions for the optimal true class fractions in three- and multi-dimensional spaces.",
      "The Trail Making Test Part A is used to characterize cognitive impairment in patients with Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Hoehn and Yahr scale, not the Koos Classification, is commonly used to classify the stages of Parkinson's disease.\n2. FALSE [correction]: The Koos Classification refers to a classification system used for cerebellopontine angle tumors based on radiological imaging. It does not entail classifying subjects into categories based on a continuous diagnostic marker for Parkinson's disease.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE: The Trail Making Test Part A is a neuropsychological test that can be used to help characterize cognitive impairment, which may include patients with Parkinson's disease.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, AZD8601 (AZD1775) is a small molecule WEE1 inhibitor that can enhance the cytotoxicity of 5-FU in p53-mutated colorectal cancer cells by increasing double-stranded DNA (DS-DNA) breaks, rather than causing premature mitosis. The combination of AZD1775 and 5-FU resulted in a significant increase in the mitotic marker pHH3 and DS-DNA break marker -H2AX, and also increased caspase-3 dependent apoptosis compared to 5-FU alone. However, the addition of exogenous nucleosides to the combination therapy significantly rescued the increased DS-DNA breaks and caspase-3 dependent apoptosis, suggesting that the optimal timing and duration of AZD1775 treatment may be important in clinical trials. Therefore, the in vivo effects of AZD8601 are likely to involve increasing DS-DNA breaks, rather than premature mitosis, in p53-mutated colorectal cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 (AZD1775) is a WEE1 inhibitor that can enhance the cytotoxicity of 5-FU in p53-mutated colorectal cancer cells.\n2. Treatment with AZD1775 and 5-FU increases the levels of the mitotic marker pHH3 and DNA damage marker -H2AX.\n3. Treatment with AZD1775 and 5-FU also increases caspase-3 dependent apoptosis in p53-mutated colorectal cancer cells compared to 5-FU alone.\n4. The addition of exogenous nucleosides can rescue the increased DS-DNA breaks and caspase-3 dependent apoptosis caused by the combination therapy of AZD1775 and 5-FU.\n5. AZD8601's in vivo effects likely include an increase in double-stranded DNA breaks in p53-mutated colorectal cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 (AZD1775) is a WEE1 inhibitor that can enhance the cytotoxicity of 5-FU in p53-mutated colorectal cancer cells.",
      "Treatment with AZD1775 and 5-FU increases the levels of the mitotic marker pHH3 and DNA damage marker -H2AX.",
      "Treatment with AZD1775 and 5-FU also increases caspase-3 dependent apoptosis in p53-mutated colorectal cancer cells compared to 5-FU alone.",
      "The addition of exogenous nucleosides can rescue the increased DS-DNA breaks and caspase-3 dependent apoptosis caused by the combination therapy of AZD1775 and 5-FU.",
      "AZD8601's in vivo effects likely include an increase in double-stranded DNA breaks in p53-mutated colorectal cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not AZD1775; AZD8601 is an mRNA-based therapy encoding for VEGF-A, which is being developed for heart disease. AZD1775, now known as adavosertib, is a WEE1 inhibitor.\n2. TRUE \n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, SAHFS (scaffold attachment factor A) is created through the interaction of several proteins, including SAF-A (heterogeneous nuclear ribonucleoprotein-U), nucleolin, Aurora-A, and TPX2. During mitosis, SAF-A is localized at the spindles, spindle midzone, and cytoplasmic bridge, where it plays a crucial role in attaching microtubules (MTs) to kinetochores and organizing the mitotic spindle.\nSAF-A specifically co-immunoprecipitates with nucleolin and the spindle regulators Aurora-A and TPX2, indicating that it is associated with these proteins. Additionally, SAF-A is colocalized with TPX2 and Aurora-A in spindle poles and MTs, suggesting that it plays a direct role in the targeting of these proteins to the mitotic spindle.\nElimination of TPX2 or Aurora-A from cells abolishes the association of SAF-A with the mitotic spindle, indicating that these proteins are essential for the formation of SAHFS. Furthermore, SAF-A can bind to MTs and contributes to the targeting of Aurora-A to mitotic spindle MTs, further highlighting its role in the organization of the mitotic spindle.\nOverall, the information provided in the document suggests that SAHFS is created through the complex interplay of several proteins, including SAF-A, nucleolin, Aurora-A, and TPX2, and plays a crucial role in the organization of the mitotic spindle during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Scaffold attachment factor A (SAHFS) is created through the interaction of several proteins, including SAF-A, nucleolin, Aurora-A, and TPX2.\n2. During mitosis, SAF-A localizes at the spindles, spindle midzone, and cytoplasmic bridge.\n3. SAF-A plays a crucial role in attaching microtubules to kinetochores and organizing the mitotic spindle.\n4. The elimination of TPX2 or Aurora-A from cells leads to the loss of SAF-A's association with the mitotic spindle.\n5. SAF-A binds to microtubules and contributes to the targeting of Aurora-A to the mitotic spindle microtubules.",
    "llama-2-7b-chat-hf_fact": [
      "Scaffold attachment factor A (SAHFS) is created through the interaction of several proteins, including SAF-A, nucleolin, Aurora-A, and TPX2.",
      "During mitosis, SAF-A localizes at the spindles, spindle midzone, and cytoplasmic bridge.",
      "SAF-A plays a crucial role in attaching microtubules to kinetochores and organizing the mitotic spindle.",
      "The elimination of TPX2 or Aurora-A from cells leads to the loss of SAF-A's association with the mitotic spindle.",
      "SAF-A binds to microtubules and contributes to the targeting of Aurora-A to the mitotic spindle microtubules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Scaffold attachment factor A is named SAF-A (not SAHFS), and it's a protein that interacts with nuclear structures, but its creation is not through the interaction with proteins like Aurora-A and TPX2.\n2. UNKNOWN: The specific localization of SAF-A during mitosis can vary and would need to be confirmed based on current scientific literature or findings.\n3. FALSE [correction]: SAF-A is known for its role in chromatin organization and the regulation of gene expression. It is not directly involved in attaching microtubules to kinetochores or organizing the mitotic spindle.\n4. FALSE [correction]: While TPX2 and Aurora-A are indeed associated with the mitotic spindle, the statement about the elimination leading to the loss of SAF-A's association with the mitotic spindle is specific and would require verification from scientific sources. SAF-A's primary role is not associated with the mitotic spindle.\n5. FALSE [correction]: SAF-A does bind to DNA and RNA rather than microtubules, and it is not directly involved in the targeting of Aurora-A to mitotic spindle microtubules. Aurora-A targeting to the spindle is typically mediated by other factors, such as TPX2.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the PDZ domain in SATB1 is to bind to the C-terminal residues of the protein target, specifically the C-terminal four residues, with the major contacts formed by the C-terminal residue (P0) and the third-last residue (P-2). The structures of seven human PDZ domains, including five members of the PDLIM family, were solved in the document, and they showed that the PDZ domain binds to the C-terminal residue in the binding groove. However, in some cases, the P-2 residue formed interactions outside of the binding groove, providing insight into the influence of remote residues on selectivity. The structures also showed that changes in the positions of PDZ domain side-chains and the alpha B helix allow noncanonical binding interactions, which may represent intermediate states between unbound and fully bound PDZ domain and target protein. The noncanonical \"perpendicular\" binding observed potentially represents the general form of a kinetic intermediate. Comparison with canonical binding suggests that the rearrangement during binding involves both the PDZ domain and its ligand. Therefore, the PDZ domain in SATB1 functions as a binding protein that recognizes and binds to the C-terminal residues of its target protein through noncanonical binding interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 binds to the C-terminal residues of the protein target.\n2. The major contacts for the PDZ domain in SATB1 are formed by the C-terminal residue (P0) and the third-last residue (P-2).\n3. Structures of seven human PDZ domains were solved in the given document.\n4. There are cases where the third-last residue (P-2) interacts outside of the binding groove affecting selectivity.\n5. Noncanonical \"perpendicular\" binding was observed, which may represent intermediate states in the binding process between the PDZ domain and target protein.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 binds to the C-terminal residues of the protein target.",
      "The major contacts for the PDZ domain in SATB1 are formed by the C-terminal residue (P0) and the third-last residue (P-2).",
      "Structures of seven human PDZ domains were solved in the given document.",
      "There are cases where the third-last residue (P-2) interacts outside of the binding groove affecting selectivity.",
      "Noncanonical \"perpendicular\" binding was observed, which may represent intermediate states in the binding process between the PDZ domain and target protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation of the Responses:\nFor all statements provided, we lack the specific document referenced for the context of these statements. Without seeing the date, methodology, and results detailed in the document, it is not possible to determine the accuracy of technical scientific statements regarding protein interactions and structures. As a result, all statements must be treated as UNKNOWN. If the document were provided, it might be possible to confirm or refute these statements based on the evidence therein.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS technique is rooted in the self-care approach to nursing practice as outlined by Betty Neuman. The BLISS technique, which stands for Breathing, Relaxation, Imagery, and Sensory Stimulation, is a relaxation technique that involves deep breathing, muscle relaxation, and imagery to promote comfort and pain relief in hospitalized oncology patients. The technique is based on the idea that by using these techniques, patients can take an active role in managing their pain and promoting their overall well-being. The BLISS technique is designed to be easy to use and can be implemented by patients themselves or with the guidance of a healthcare provider. The technique is also based on the idea that by using these techniques, patients can reduce their reliance on analgesic medication and manage their pain in a more holistic way.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is rooted in the self-care approach to nursing practice as outlined by Betty Neuman.\n2. The acronym BLISS stands for Breathing, Relaxation, Imagery, and Sensory Stimulation.\n3. The BLISS technique includes deep breathing, muscle relaxation, and imagery.\n4. It is designed to promote comfort and pain relief in hospitalized oncology patients.\n5. The technique aims to help patients reduce their reliance on analgesic medication.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is rooted in the self-care approach to nursing practice as outlined by Betty Neuman.",
      "The acronym BLISS stands for Breathing, Relaxation, Imagery, and Sensory Stimulation.",
      "The BLISS technique includes deep breathing, muscle relaxation, and imagery.",
      "It is designed to promote comfort and pain relief in hospitalized oncology patients.",
      "The technique aims to help patients reduce their reliance on analgesic medication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS method is not rooted in the self-care approach to nursing practice as outlined by Betty Neuman. Instead, Neuman is known for her systems model in nursing. BLISS is a different concept not directly connected to Neuman's work.\n2. UNKNOWN: The acronym BLISS could stand for Breathing, Listening, Imagery, and Sensory Stimulation, or a variant thereof, but without the exact definition from the given context, the full and correct meaning of the acronym cannot be determined.\n3. TRUE: The BLISS technique includes elements such as deep breathing, muscle relaxation, and imagery which are commonly used modalities for stress reduction and pain management.\n4. UNKNOWN: Without additional context, it's unclear whether the BLISS technique is specifically designed to promote comfort and pain relief in hospitalized oncology patients, although it could potentially be applied to this patient population.\n5. UNKNOWN: While techniques similar to BLISS are often used to reduce stress and possibly minimize pain, which could reduce reliance on medications, it's unclear if the BLISS technique specifically aims to reduce analgesic medication without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are 3 NK3R antagonists:\n1. 8m - The lead compound mentioned in the passage, which occupies receptors within the central nervous system (CNS) following oral dosing and has good selectivity and excellent pharmacokinetic (PK) properties.\n2. N',2-diphenylquinoline-4-carbohydrazide - The starting material for the synthesis of NK3R antagonists, which is modified by introducing amine-containing side chains into the 3-position to abolish unwanted hPXR activation.\n3. 4-chloro-N',2-diphenylquinoline-8-carboxylic acid - Another compound that is synthesized from N',2-diphenylquinoline-4-carbohydrazide by introducing a fluorine at the 8-position to minimize unwanted hI(Kr) affinity.\nIt is important to note that these are just examples of NK3R antagonists and there may be other compounds that also fit this category. Additionally, the information provided is based on the specific context of the passage and may not be applicable to other situations.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"8m\" is a compound that acts as an NK3R antagonist and has good selectivity and excellent pharmacokinetic properties.\n2. N',2-diphenylquinoline-4-carbohydrazide is a starting material in the synthesis of NK3R antagonists.\n3. 4-chloro-N',2-diphenylquinoline-8-carboxylic acid is a synthesized compound derived from N',2-diphenylquinoline-4-carbohydrazide by introducing fluorine at the 8-position.",
    "llama-2-7b-chat-hf_fact": [
      "\"8m\" is a compound that acts as an NK3R antagonist and has good selectivity and excellent pharmacokinetic properties.",
      "N',2-diphenylquinoline-4-carbohydrazide is a starting material in the synthesis of NK3R antagonists.",
      "4-chloro-N',2-diphenylquinoline-8-carboxylic acid is a synthesized compound derived from N',2-diphenylquinoline-4-carbohydrazide by introducing fluorine at the 8-position."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or scientific references, the properties and actions of \"8m\" as an NK3R antagonist cannot be confirmed.\n2. UNKNOWN: Without specific context or scientific literature to validate, it is unclear whether N',2-diphenylquinoline-4-carbohydrazide is used as a starting material for the synthesis of NK3R antagonists.\n3. FALSE [correction]: The compound described is \"4-chloro-N',2-diphenylquinoline-8-carboxylic acid\", but the mention of introducing fluorine at the 8-position is inconsistent with the name of the compound which suggests a chlorine at the 8-position instead. If fluorine were introduced, it would be named differently, perhaps as \"4-fluoro-N',2-diphenylquinoline-8-carboxylic acid\" or another appropriate compound name reflecting the presence of fluorine.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is [D-Arg(1), D-Phe(5), D-Trp(7,9), Leu(11)]-substance P. This peptide selectively displays inverse agonism at the ghrelin receptor and was shown to decrease food intake and body weight in rats, as well as decrease the expression of neuropeptide Y and uncoupling protein 2 in the hypothalamus. The study suggests that the high constitutive signaling activity of the ghrelin receptor is important for its in vivo function in the control of food intake and body weight, and that inverse agonists of the ghrelin receptor may be a useful tool for modulating appetite and weight regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. [D-Arg(1), D-Phe(5), D-Trp(7,9), Leu(11)]-substance P is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. This peptide showed the ability to decrease food intake and body weight in rats during studies.\n3. It also led to a decrease in the expression of neuropeptide Y and uncoupling protein 2 in the hypothalamus.\n4. The peptide selectively displays inverse agonism at the ghrelin receptor.\n5. The ghrelin receptor's high constitutive signaling activity is important for in vivo function concerning the control of food intake and body weight.",
    "llama-2-7b-chat-hf_fact": [
      "[D-Arg(1), D-Phe(5), D-Trp(7,9), Leu(11)]-substance P is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "This peptide showed the ability to decrease food intake and body weight in rats during studies.",
      "It also led to a decrease in the expression of neuropeptide Y and uncoupling protein 2 in the hypothalamus.",
      "The peptide selectively displays inverse agonism at the ghrelin receptor.",
      "The ghrelin receptor's high constitutive signaling activity is important for in vivo function concerning the control of food intake and body weight."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The specific claim about [D-Arg(1), D-Phe(5), D-Trp(7,9), Leu(11)]-substance P being the first oral ghrelin receptor inverse agonist profiled in healthy subjects requires specific scientific literature or studies for verification, and without the context or sources, this cannot be assessed.\n2. UNKNOWN: The statement regarding the peptide's effect on food intake and body weight in rats would also need referencing from specific scientific studies, which are not provided here.\n3. UNKNOWN: Similar to the previous statements, the claim about the decrease in the expression of neuropeptide Y and uncoupling protein 2 in the hypothalamus requires specific data or research to verify.\n4. UNKNOWN: The specificity of the peptide's selectivity for inverse agonism at the ghrelin receptor is another statement that requires particular scientific evidence for validation.\n5. TRUE: This is a statement reflecting a basic understanding of ghrelin receptor function. The ghrelin receptor is known for its high constitutive signaling activity which is implicated in the control of food intake and body weight; hence, the statement is in line with current scientific knowledge. However, detailed mechanisms and implications can be intricate and may require more complex explanations in scientific contexts.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the protective efficacy of vaxchora against moderate to severe cholera is estimated to be 86.6% (95% CI: 56.7-95.8%). This means that among individuals who received two complete doses of vaxchora, 86.6% were protected against developing moderate to severe cholera, compared to 13.4% of unvaccinated individuals. The study found that vaxchora was effective in providing protection against cholera in response to an outbreak in Guinea.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protective efficacy of vaxchora against moderate to severe cholera is estimated to be 86.6%.\n2. The study provided a 95% Confidence Interval (CI) for the vaccine efficacy, ranging from 56.7% to 95.8%.\n3. Two complete doses of vaxchora were used in the individuals who were protected against developing moderate to severe cholera in the study.\n4. 13.4% of unvaccinated individuals were not protected against developing moderate to severe cholera according to the report.\n5. Vaxchora was found to be effective in providing protection against cholera during an outbreak in Guinea.",
    "llama-2-7b-chat-hf_fact": [
      "The protective efficacy of vaxchora against moderate to severe cholera is estimated to be 86.6%.",
      "The study provided a 95% Confidence Interval (CI) for the vaccine efficacy, ranging from 56.7% to 95.8%.",
      "Two complete doses of vaxchora were used in the individuals who were protected against developing moderate to severe cholera in the study.",
      "13.4% of unvaccinated individuals were not protected against developing moderate to severe cholera according to the report.",
      "Vaxchora was found to be effective in providing protection against cholera during an outbreak in Guinea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Vaxchora is a single-dose vaccine; thus, individuals were protected with one dose, not two complete doses.\n4. FALSE [correction]: This statement is difficult to assess without additional context. The 13.4% figure is likely related to the contrasting percentage of 86.6% efficacy (100% - 86.6% = 13.4%), but it does not inherently mean that 13.4% of unvaccinated individuals were not protected. Without specific data on the protection rate in the unvaccinated control group, this statement cannot be confirmed.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first cholera vaccine approved in the US is not explicitly mentioned. However, the document does mention that orally-administered cholera vaccines (OCV) have been increasingly examined as an additional tool to intervene against endemic and epidemic cholera, and that field experience with OCV has been reported from several countries including India, Bangladesh, Vietnam, Guinea, Haiti, and Thailand. It also mentions a symposium held in Bangkok in 2013 where lead investigators from each of these projects presented their findings. Therefore, while the document does not provide a direct answer to the user's question, it does provide information on the current state of cholera vaccine research and development, which may be helpful in addressing the user's question.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the TACI gene. The document states that mutations in TACI were found in 5% of patients with CVID and in relatives of patients with CVID who suffered from IgA deficiency (IgAD). Additionally, the document suggests that TACI mutations can lead to CVID, as B cells from individuals with TACI mutations did not produce IgG and IgA in response to the TACI ligand, APRIL, probably reflecting impaired isotype switching. These findings suggest that TACI mutations are a significant genetic cause of CVID in Europeans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the TACI gene are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. Mutations in TACI were found in 5% of patients with CVID.\n3. Relatives of patients with CVID who suffered from IgA deficiency (IgAD) were also found to have mutations in TACI.\n4. Individuals with TACI mutations did not produce IgG and IgA in response to the TACI ligand, APRIL.\n5. The impaired production of IgG and IgA in individuals with TACI mutations is likely due to impaired isotype switching.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the TACI gene are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "Mutations in TACI were found in 5% of patients with CVID.",
      "Relatives of patients with CVID who suffered from IgA deficiency (IgAD) were also found to have mutations in TACI.",
      "Individuals with TACI mutations did not produce IgG and IgA in response to the TACI ligand, APRIL.",
      "The impaired production of IgG and IgA in individuals with TACI mutations is likely due to impaired isotype switching."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in TACI were found in approximately 8-10% of patients with CVID, not specifically 5%.\n3. TRUE\n4. FALSE [correction]: Individuals with TACI mutations typically have an impaired response to the TACI ligand, APRIL, which can result in the inability to produce normal levels of immunoglobulins, including IgG and IgA, but it does not mean they do not produce any IgG and IgA at all.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is that it is involved in the regulation of T cell function. Specifically, the document states that IFIT1 expression is bimodal and correlated moderately with disease activity in SLE T cell samples. Additionally, the document mentions that estradiol uniquely upregulated six pathways in SLE T cells that control T cell function, including interferon-alpha signaling, and that measurement of interferon-alpha pathway target gene expression revealed significant differences in DRIP150 expression (+/- estradiol) in SLE T cell samples. These findings suggest that the IFIT1 gene may play a role in the regulation of T cell function in SLE, possibly by controlling the expression of interferon-alpha signaling pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is involved in the regulation of T cell function in Systemic Lupus Erythematosus (SLE).\n2. IFIT1 expression is bimodal and correlated moderately with disease activity in SLE T cell samples.\n3. Estradiol upregulated six pathways in SLE T cells that control T cell function, including interferon-alpha signaling.\n4. There are significant differences in DRIP150 expression (+/- estradiol) in SLE T cell samples.\n5. The IFIT1 gene may control the expression of interferon-alpha signaling pathways in the context of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is involved in the regulation of T cell function in Systemic Lupus Erythematosus (SLE).",
      "IFIT1 expression is bimodal and correlated moderately with disease activity in SLE T cell samples.",
      "Estradiol upregulated six pathways in SLE T cells that control T cell function, including interferon-alpha signaling.",
      "There are significant differences in DRIP150 expression (+/- estradiol) in SLE T cell samples.",
      "The IFIT1 gene may control the expression of interferon-alpha signaling pathways in the context of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene is known to be involved in immune response and has been associated with the regulation of T cell function in Systemic Lupus Erythematosus (SLE).\n\n2. FALSE [correction]: The original statement is too specific regarding the pattern of IFIT1 expression and its correlation with disease activity without proper context. Without additional context, it could be true or false, but in the absence of specific data or a reference, a definitive correction cannot be provided.\n\n3. TRUE: Estradiol is known to have various effects on the immune system, and it could upregulate pathways in SLE T cells that control T cell function, including interferon-alpha signaling.\n\n4. UNKNOWN: Without specific data or referencing literature, it is not possible to confirm or deny the presence of differences in DRIP150 expression with or without estradiol in SLE T cell samples.\n\n5. UNKNOWN: IFIT1 may play a role in interferon-alpha signaling pathways, but without additional evidence, it is not possible to definitively say that it controls the expression of these pathways in the context of SLE.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the Liverpool Elbow Score is a measurement tool used to assess the function and performance of the upper extremity in professional baseball players. The study aimed to establish normative data for the KJOC score in professional baseball players in the United States and to evaluate the effect of various demographic factors on the score.\nThe results of the study showed that the average KJOC score among healthy players with no history of injury was 97.1 for major league players and 96.8 for minor league players. The time point of administration did not significantly affect the final KJOC score, and KJOC outcomes did not vary with player age. However, significantly lower average KJOC scores were reported by players with a history of upper extremity injury and surgery. The KJOC results also varied with playing position, with the lowest average scores being reported by pitchers and infielders.\nOverall, the Liverpool Elbow Score is a useful tool for assessing the function and performance of the upper extremity in professional baseball players, particularly in detecting subtle changes in performance. The study highlights the importance of considering demographic factors such as injury history and playing position when interpreting KJOC scores.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is used to assess the function and performance of the upper extremity in professional baseball players.\n2. The study established normative data for the Kerlan-Jobe Orthopedic Clinic (KJOC) score in professional baseball players in the United States.\n3. The average KJOC score among healthy major league players with no history of injury was 97.1.\n4. The average KJOC score among healthy minor league players with no history of injury was 96.8.\n5. Players with a history of upper extremity injury and surgery reported significantly lower average KJOC scores.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is used to assess the function and performance of the upper extremity in professional baseball players.",
      "The study established normative data for the Kerlan-Jobe Orthopedic Clinic (KJOC) score in professional baseball players in the United States.",
      "The average KJOC score among healthy major league players with no history of injury was 97.1.",
      "The average KJOC score among healthy minor league players with no history of injury was 96.8.",
      "Players with a history of upper extremity injury and surgery reported significantly lower average KJOC scores."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score is actually designed to assess the outcome of elbow surgery in general, not specifically for the function and performance of the upper extremity in professional baseball players.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the 100,000 Genomes Project has made efforts to develop a genetic variant site explorer called ENGINES, which is capable of retrieving data for single nucleotide variations (SNVs) from entire genomes without compromising future scalability and agility. The tool uses data from the 1000 Genomes Phase I interim analysis and demonstrates its capacity to handle large amounts of genetic variation, including over 7.3 billion genotypes and 28 million SNVs.\nENGINES allows users to query the dataset by using various filters, such as rs-number list, chromosome region, or genes of interest, and provides summary statistics of interest for medical and population genetics applications. The tool also allows users to visually compare the results with other large-scale SNP repositories such as HapMap or Perlegen.\nOverall, the 100,000 Genomes Project has made significant efforts in developing ENGINES, a powerful tool for exploring and analyzing large-scale genetic variation data, which can be accessed through a web interface at <http://spsmart.cesga.es/engines.php>.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project developed a genetic variant site explorer called ENGINES.\n2. ENGINES is capable of retrieving data for single nucleotide variations from entire genomes.\n3. The tool uses data from the 1000 Genomes Phase I interim analysis.\n4. ENGINES handles over 7.3 billion genotypes and 28 million single nucleotide variations.\n5. ENGINES can be accessed through a web interface at http://spsmart.cesga.es/engines.php.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project developed a genetic variant site explorer called ENGINES.",
      "ENGINES is capable of retrieving data for single nucleotide variations from entire genomes.",
      "The tool uses data from the 1000 Genomes Phase I interim analysis.",
      "ENGINES handles over 7.3 billion genotypes and 28 million single nucleotide variations.",
      "ENGINES can be accessed through a web interface at http://spsmart.cesga.es/engines.php."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project did not develop ENGINES. It is not clear from the statement who developed ENGINES.\n2. TRUE\n3. UNKNOWN: The statement does not provide enough information to determine if the ENGINES tool uses data specifically from the 1000 Genomes Project Phase I interim analysis without additional context.\n4. UNKNOWN: The statement provides specific figures regarding genotypes and single nucleotide variations, but without additional context, these figures' accuracy cannot be verified.\n5. UNKNOWN: Without checking the current availability of the web interface, the validity of this statement cannot be ascertained. URLs can change or become outdated, and web resources may no longer be available.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, protein ALEX1 does not contain armadillo repeats. The document discusses the structure and function of armadillo repeat proteins (ArmRPs) and their ability to recognize and bind to specific peptides, but there is no mention of ALEX1 having these repeats. Therefore, the answer to the user's question is no, protein ALEX1 does not contain armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.\n2. Armadillo repeat proteins (ArmRPs) have the ability to recognize and bind to specific peptides.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats.",
      "Armadillo repeat proteins (ArmRPs) have the ability to recognize and bind to specific peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following enzymes are known to remove histone modifications:\n1. RIZ1 (PRDM2): RIZ1 is a tumor suppressor that methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers.\n2. HMT (Histone methyltransferase): HMTs are enzymes that methylate lysine residues of histones or proteins, and they contain a conserved catalytic core termed the SET domain. While it is unclear whether it is histone methyltransferase activity that underlies tumor suppression, the document suggests that HMTs may play a role in carcinogenesis associated with dietary methyl donor deficiency.\nIt is important to note that these enzymes are involved in the removal of histone modifications, rather than the addition of modifications.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is a potential increased risk of brain tumors associated with head CT scans. The study found that patients who received both cranial radiation and intrathecal chemotherapy were more likely to have abnormally low growth hormone responses and ventricular dilatation on CT brain scans compared to those who did not receive these treatments. While the study did not directly investigate the link between head CT scans and brain tumor risk, the findings suggest that there may be a correlation between the two. Therefore, it is important for individuals to weigh the potential benefits and risks of head CT scans, particularly in the context of cancer treatment, and to discuss any concerns with their healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Otx2 is associated with the pluripotency of dopaminergic neurons. The study shows that Otx2 is required from E10.5 onward to regulate neuronal subtype identity and neurogenesis in the midbrain, including the formation of dopaminergic neurons. The data demonstrate that Otx2 controls the development of several neuronal populations in the midbrain by regulating progenitor identity and neurogenesis, and that loss of Otx2 leads to ectopic expression of Math1 and the formation of an ectopic cerebellar-like structure in the dorsal midbrain. Therefore, Otx2 is associated with the pluripotency of dopaminergic neurons in the midbrain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with the pluripotency of dopaminergic neurons.\n2. Otx2 is required from embryonic day 10.5 (E10.5) onward to regulate neuronal subtype identity and neurogenesis in the midbrain.\n3. Loss of Otx2 results in ectopic expression of Math1.\n4. A loss of Otx2 can lead to the formation of an ectopic cerebellar-like structure in the dorsal midbrain.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with the pluripotency of dopaminergic neurons.",
      "Otx2 is required from embryonic day 10.5 (E10.5) onward to regulate neuronal subtype identity and neurogenesis in the midbrain.",
      "Loss of Otx2 results in ectopic expression of Math1.",
      "A loss of Otx2 can lead to the formation of an ectopic cerebellar-like structure in the dorsal midbrain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN - The statement is specific and would require access to scientific literature on the role of the Otx2 gene in dopaminergic neuron development to confirm its association with pluripotency.\n2. TRUE - Otx2 is indeed involved in regulating neuronal subtype identity and neurogenesis in the midbrain, and it starts exerting its roles during embryonic development around the time specified.\n3. TRUE - According to scientific literature, loss of Otx2 can result in ectopic expression of other genes, such as Math1, which is consistent with the way genetic regulatory pathways work.\n4. TRUE - There is evidence suggesting that the loss of Otx2 can lead to the development of ectopic structures in the brain due to its role in specifying neuronal identities during development. An ectopic cerebellar-like structure in the dorsal midbrain is a possible outcome of Otx2 loss.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 4 DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 4 DNaseI hypersensitive sites marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact": [
      "There are 4 DNaseI hypersensitive sites marking the murine beta globin locus region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nExplanation: Without the specific scientific context or a reference to validate this statement, it is difficult to determine its truthfulness. The number of DNase I hypersensitive sites can vary among different species and even within different regions of the genome for a specific species. Only someone with access to the precise scientific research or data on the murine beta globin locus region could confirm or correct this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the following European influenza vaccines are listed:\n1. Inactivated quadrivalent influenza vaccine (IIV4)\n2. A/H1N1 vaccine-mismatched strains\n3. A/H3N2 vaccine-mismatched strains\n4. B/Victoria vaccine-mismatched strains\n5. B/Yamagata vaccine-mismatched strains\nIt is important to note that the study focused on the efficacy of IIV4 in children aged 6-35 months, and the vaccine efficacy was highest against moderate-to-severe disease. The study also found that there were no clinically meaningful safety differences between IIV4 and the control vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inactivated quadrivalent influenza vaccine (IIV4) is a type of influenza vaccine available in Europe.\n2. There are influenza vaccines available that target A/H1N1 vaccine-mismatched strains.\n3. There are influenza vaccines available that target A/H3N2 vaccine-mismatched strains.\n4. There are influenza vaccines available that target B/Victoria vaccine-mismatched strains.\n5. There are influenza vaccines available that target B/Yamagata vaccine-mismatched strains.",
    "llama-2-7b-chat-hf_fact": [
      "Inactivated quadrivalent influenza vaccine (IIV4) is a type of influenza vaccine available in Europe.",
      "There are influenza vaccines available that target A/H1N1 vaccine-mismatched strains.",
      "There are influenza vaccines available that target A/H3N2 vaccine-mismatched strains.",
      "There are influenza vaccines available that target B/Victoria vaccine-mismatched strains.",
      "There are influenza vaccines available that target B/Yamagata vaccine-mismatched strains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nInfluenza vaccines are designed to target the most common and potentially severe strains predicted for the upcoming flu season. Vaccine mismatches can occur when circulating strains change after vaccine composition has been determined. Vaccine manufacturers may include components to guard against anticipated mismatches whenever possible. Quadrivalent influenza vaccines are designed to protect against two strains of influenza A and two strains of influenza B (usually one from the Victoria lineage and one from the Yamagata lineage), hence the statements about vaccines targeting mismatched strains of A/H1N1, A/H3N2, B/Victoria, and B/Yamagata could all be potentially true depending on the specific make-up and purpose of the vaccine for a given flu season.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nThe document states that the F gene of the isolates was sequenced and analyzed, and it contains conserved motifs homologous to those described for other members of the family Paramyxoviridae, including a signal peptide, transmembrane domain, furin cleavage site, fusion peptide, N-linked glycosylation sites, and two heptad repeats. The document also mentions that the F gene of the isolate Gono-GER85 was inserted into a prokaryotic expression system to generate recombinant protein fragments, and Western blot analysis with virus-neutralizing rabbit-antiserum against this isolate demonstrated that only the longest construct reacted with the antiserum. These results suggest that the F gene of reptilian paramyxoviruses contains highly conserved motifs typical of other members of the family, and that the HRB-LZ domain of the reptilian paramyxovirus F protein contains a linear antigenic epitope.\nTherefore, based on the information provided in the document, it can be concluded that the Paramyxovirus geneome is segmented, negative-sense RNA, which is a characteristic of many viruses in the family Paramyxoviridae.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is a negative-sense RNA genome.\n2. The F gene of Paramyxovirus isolates contains conserved motifs homologous to those in other members of the family Paramyxoviridae.\n3. The F gene includes a signal peptide, transmembrane domain, furin cleavage site, fusion peptide, N-linked glycosylation sites, and two heptad repeats.\n4. The F gene from the isolate Gono-GER85 was inserted into a prokaryotic expression system to produce recombinant protein fragments.\n5. Western blot analysis with virus-neutralizing rabbit-antiserum against isolate Gono-GER85 reacted only with the longest construct, indicating the presence of a linear antigenic epitope in the HRB-LZ domain of the reptilian paramyxovirus F protein.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is a negative-sense RNA genome.",
      "The F gene of Paramyxovirus isolates contains conserved motifs homologous to those in other members of the family Paramyxoviridae.",
      "The F gene includes a signal peptide, transmembrane domain, furin cleavage site, fusion peptide, N-linked glycosylation sites, and two heptad repeats.",
      "The F gene from the isolate Gono-GER85 was inserted into a prokaryotic expression system to produce recombinant protein fragments.",
      "Western blot analysis with virus-neutralizing rabbit-antiserum against isolate Gono-GER85 reacted only with the longest construct, indicating the presence of a linear antigenic epitope in the HRB-LZ domain of the reptilian paramyxovirus F protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Paramyxovirus genome is indeed a negative-sense single-stranded RNA genome, which is characteristic of the Paramyxoviridae family.\n2. TRUE: The F (fusion) gene of Paramyxovirus typically contains conserved motifs that are homologous to those found in other members of the family Paramyxoviridae.\n3. TRUE: The F gene does include a signal peptide, transmembrane domain, furin cleavage site, fusion peptide, N-linked glycosylation sites, and two heptad repeats; these are features relevant to the fusion protein's function and its role in mediating viral entry into host cells.\n4. UNKNOWN: Without specific information confirming that the F gene from the isolate Gono-GER85 was inserted into a prokaryotic expression system to produce recombinant protein fragments, the truth value of the statement cannot be determined.\n5. UNKNOWN: Similarly, without access to the results of the Western blot analysis or additional details, the claim regarding the reaction of virus-neutralizing rabbit-antiserum with specific protein constructs and the presence of a linear antigenic epitope in a particular domain (HRB-LZ) of the reptilian paramyxovirus F protein cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Roflumilast Cream is effective for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Studies have shown that Roflumilast can increase the forced expiratory volume in one second (FEV1) and reduce the rate of COPD exacerbations. However, it is important to note that Roflumilast can cause drug-related nausea and weight loss in some patients, and it is currently only available in Germany.\nOn the other hand, Indacaterol is a new beta-2-adrenergic bronchodilator that can be taken once a day. Studies have shown that Indacaterol has a good therapeutic window and is available in Switzerland. There is no reason why Indacaterol cannot be prescribed together with Tiotropium, a once-a-day anti-cholinergic bronchodilator. However, no studies have specifically evaluated the combination of Indacaterol and Tiotropium in COPD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is used for the treatment of Chronic Obstructive Pulmonary Disease (COPD).\n2. Roflumilast can increase the forced expiratory volume in one second (FEV1).\n3. Roflumilast can reduce the rate of COPD exacerbations.\n4. Roflumilast may cause drug-related nausea and weight loss in some patients.\n5. Indacaterol is a beta-2-adrenergic bronchodilator that can be taken once a day and is available in Switzerland.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is used for the treatment of Chronic Obstructive Pulmonary Disease (COPD).",
      "Roflumilast can increase the forced expiratory volume in one second (FEV1).",
      "Roflumilast can reduce the rate of COPD exacerbations.",
      "Roflumilast may cause drug-related nausea and weight loss in some patients.",
      "Indacaterol is a beta-2-adrenergic bronchodilator that can be taken once a day and is available in Switzerland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is an oral tablet used for the treatment of severe COPD. Roflumilast Cream is not a recognized form for treating COPD.\n2. TRUE: Roflumilast can increase the forced expiratory volume in one second (FEV1) as part of its therapeutic effects in improving lung function.\n3. TRUE: Roflumilast can reduce the rate of COPD exacerbations in patients with severe disease.\n4. TRUE: Roflumilast may cause side effects such as drug-related nausea and weight loss in some patients.\n5. TRUE: Indacaterol is a long-acting beta-2-adrenergic agonist (LABA) bronchodilator that is taken once a day and is available in Switzerland, among other countries.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, several tools have been developed for identifying and visualizing ncRNA promoters:\n1. NBLDA (Network-based Bayesian Learning for Disease Associations): This is a network-based model proposed in the document for discovering potential lncRNA-disease associations. NBLDA constructs two novel lncRNA-disease weighted networks based on known lncRNA-disease associations and topological similarity of the lncRNA-disease association network.\n2. lncRNA-lncRNA weighted matrix: This is a matrix obtained based on a resource allocation strategy of unequal allocation and unbiased consistence. It is used to predict associated lncRNAs for the investigated diseases.\n3. Disease-disease weighted matrix: This is a matrix obtained based on a resource allocation strategy of unequal allocation and unbiased consistence. It is used to predict associated diseases for the investigated lncRNAs.\n4. Leave-one-out cross-validation (LOOCV): This is a framework implemented in the document for evaluating the prediction performance of NBLDA. LOOCV is a method for assessing the generalization ability of a predictive model by training and testing the model on a series of leave-one-out samples.\nThese tools can be used to identify potential lncRNA-disease associations and predict associated lncRNAs for investigated diseases. They can also be used to evaluate the prediction performance of NBLDA and other computational models for identifying lncRNA-disease associations.",
    "llama-2-7b-chat-hf_fact_raw": "1. NBLDA is a network-based model used for discovering potential lncRNA-disease associations.\n2. The NBLDA model constructs lncRNA-disease weighted networks based on known associations and topological similarity of the lncRNA-disease association network.\n3. An lncRNA-lncRNA weighted matrix, used to predict associated lncRNAs for diseases, is obtained using a resource allocation strategy of unequal allocation and unbiased consistence.\n4. A disease-disease weighted matrix is used to predict associated diseases for investigated lncRNAs and is obtained using the same resource allocation strategy.\n5. Leave-one-out cross-validation (LOOCV) is implemented for evaluating the prediction performance of the NBLDA model.",
    "llama-2-7b-chat-hf_fact": [
      "NBLDA is a network-based model used for discovering potential lncRNA-disease associations.",
      "The NBLDA model constructs lncRNA-disease weighted networks based on known associations and topological similarity of the lncRNA-disease association network.",
      "An lncRNA-lncRNA weighted matrix, used to predict associated lncRNAs for diseases, is obtained using a resource allocation strategy of unequal allocation and unbiased consistence.",
      "A disease-disease weighted matrix is used to predict associated diseases for investigated lncRNAs and is obtained using the same resource allocation strategy.",
      "Leave-one-out cross-validation (LOOCV) is implemented for evaluating the prediction performance of the NBLDA model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: An lncRNA-lncRNA weighted matrix is derived from the integration of lncRNA functional similarity and the Gaussian interaction profile kernel similarity of the lncRNAs.\n4. FALSE [correction]: A disease-disease weighted matrix is derived from the integration of disease semantic similarity and the Gaussian interaction profile kernel similarity of the diseases.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, SWIM tool has identified several down-regulated genes in glioblastoma. These genes include:\n1. CTGF (Connective Tissue Growth Factor): This gene was identified as an invasion candidate gene in the study, and its down-regulation was found to be associated with reduced in vitro migration and ex vivo invasion.\n2. EGFR (Epidermal Growth Factor Receptor): The expression of this gene was found to be down-regulated in migratory glioma cells compared to stationary cells.\n3. MMP2 (Matrix Metalloproteinase 2): The expression of this gene was found to be down-regulated in migratory glioma cells, and its down-regulation was associated with reduced in vitro migration.\n4. MMP9 (Matrix Metalloproteinase 9): The expression of this gene was found to be down-regulated in migratory glioma cells, and its down-regulation was associated with reduced in vitro migration.\n5. TIMP1 (Tissue Inhibitor of Metalloproteinases 1): The expression of this gene was found to be down-regulated in migratory glioma cells, and its down-regulation was associated with reduced in vitro migration.\n6. TIMP2 (Tissue Inhibitor of Metalloproteinases 2): The expression of this gene was found to be down-regulated in migratory glioma cells, and its down-regulation was associated with reduced in vitro migration.\n7. VEGFA (Vascular Endothelial Growth Factor A): The expression of this gene was found to be down-regulated in migratory glioma cells, and its down-regulation was associated with reduced in vitro migration.\nThese genes were found to be down-regulated in glioblastoma cells compared to normal brain tissue, and their down-regulation was associated with increased migration and invasion of glioblastoma cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. CTGF (Connective Tissue Growth Factor) is down-regulated in glioblastoma and is associated with reduced in vitro migration and ex vivo invasion.\n2. EGFR (Epidermal Growth Factor Receptor) is down-regulated in migratory glioma cells compared to stationary cells.\n3. MMP2 (Matrix Metalloproteinase 2) is down-regulated in migratory glioma cells and associated with reduced in vitro migration.\n4. MMP9 (Matrix Metalloproteinase 9) is down-regulated in migratory glioma cells and associated with reduced in vitro migration.\n5. TIMP1 (Tissue Inhibitor of Metalloproteinases 1) is down-regulated in migratory glioma cells and associated with reduced in vitro migration.",
    "llama-2-7b-chat-hf_fact": [
      "CTGF (Connective Tissue Growth Factor) is down-regulated in glioblastoma and is associated with reduced in vitro migration and ex vivo invasion.",
      "EGFR (Epidermal Growth Factor Receptor) is down-regulated in migratory glioma cells compared to stationary cells.",
      "MMP2 (Matrix Metalloproteinase 2) is down-regulated in migratory glioma cells and associated with reduced in vitro migration.",
      "MMP9 (Matrix Metalloproteinase 9) is down-regulated in migratory glioma cells and associated with reduced in vitro migration.",
      "TIMP1 (Tissue Inhibitor of Metalloproteinases 1) is down-regulated in migratory glioma cells and associated with reduced in vitro migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CTGF (Connective Tissue Growth Factor) is generally considered to be upregulated in glioblastoma and is associated with increased in vitro migration and ex vivo invasion.\n2. UNKNOWN\n3. FALSE [correction]: MMP2 (Matrix Metalloproteinase 2) is typically upregulated in migratory glioma cells and is associated with increased in vitro migration.\n4. FALSE [correction]: MMP9 (Matrix Metalloproteinase 9) is generally upregulated in migratory glioma cells and is associated with increased in vitro migration.\n5. UNKNOWN\n\nNote: The statements regarding EGFR, MMP2, MMP9, and TIMP1 can vary depending on the context and specific study. Therefore, the responses are based on common findings in glioma research, but specific studies might present different results.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the package being referred to is likely \"Document-0,\" which was developed for studying Transcriptional Activation Domains (TADs). The package was written in Fortran 77 and is suitable for use on a variety of computers, including those with a Vax 11. The developers aimed to create small, comprehensible, and well-documented programs with fast execution times that are comfortable to use and can be easily modified by users with little understanding of computer languages.\nTherefore, some of the R packages that have been developed for studying TADs are:\n1. Document-0: This package was specifically designed for studying TADs and is suitable for use on a variety of computers.\n2. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify and visualize TADs, as well as to predict their functional effects on gene expression.\n3. TADeep: This package uses deep learning techniques to predict TADs and their functional effects on gene expression.\n4. TADmap: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify and visualize TADs, as well as to predict their functional effects on gene expression.\n5. TADseq: This package provides a comprehensive set of tools for the analysis of TADs in sequencing data, including the ability to identify and visualize TADs, as well as to predict their functional effects on gene expression.\nThese are just a few examples of the many R packages that have been developed for studying TADs. It is important to note that the field of TAD research is constantly evolving, and new packages are being developed all the time.",
    "llama-2-7b-chat-hf_fact_raw": "1. The package \"Document-0\" was developed for studying Transcriptional Activation Domains (TADs).\n2. The \"Document-0\" package was written in Fortran 77.\n3. The \"Document-0\" package is compatible with a variety of computers, including Vax 11.\n4. The \"TADbit\" package is designed to analyze TADs and can identify, visualize, and predict their functional effects on gene expression.\n5. The \"TADeep\" package utilizes deep learning techniques to predict TADs and their impacts on gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The package \"Document-0\" was developed for studying Transcriptional Activation Domains (TADs).",
      "The \"Document-0\" package was written in Fortran 77.",
      "The \"Document-0\" package is compatible with a variety of computers, including Vax 11.",
      "The \"TADbit\" package is designed to analyze TADs and can identify, visualize, and predict their functional effects on gene expression.",
      "The \"TADeep\" package utilizes deep learning techniques to predict TADs and their impacts on gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the packages \"Document-0\", \"TADbit\", or \"TADeep\" and their functionalities, it's impossible to ascertain the veracity of these statements. The statements regarding \"Document-0\" might relate to a specialized tool within a scientific community that may not be widely known. \"TADbit\" and \"TADeep\" could be hypothetical or real bioinformatics packages for TAD analysis, but without additional context or a known reference, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the paper, the bioconductor tool that has been developed for accessing bacterial regulatory networks is likely the aptasensors used in the study. The authors of the paper describe the development of aptasensors, which are a type of biosensor that uses aptamers (a type of RNA or DNA molecule that binds specifically to a target molecule) as the sensing layer of the biosensor. These aptasensors are capable of detecting microorganisms, including bacteria, in a highly sensitive and selective manner, and could potentially be used to access bacterial regulatory networks by detecting changes in gene expression or other cellular processes in response to environmental stimuli.",
    "llama-2-7b-chat-hf_fact_raw": "1. A bioconductor tool developed for accessing bacterial regulatory networks is referred to as aptasensors in the mentioned study.\n2. Aptasensors are a type of biosensor that use aptamers as their sensing layer.\n3. Aptamers used in aptasensors are a type of RNA or DNA molecule.\n4. Aptasensors are capable of detecting microorganisms, including bacteria.\n5. Aptasensors can potentially be used to detect changes in gene expression or other cellular processes in bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "A bioconductor tool developed for accessing bacterial regulatory networks is referred to as aptasensors in the mentioned study.",
      "Aptasensors are a type of biosensor that use aptamers as their sensing layer.",
      "Aptamers used in aptasensors are a type of RNA or DNA molecule.",
      "Aptasensors are capable of detecting microorganisms, including bacteria.",
      "Aptasensors can potentially be used to detect changes in gene expression or other cellular processes in bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: A bioconductor tool developed for accessing bacterial regulatory networks would not be referred to as aptasensors; aptasensors are a specific type of biosensor and not a software tool for regulatory network access.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the end products of the shikimate pathway are aromatic compounds. The study suggests that the shikimate pathway is absent in animals, but present in malaria-causing parasites, making it a potential target for antimalarial drug development. The study also shows that combinations of shikimate analogues with antimalarial drugs like pyrimethamine and atovaquone exhibit synergistic effects, highlighting the potential use of shikimate pathway inhibitors in combination therapy. Therefore, the end products of the shikimate pathway are aromatic compounds that could be used as a target for antimalarial drug development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The end products of the shikimate pathway are aromatic compounds.\n2. The shikimate pathway is absent in animals.\n3. The shikimate pathway is present in malaria-causing parasites.\n4. The shikimate pathway could be a potential target for antimalarial drug development.\n5. Combinations of shikimate analogues with antimalarial drugs exhibit synergistic effects.",
    "llama-2-7b-chat-hf_fact": [
      "The end products of the shikimate pathway are aromatic compounds.",
      "The shikimate pathway is absent in animals.",
      "The shikimate pathway is present in malaria-causing parasites.",
      "The shikimate pathway could be a potential target for antimalarial drug development.",
      "Combinations of shikimate analogues with antimalarial drugs exhibit synergistic effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline can be used to treat Nelson's syndrome, which is a rare endocrine disorder characterized by excessive production of cortisol. While the information provided does not specifically mention Nelson's syndrome, it does suggest that cabergoline can be effective in controlling cortisol secretion, which is a key symptom of the condition.\nNelson's syndrome is caused by the excessive production of cortisol in the adrenal glands, leading to a range of symptoms including weight gain, fatigue, and muscle weakness. Cabergoline, as a dopamine receptor agonist, can help to reduce cortisol production by inhibiting the release of ACTH from the pituitary gland.\nWhile the information provided does not provide direct evidence of cabergoline's effectiveness in treating Nelson's syndrome, it does suggest that it can be considered as a first-line treatment for patients with Cushing's disease (CD), which is a related condition that can also cause excessive cortisol production.\nTherefore, based on the information provided, it is possible that cabergoline may be effective in treating Nelson's syndrome, and it could be considered as a potential treatment option for patients with this condition. However, it is important to note that more research is needed to confirm the efficacy and safety of cabergoline in treating Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare endocrine disorder characterized by excessive production of cortisol.\n3. Symptoms of Nelson's syndrome include weight gain, fatigue, and muscle weakness.\n4. Cabergoline works as a dopamine receptor agonist.\n5. Cabergoline can inhibit the release of ACTH from the pituitary gland, potentially reducing cortisol production.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare endocrine disorder characterized by excessive production of cortisol.",
      "Symptoms of Nelson's syndrome include weight gain, fatigue, and muscle weakness.",
      "Cabergoline works as a dopamine receptor agonist.",
      "Cabergoline can inhibit the release of ACTH from the pituitary gland, potentially reducing cortisol production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used to treat conditions like hyperprolactinemia and Parkinson's disease, not Nelson's syndrome.\n2. FALSE [correction]: Nelson's syndrome is characterized by excessive production of adrenocorticotropic hormone (ACTH) after the removal of adrenal glands, not cortisol. It can lead to high levels of ACTH, causing abnormal growth of the remaining pituitary tissue.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome is the \"eye-of-the-tiger sign\" in the medial globus pallidus, which is characterized by increased signal intensity on magnetic resonance imaging (MRI) due to gliosis and accumulation of surrounding iron. This sign is a distinctive feature of Liebenberg syndrome and can be used to diagnose the condition through MRI.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are orally bioavailable MPS1 kinase inhibitors:\n1. Reversine: Reversine is a small molecule inhibitor of MPS1 that features similar binding affinity characteristics to both MPS1WT and MPS1C604Y.\n2. Cpd-5: Cpd-5 is another small molecule inhibitor of MPS1 that exhibits higher binding affinity to MPS1WT than to MPS1C604Y.\n3. NMS-P715: NMS-P715 is a small molecule inhibitor of MPS1 that features a higher binding affinity to MPS1WT than to MPS1C604Y.\nIt is important to note that these inhibitors exhibit different resistance mechanisms to the C604Y mutation. Reversine and Cpd-5 both exhibit similar dissociation processes from both MPS1WT and MPS1C604Y, but Cpd-5 and NMS-P715 were found to dissociate more easily from MPS1C604Y than from MPS1WT, thus a reduced residence time was responsible for the inhibitors' resistance to the C604Y mutation.\nTherefore, based on the information provided in the document, the orally bioavailable MPS1 kinase inhibitors that are most effective against the C604Y mutation are reversine and Cpd-5.",
    "llama-2-7b-chat-hf_fact_raw": "1. Reversine is an orally bioavailable inhibitor of MPS1.\n2. Cpd-5 is an orally bioavailable inhibitor of MPS1 that has a higher binding affinity to MPS1WT than to MPS1C604Y.\n3. NMS-P715 is an orally bioavailable inhibitor of MPS1.\n4. Reversine and Cpd-5 both exhibit similar dissociation processes from MPS1WT and MPS1C604Y.\n5. Both Cpd-5 and NMS-P715 dissociate more easily from MPS1C604Y than from MPS1WT.",
    "llama-2-7b-chat-hf_fact": [
      "Reversine is an orally bioavailable inhibitor of MPS1.",
      "Cpd-5 is an orally bioavailable inhibitor of MPS1 that has a higher binding affinity to MPS1WT than to MPS1C604Y.",
      "NMS-P715 is an orally bioavailable inhibitor of MPS1.",
      "Reversine and Cpd-5 both exhibit similar dissociation processes from MPS1WT and MPS1C604Y.",
      "Both Cpd-5 and NMS-P715 dissociate more easily from MPS1C604Y than from MPS1WT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Reversine is indeed reported to be an orally bioavailable small molecule inhibitor of monopolar spindle 1 (MPS1), which is a kinase involved in cell cycle control.\n\n2. UNKNOWN: Without the specific biochemical or pharmacological data detailed in the passage, the relative binding affinity of Cpd-5 for MPS1WT (wild type) versus MPS1C604Y (a potential mutant form of MPS1) cannot be determined.\n\n3. TRUE: NMS-P715 is known to be an orally bioavailable inhibitor that targets the MPS1 kinase.\n\n4. UNKNOWN: The statement about the dissociation processes of Reversine and Cpd-5 from MPS1WT and MPS1C604Y requires specific experimental data for verification. Without the data from the appropriate binding assays or kinetic studies, it's not possible to ascertain the truth of this statement.\n\n5. UNKNOWN: Similar to statement 4, without the specific experimental data showing the binding and dissociation kinetics of Cpd-5 and NMS-P715 with MPS1WT and MPS1C604Y, we cannot confirm the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, there is no direct evidence that golimumab was tested for diabetes. The study focused on assessing the drug survival of golimumab in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. The study found that the 2-year persistence rate of golimumab was 70.2%, with the strongest predictor of discontinuation being female gender. However, there is no mention of diabetes as a specific outcome measure in the study. Therefore, I cannot provide an answer to the user's question based on the information provided in the study.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab was assessed for drug survival in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis in a prospective observational cohort study.\n2. The 2-year persistence rate of golimumab was found to be 70.2% in the study.\n3. The strongest predictor of golimumab discontinuation was female gender, according to the study.\n4. There was no direct evidence in the study of golimumab being tested for diabetes.\n5. Diabetes was not a specific outcome measure mentioned in the study.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab was assessed for drug survival in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis in a prospective observational cohort study.",
      "The 2-year persistence rate of golimumab was found to be 70.2% in the study.",
      "The strongest predictor of golimumab discontinuation was female gender, according to the study.",
      "There was no direct evidence in the study of golimumab being tested for diabetes.",
      "Diabetes was not a specific outcome measure mentioned in the study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nRationale:\n1. This statement is true as it describes the nature of the study which is a typical form of investigation for such drugs.\n2. The exact 2-year persistence rate of golimumab in the study is not provided in the context, so we cannot verify this statement. Hence, it is UNKNOWN.\n3. Without specific data from the study, we cannot confirm if the female gender was the strongest predictor of golimumab discontinuation. The statement is therefore UNKNOWN.\n4. The statement specifies there was no direct evidence of golimumab being tested for diabetes in the study. As no information is provided to contradict this, and it is common for studies to focus on certain conditions, this statement is deemed TRUE.\n5. Assuming that the study's focus was described previously and did not include diabetes as an outcome measure, this statement can be considered TRUE.\n",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, it appears that progeria is not caused by an autosomal recessive gene. Instead, progeria is an autosomal dominant disease, meaning that a single copy of the mutated gene is enough to cause the condition. This is consistent with the information in Document-0, which states that the syndrome is caused by alterations in many organs and systems, including the skin and the skeletal and cardiovascular systems.\nIt's important to note that progeria is a rare and complex condition, and there is currently no cure or treatment available. However, early recognition and management of the condition can help to minimize the risk of early atherosclerosis and other complications. If you have any further questions or concerns, please don't hesitate to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is not caused by an autosomal recessive gene.\n2. Progeria is an autosomal dominant disease.\n3. A single copy of the mutated gene is enough to cause progeria.\n4. Progeria causes alterations in many organs and systems, including the skin, skeletal, and cardiovascular systems.\n5. There is currently no cure or treatment available for progeria.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is not caused by an autosomal recessive gene.",
      "Progeria is an autosomal dominant disease.",
      "A single copy of the mutated gene is enough to cause progeria.",
      "Progeria causes alterations in many organs and systems, including the skin, skeletal, and cardiovascular systems.",
      "There is currently no cure or treatment available for progeria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Progeria is not typically inherited, but it's caused by a de novo mutation that is autosomal dominant in nature. It is not considered an autosomal dominant disease in the traditional sense because it generally does not affect the reproductive lifespan of the individual due to its severity and the early age of onset.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While there is no cure for progeria, there are treatments available that focus on reducing complications or symptoms. For example, growth hormone treatment has been used to help with growth and to improve body composition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the common variants at 12q14 and 12q24 associated with bladder cancer are:\n* rs9642880 G>T on 8q24: This variant is associated with an increased risk of bladder cancer, particularly in young men and for low-risk tumors.\nThe document states that a recent genome-wide association study identified two common variants that confer susceptibility to bladder cancer, and that one of these variants, rs9642880 G>T, was associated with an increased risk of bladder cancer in Chinese populations. The study found that the GT/TT genotypes of rs9642880 were associated with an odds ratio of 1.65 (95% confidence interval = 1.25-2.17) compared to the GG genotype.\nAdditionally, the document mentions that the rs9642880 GT/TT genotypes were associated with enhanced levels of both MYC mRNA and protein in bladder tissues. This suggests that the variant may play a role in the development or progression of bladder cancer.\nTherefore, based on the information provided in the document, the common variants at 12q14 and 12q24 associated with bladder cancer are rs9642880 G>T on 8q24.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variant rs9642880 G>T is associated with an increased risk of bladder cancer.\n2. The variant rs9642880 G>T was identified in a recent genome-wide association study as conferring susceptibility to bladder cancer.\n3. The GT/TT genotypes of rs9642880 were associated with an odds ratio of 1.65 for bladder cancer compared to the GG genotype.\n4. Individuals with the GT/TT genotypes of rs9642880 have enhanced levels of both MYC mRNA and protein in bladder tissues.\n5. Rs9642880 G>T is more commonly associated with bladder cancer risk in young men and for low-risk tumors.",
    "llama-2-7b-chat-hf_fact": [
      "Variant rs9642880 G>T is associated with an increased risk of bladder cancer.",
      "The variant rs9642880 G>T was identified in a recent genome-wide association study as conferring susceptibility to bladder cancer.",
      "The GT/TT genotypes of rs9642880 were associated with an odds ratio of 1.65 for bladder cancer compared to the GG genotype.",
      "Individuals with the GT/TT genotypes of rs9642880 have enhanced levels of both MYC mRNA and protein in bladder tissues.",
      "Rs9642880 G>T is more commonly associated with bladder cancer risk in young men and for low-risk tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Variant rs9642880 G>T has been reported to be associated with an increased risk of bladder cancer in several genetic association studies.\n2. TRUE: The variant rs9642880 G>T was identified in genome-wide association studies as a genetic factor that can confer susceptibility to bladder cancer.\n3. UNKNOWN: Without the specific study or its results, it is not possible to verify the exact odds ratio for bladder cancer associated with the GT/TT genotypes compared to the GG genotype.\n4. UNKNOWN: The association of the GT/TT genotypes of rs9642880 with levels of MYC mRNA and protein in bladder tissues would need to be supported by specific research findings. Without access to relevant studies, the truth of this statement cannot be determined.\n5. UNKNOWN: The prevalence and association of rs9642880 G>T with bladder cancer risk in young men and for low-risk tumors would depend on additional epidemiological data specific to these subgroups. Without such information, the accuracy of this statement is unclear.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the ligands of the Roundabout (Robo) receptors are:\n1. Slit: Slit is a known ligand of Robo1 and has been shown to influence axon guidance and CNS patterning in both vertebrate and nonvertebrate systems.\nIn the context of the document, the authors investigate the role of Robo1 in the development of a subset of neurons and axon tracts in the Xenopus forebrain, and identify Slit as a ligand of Robo1 that plays a role in this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Slit is a ligand of the Robo1 receptor.",
    "llama-2-7b-chat-hf_fact": [
      "Slit is a ligand of the Robo1 receptor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is no direct role for TFII-I in megakaryopoiesis. The information provided refers to the study of transcriptional factor IIIA (TFIIIA) and its recognition of 5S rRNAs in eukaryotic cells, including plant and Xenopus cells. TFIIIA is a transcription factor that plays a crucial role in the initiation of transcription of rRNAs in eukaryotic cells. However, there is no mention of TFII-I in the provided information.\nMegakaryopoiesis is the process by which platelets are produced in the bone marrow. It involves the proliferation and differentiation of hematopoietic stem cells into platelet precursors, which then mature into platelets. TFII-I is a transcription factor that plays a role in the regulation of gene expression during the G1 phase of the cell cycle, but it is not directly involved in megakaryopoiesis.\nTherefore, based on the information provided, there is no direct role for TFII-I in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transcriptional factor IIIA (TFIIIA) is a transcription factor involved in the initiation of transcription of rRNAs in eukaryotic cells.\n2. TFIIIA recognizes 5S rRNAs in eukaryotic cells, including plant and Xenopus cells.\n3. Megakaryopoiesis is the process where platelets are produced in the bone marrow.\n4. The proliferation and differentiation of hematopoietic stem cells into platelet precursors is part of megakaryopoiesis.\n5. TFII-I is a transcription factor that regulates gene expression during the G1 phase of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Transcriptional factor IIIA (TFIIIA) is a transcription factor involved in the initiation of transcription of rRNAs in eukaryotic cells.",
      "TFIIIA recognizes 5S rRNAs in eukaryotic cells, including plant and Xenopus cells.",
      "Megakaryopoiesis is the process where platelets are produced in the bone marrow.",
      "The proliferation and differentiation of hematopoietic stem cells into platelet precursors is part of megakaryopoiesis.",
      "TFII-I is a transcription factor that regulates gene expression during the G1 phase of the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFIIIA recognizes the 5S rRNA genes for transcription, not the rRNAs themselves.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, atenolol is not metabolized by CYP2D6. The study mentioned in the passage investigated the metabolism of methylphenidate (MPH) by CYP2D6, and found that quinidine, a potent CYP2D6 inhibitor, had no significant effect on the pharmacokinetics of MPH or its major metabolite, ritalinic acid, in either extensive or poor metabolizers of CYP2D6. Since quinidine is a specific inhibitor of CYP2D6, it is unlikely that other drugs metabolized by this enzyme, such as atenolol, would be affected by quinidine. Therefore, it can be concluded that atenolol is not metabolized by CYP2D6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is not metabolized by CYP2D6.\n2. Quinidine is a potent CYP2D6 inhibitor.\n3. The study mentioned investigated the metabolism of methylphenidate (MPH) by CYP2D6.\n4. Quinidine had no significant effect on the pharmacokinetics of methylphenidate or its major metabolite, ritalinic acid.\n5. The study compared the effects of quinidine in both extensive and poor metabolizers of CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is not metabolized by CYP2D6.",
      "Quinidine is a potent CYP2D6 inhibitor.",
      "The study mentioned investigated the metabolism of methylphenidate (MPH) by CYP2D6.",
      "Quinidine had no significant effect on the pharmacokinetics of methylphenidate or its major metabolite, ritalinic acid.",
      "The study compared the effects of quinidine in both extensive and poor metabolizers of CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Atenolol is primarily eliminated by renal excretion and is not significantly metabolized by the liver cytochrome P450 system, including CYP2D6.\n2. TRUE: Quinidine is known to be a potent inhibitor of the CYP2D6 enzyme.\n3. UNKNOWN: Without additional context on the specific study, it is impossible to confirm whether the study in question investigated the metabolism of methylphenidate (MPH) by CYP2D6.\n4. FALSE [correction]: Since quinidine is a potent CYP2D6 inhibitor, it is expected to have a significant effect on the pharmacokinetics of drugs metabolized by CYP2D6, including potentially methylphenidate and its major metabolite ritalinic acid, by slowing down their metabolism and increasing their plasma concentrations. However, without specific study details, the general statement should assume known pharmacologic interactions.\n5. UNKNOWN: Without additional context on the study, it cannot be confirmed whether the study compared the effects of quinidine in both extensive and poor metabolizers of CYP2D6.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the versions of ExpansionHunter:\n1. Grey Wolf Optimizer (GWO)\n2. Ant Lion Optimizer (ALO)\n3. Moth Flame Optimizer (MFO)",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Adamts18 appears to play a role in regulating the activity of the PACAP type 1 receptor (PAC1R) during spermatogenesis in the rat testis. Specifically, the document reports the existence of a novel exon in the extracellular domain of the PAC1R that is alternatively spliced during the spermatogenic cycle, resulting in the expression of a receptor isoform (PAC1R(3a)) that has an additional 72 base pairs encoding 24 amino acids in its extracellular domain. This splice variant is preferentially expressed in seminiferous tubules and Sertoli cells, and analyses of ligand binding and signaling functions in stably transfected HEK293 cells reveal that it has a 6-fold increase in the affinity for binding PACAP-38, and alterations in its coupling to both cAMP and inositol phosphate signaling pathways relative to the wild type PAC1R. These findings suggest that the extracellular region between coding exons 3 and 6 of PAC1R may play an important role in regulating the relative ligand affinities and the relative coupling to G(s) (cAMP) and G(q) (inositol phosphates) signal transduction pathways during spermatogenesis. Therefore, Adamts18 may play a role in regulating the activity of the PAC1R during this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is implicated in regulating the PACAP type 1 receptor (PAC1R) activity during rat spermatogenesis.\n2. A novel exon in the extracellular domain of PAC1R is alternatively spliced during the spermatogenic cycle.\n3. The PAC1R splice variant, PAC1R(3a), includes an additional 72 base pairs encoding 24 amino acids in its extracellular domain.\n4. PAC1R(3a) shows a 6-fold increase in affinity for binding PACAP-38 compared to the wild type PAC1R.\n5. The PAC1R(3a) splice variant demonstrates alterations in its coupling to cAMP and inositol phosphate signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is implicated in regulating the PACAP type 1 receptor (PAC1R) activity during rat spermatogenesis.",
      "A novel exon in the extracellular domain of PAC1R is alternatively spliced during the spermatogenic cycle.",
      "The PAC1R splice variant, PAC1R(3a), includes an additional 72 base pairs encoding 24 amino acids in its extracellular domain.",
      "PAC1R(3a) shows a 6-fold increase in affinity for binding PACAP-38 compared to the wild type PAC1R.",
      "The PAC1R(3a) splice variant demonstrates alterations in its coupling to cAMP and inositol phosphate signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The PAC1R(3a) splice variant includes an additional 27 base pairs encoding 9 amino acids in its extracellular domain.\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 3 comes from research literature, but without specific context or source material for other statements, it is not possible to verify the accuracy of statements 1, 2, 4, and 5. They could be true in reality, but without concrete evidence or citation, they remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mode of action of Thiazovivin is likely to be an anticonvulsant. The document states that the novel compounds, including Thiazovivin, were tested for anticonvulsant activity using pentylenetetrazole-induced seizure (PTZ) and maximal electroshock seizure (MES) tests, and Thiazovivin was found to afford 90 and 100% protection in PTZ and MES tests at a dose of 50mg/kg, respectively. This suggests that Thiazovivin has a significant effect in preventing or reducing seizures, which is a common mode of action of anticonvulsant drugs.\nIt is worth noting that the document also mentions that Thiazovivin was not active against Mycobacterium tuberculosis H37Rv at a concentration of 6.25 microg/mL, and that selected compounds were evaluated for in vitro anti-HIV activity and were all negative. However, these findings do not necessarily indicate that Thiazovivin does not have an anticonvulsant mode of action, as the lack of activity against Mycobacterium tuberculosis and the negative results for anti-HIV activity may be due to other factors unrelated to its anticonvulsant effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin has been tested for anticonvulsant activity.\n2. The compound afforded 90% protection in the pentylenetetrazole-induced seizure (PTZ) test at a dose of 50mg/kg.\n3. The compound afforded 100% protection in the maximal electroshock seizure (MES) test at a dose of 50mg/kg.\n4. Thiazovivin was not active against Mycobacterium tuberculosis H37Rv at a concentration of 6.25 microg/mL.\n5. Selected compounds, including Thiazovivin, were evaluated for in vitro anti-HIV activity and the results were negative.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin has been tested for anticonvulsant activity.",
      "The compound afforded 90% protection in the pentylenetetrazole-induced seizure (PTZ) test at a dose of 50mg/kg.",
      "The compound afforded 100% protection in the maximal electroshock seizure (MES) test at a dose of 50mg/kg.",
      "Thiazovivin was not active against Mycobacterium tuberculosis H37Rv at a concentration of 6.25 microg/mL.",
      "Selected compounds, including Thiazovivin, were evaluated for in vitro anti-HIV activity and the results were negative."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information from the original passage or scientific study results, it is impossible to accurately verify or correct the provided statements regarding Thiazovivin's activity in various tests. These statements depend on experimental data that has not been supplied.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]